deoxycytidine and Ovarian Neoplasms
deoxycytidine has been researched along with Ovarian Neoplasms in 433 studies
Research
Studies (433)
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 46 (10.62) | 18.2507 |
2000's | 187 (43.19) | 29.6817 |
2010's | 171 (39.49) | 24.3611 |
2020's | 29 (6.70) | 2.80 |
Authors
Authors | Studies |
---|---|
Cheng, SC; Chowdhury, D; Curtis, J; D'Andrea, AD; da Costa, AABA; Färkkilä, A; Gulhan, D; Hendrickson, AEW; Kochupurakkal, B; Kohn, EC; Kolin, DL; Konstantinopoulos, PA; Lee, EK; Liu, JF; Matulonis, UA; Polak, M; Shapiro, GI; Stover, EH; Tayob, N | 1 |
Mo, DC; Ren, T | 1 |
Katsuda, T; Matsukuma, K; Nasu, H; Nishio, S; Park, J; Tasaki, K; Terada, A; Tsuda, N; Ushijima, K; Yoshimitsu, T | 1 |
Ahmad, M; Alharbi, H; Aloahd, MS; Alrashed, MM; Alshehry, AS | 1 |
Anjum, MM; Bhattacharya, S; Patel, KK | 1 |
Al-Mutairi, AA; Alkhatib, MH | 1 |
Arakawa, A; Goto, M; Hori, K; Ito, K; Kaneda, M; Kawabata, A; Kaya, R; Kondo, E; Motohashi, T; Nagasawa, T; Nakagawa, M; Nasu, H; Nishio, S; Park, J; Shimokawa, M; Suzuki, J; Tashima, L; Tsubamoto, H; Yamada, K; Yanagida, S | 1 |
Azzouqa, AG; Colon-Otero, G; Kase, AM; Kochuveettil, S | 1 |
Bastière-Truchot, L; Berger, R; Berton-Rigaud, D; Cardona, A; Colombo, N; du Bois, A; González Martin, A; Greimel, E; Grischke, EM; Hilpert, F; Kroep, JR; Kurzeder, C; Lorusso, D; Lück, HJ; Martinez-Garcia, J; Mirza, MR; Ottevanger, P; Pardo, B; Rau, J; Redondo, A; Selle, F; Vergote, I | 1 |
Feng, W; Tang, Z; Wang, Q; Yang, Y | 1 |
Berg, T; Nøttrup, TJ; Roed, H | 1 |
Kato, T; Kiyokawa, T; Kohno, T; Kuroda, T; Ogiwara, H; Okamoto, A; Sasaki, M; Sudo, K; Takahashi, K; Tamura, K; Yoshida, H | 1 |
Arcieri, M; Ergasti, R; Fagotti, A; Marchetti, C; Palluzzi, E; Pietragalla, A; Rosati, A; Scaletta, G; Scambia, G | 1 |
Bell, R; Bell-McGuinn, K; Buderath, P; Campbell, R; Farrington, DL; Fiorica, J; Golden, L; Hamilton, A; Heitz, F; Lee, CM; Moore, KN; Pitou, C; Powell, M; Sehouli, J; Teneriello, M; Vergote, I; Wenham, RM; Zhang, W | 1 |
Alvarez Secord, A; Armstrong, DK; Azab, M; Banerjee, S; Basu, B; Birrer, MJ; Blagden, SP; Braly, P; Fleming, GF; Ghamande, S; Hall, GD; Hao, Y; Hirte, HW; Jueliger, S; Keer, H; Kristeleit, R; Markham, MJ; Matei, D; Matulonis, UA; McGuire, WP; Naim, S; Nemunaitis, J; Nephew, KP; Oganesian, A; Oza, AM; Provencher, DM; Roman, LD; Schwartz, B | 1 |
Kohno, T; Kuroda, T | 1 |
Jimi, T; Kitai, M; Kogiku, A; Matsuoka, K; Nagao, S; Shibutani, T; Shiozaki, T; Suzuki, K; Yamaguchi, S; Yamamoto, K | 1 |
Bun, S; Kato, MK; Kato, T; Miyasaka, N; Shimoi, T; Tamura, K; Yonemori, K; Yunokawa, M | 1 |
Hada, T; Ishibashi, H; Iwahashi, H; Kakimoto, S; Matsuura, H; Miyamoto, M; Sakamoto, T; Soyama, H; Suminokura, J; Takano, M | 1 |
Abbasnezhad, A; Abd El-Ghafar, OA; Abhilash, L; Abouzid, KAM; Achberger, AM; Ackerman, S; Akhatayeva, Z; Akin, D; Al-Kaysi, RO; Alakhdar, AA; Alame, M; Aleksic Sabo, V; Alinezhadbalalami, N; Allen, JD; Alonso, JM; Alqatani, S; Alsayed, B; Álvarez Larraondo, M; Alvarez, M; Amini, SB; An, Z; Anasir, MI; Anderson, GH; Andremont, A; Andrés, S; Angel, S; Anigboro, AA; Anini, Y; Antonides, CFJ; Arafa, K; Arafa, RK; Aryal, UK; Asbaghi, O; Assefa, MK; Atyah, M; Avwioroko, OJ; Ayora-Talavera, G; Azpilikueta, A; Azyazov, VN; Ba, YF; Bachmann, KF; Badoual, J; Bae, SJ; Baek, SH; Bahrami, B; Bai, J; Baid-Agrawal, S; Bailey, MR; Baillie, JK; Balani, N; Balcar, VJ; Banica, T; Banks, L; Barb, J; Bardeen, CJ; Barrett, HE; Bartnikowski, N; Bashir, R; Battaglia, M; Bautista-Hernández, V; Becker, B; Beekman, FJ; Benidir, M; Benjelloun, M; Bentley, RF; Bergé, J; Berger, D; Bernsen, MR; Berraondo, P; Bhattacharya, R; Bhayani, SB; Bi, W; Bi, X; Bi, YL; Bi, Z; Bian, K; Biesecker, LG; Billadeau, DD; Blaszczyk, R; Blum, JL; Boachie, R; Boelte, K; Bogers, AJJC; Boileau, I; Bonduelle, C; Bonny, O; Bonsu, JM; Boos, LA; Borges-Argáez, R; Bouchard, PA; Boudot, C; Bourgeade-Delmas, S; Boutet-Robinet, E; Boyle, AJ; Branigan, D; Briones, S; Broniowska, KA; Brossas, JY; Brown, WA; Brzezinska, J; Buitron, G; Burnier, M; Bursulaya, B; Burton, PR; Bush, AA; Busuttil, RW; Cabello-Aguilar, S; Cáceres-Farfán, M; Cacheux, V; Caffrey, PJ; Cai, B; Cai, Q; Cai, S; Cai, Y; Calders, P; Cammarota, G; Campbell, DA; Cancelli, C; Cao, Q; Cao, WH; Cao, X; Capet, M; Capoluongo, E; Carey, ME; Carnero, M; Carrasco, LI; Carreno, J; Carrillo-Reyes, J; Casini, I; Cassar, M; Catalan, G; Cattamanchi, A; Cazares-Granillo, M; Celie, B; Cen, YK; Cena, H; Cerbo, RM; Ceron, E; Cetina-Montejo, L; Chaâbane-Banaoues, R; Chabanet, C; Chace-Donahue, F; Chalfun-Júnior, A; Chan-Balan, R; Chang, CS; Chen, CS; Chen, D; Chen, J; Chen, L; Chen, PN; Chen, Q; Chen, S; Chen, W; Chen, WP; Chen, X; Chen, Z; Cheng, H; Cheng, J; Cheng, Q; Cheng, T; Chi, T; Chianelli, D; Chieppa, M; Child, CJ; Cho, JH; Cho, JY; Chogtu, B; Choi, GH; Choi, J; Choi, M; Choi, NG; Cholu, CO; Chow, ES; Chowdhury, AH; Chu, PC; Chu, Q; Chu, S; Chua, H; Chung, T; Chunyan, L; Church, JS; Civardi, E; Cobiella, J; Colinge, J; Collado, CJ; Collins, TJ; Cong, LM; Conkrite, KL; Cope, SJ; Corbett, JA; Cornet, M; Cornillot, E; Corvaisier, S; Costes-Martineau, V; Courtioux, B; Coussens, M; Covino, M; Criado, A; Cui, J; Cui, Y; Cunitz, BW; Curry, AE; Cussó, L; D'Urzo, AD; D'Urzo, KA; Dabbous, S; Dahlgren, RA; Dai, H; Dai, T; Dai, W; Dalinghaus, M; Dang, S; Davalos, RV; Davidson, H; de Andrea, CE; De Angelis, M; de Blois, E; de Carvalho, PA; De Clercq, E; De Giuseppe, R; de Jong, M; De Langhe, S; De Oliveira, L; de Souza Pinto Lemgruber, R; de Souza, LB; de Swart, J; De Wandele, I; de Woestijne, PCV; Delaney, S; Delorme, M; Delvenne, P; Deng, L; Deng, Z; Denkinger, CM; der Meulen, MHV; Deraeve, C; Desco, M; DeSilva, S; Destere, A; Dhali, A; Di Ciano, P; Dias-Santagata, D; Diskin, SJ; Djè, MK; Doddipatla, S; Doerr, AJ; Dokla, EME; Domiciano, D; Domingo, N; Dong, C; Dong, J; Dong, Q; Dong, S; Dong, X; Dong, Z; Douair, I; Douglas, TA; Doyle, SM; Drain, PK; Du, K; Du, L; Du, Q; Du, S; Duan, C; Duan, H; Duan, J; Duan, S; Duan, W; Dueluzeau, R; Dukic, L; Dunmire, BL; Duvauchelle, T; Dymek, B; Dzwonek, K; Earnest, A; Eckardt, KU; El Ghadraoui, L; El Massoudi, S; Elloumi, F; Elnour, IE; Embarak, S; Ende, M; England, K; Enikeev, D; Enyedy, I; Epple, R; Erickson, GE; Eriksson, J; Erndt-Marino, J; Errachidi, F; Etxeberria, I; Evan, AP; Fairlamb, AH; Falahi, E; Fan, CC; Fan, H; Fan, M; Fan, MZ; Fan, S; Fan, Y; Fang, CS; Fang, J; Fang, X; Fang, Z; Farmany, A; Farooqi, A; Farouk, HO; Fazelipour, S; Feng, D; Feng, J; Feng, JX; Feng, YL; Ferraz, SL; Ferreira, CR; Figenshau, RS; Finn, AV; Fiseha, T; Fleischer, AS; Fogleman, AD; Fontaine, O; Ford, CR; Fouladvand, F; Four, M; Fousteri, G; Francis, JR; Fraser, JF; Frazier, RP; Fu, H; Fu, P; Fu, YJ; Fujishima, A; Fuster, V; Gabilan, JC; Gagliani, N; Gai, QY; Galán-Arriola, C; Gale, P; Galimova, GR; Galkin, A; Gallo, A; Gallo, AA; Gang, DD; Ganschow, S; Gao, C; Gao, F; Gao, GP; Gao, H; Gao, K; Gao, M; Gao, MY; Gao, P; Gao, R; Gao, S; Gao, WJ; Gao, Y; Garbacz, P; García Ruiz, L; Garcia, EM; Garofoli, F; Gasbarrini, A; Gattinoni, L; Gaudig, M; Gbureck, U; Ge, X; Genko, N; Gentile, GL; George, MW; Gerety, GF; Gestwicki, JE; Geusens, PP; Ghassemi, M; Giardina, JD; Giebultowicz, JM; Gifford, CA; Gijsen, FJH; Gilfillan, R; Gilson, E; Gingl, K; Giuliano, C; Glybochko, P; Goessler, W; Gofflot, S; Golab, J; Goldstein, A; Golebiowski, A; Gómez, L; Gómez-Carballo, J; Gonçalves, PEO; Gonzales, R; Gonzalez-Cotto, M; González-Fernández, D; Gonzalez-Lopez de Turiso, F; Goodman, JM; Govinda Raju, S; Grimm, J; Gross, AJ; Gruenheid, S; Gu, C; Gu, FF; Gu, S; Gu, Z; Guest, RL; Gui, C; Gui, J; Guillem, A; Guo, G; Guo, L; Guo, Q; Guo, S; Guo, SW; Guo, W; Guo, Y; Guo, YG; Guo, Z; Guretzky, JA; Haenggi, M; Hahn, MS; Hakkola, J; Halim, AA; Hampel, D; Han, B; Han, BH; Han, D; Han, G; Han, J; Han, LZ; Han, R; Han, S; Han, X; Han, Z; Handley, MA; Hanke, I; Hannongbua, S; Hao, P; Happ, JT; Hara, M; Haraux, F; Hare, JL; Harper, JD; Hartley, AM; Harvey, E; Hashimoto, K; Hassan, HM; Hautajärvi, H; Hayton, TW; He, C; He, H; He, HJ; He, WP; He, Y; He, Z; Hedrick, V; Heffernan, JK; Hegrová, J; Heidarimoghadam, R; Helms, K; Hengphasatporn, K; Henry, D; Herrmann, TRW; Hesson, T; Himmelbauer, MK; Hindle, A; Hoffmann, R; Hogg, N; Hong, KB; Hong, SK; Honjol, Y; Hood, C; Hsi, RS; Hsu, JL; Hu, B; Hu, BC; Hu, D; Hu, H; Hu, J; Hu, K; Hu, M; Hu, MK; Hu, T; Hu, W; Hu, Y; Hu, Z; Hua, S; Huang, H; Huang, J; Huang, L; Huang, M; Huang, P; Huang, X; Huang, Y; Huang, Z; Hukkanen, J; Hung, MC; Huo, X; Hyötyläinen, T; Ianiro, G; Ibanez, B; Imran, M; Ireland, S; Irwin, MS; Ishiguro, H; Jackowski, K; Jackson, C; Jacob, SI; Jahromy, MH; Jakob, SM; Jang, J; Javvaji, PK; Jefferson, KK; Jena, P; Ji, H; Jiang, F; Jiang, GH; Jiang, H; Jiang, J; Jiang, X; Jiang, Z; Jiao, J; Jiménez, A; Jin, X; Jincai, W; Jintao, X; Jo, K; Jofra, T; Johari, Y; Johnson, ACM; Jones, JH; Josephine Fauci, A; Juhl, AK; Jun, S; Kaiser, RI; Kajioka, J; Kajiyama, H; Kalliyil, A; Kalthur, SG; Kamalanathan, M; Kamaldinov, T; Kanaani, L; Kang, D; Kang, J; Kang, S; Känsäkoski, P; Kaplan, DL; Karwan, M; Kasibhatla, S; Kaur, A; Kawazoe, Y; Ke, C; Keyser, J; Khalique, A; Khan, IT; Kharshoum, RM; Kher, R; Kherani, J; Ki, KK; Kikkawa, F; Kikkawa, R; Kim, BT; Kim, EH; Kim, GA; Kim, GD; Kim, HB; Kim, HG; Kim, JS; Kim, MJ; Kim, SI; Kim, SJ; Kim, Y; King, K; Kinyamu-Akunda, J; Kirkkala, T; Kjaer-Sorensen, K; Kleppinger, EL; Kloner, RA; Klopfenstein, TJ; Knappe, D; Knezevic, P; Kobos, LM; Kohli, M; Kolano, L; Kolodgie, FD; Kolte, AP; Koneru, B; Kong, D; Kong, F; Kong, X; Konggidinata, MI; Köpke, M; Koski, KG; Kotsis, F; Köttgen, A; Kouakou-Kouamé, CA; Kraemer, US; Krane, V; Krehbiel, CR; Krenning, BJ; Kretzschmar, D; Ku, KB; Kubota, Y; Kulich, P; Kumar, NG; Kupiec-Weglinski, JW; Lalani, SS; Lan, X; Landfeldt, E; Langenberg, E; Lapauw, B; Larkin, J; Lassoued, MA; Laukhtina, E; Laura Martinez, J; Laveillé, A; Lavela, P; Law, AD; Lazraq, A; Le Foll, B; Lee, BK; Lee, C; Lee, CS; Lee, EJ; Lee, EY; Lee, G; Lee, HY; Lee, JH; Lee, JJ; Lee, JO; Lee, JS; Lee, R; Lei, H; Lei, P; Lellouche, F; Lennerz, JK; Leong, W; Leslie, I; Lessem, E; Levin, M; Levinger, I; Li, C; Li, CW; Li, CX; Li, CY; Li, D; Li, H; Li, HM; Li, J; Li, L; Li, LM; Li, N; Li, S; Li, W; Li, X; Li, XX; Li, Y; Li, Z; Li, ZL; Li, ZX; Lian, Q; Liang, C; Liang, GH; Liang, H; Liang, J; Liang, X; Liao, CX; Liao, R; Ličbinský, R; Lim, YS; Lima, HK; Lin, JG; Lin, L; Lin, S; Lin, WP; Lin, Z; Liso, M; Liu, BX; Liu, C; Liu, H; Liu, J; Liu, M; Liu, Q; Liu, S; Liu, SF; Liu, SL; Liu, T; Liu, W; Liu, X; Liu, XB; Liu, Y; Liu, YY; Liu, Z; Liu, ZQ; Lobo, M; Loitzenbauer, M; López, F; Lopez, G; López, GJ; Lou, Z; Lu, IC; Lu, J; Lu, M; Lu, W; Lu, X; Lu, Y; Luhovyy, BL; Luna-Abanto, J; Luo, J; Luo, K; Luo, L; Luo, M; Luo, W; Luo, X; Luo, XM; Lv, Y; Lv, YQ; Lyu, HD; Lyu, J; Ma, C; Ma, G; Ma, L; Ma, Q; Ma, X; Ma, Y; Macha, SJ; MacLean, E; Mahalapbutr, P; Maina, T; Malfait, F; Malfertheiner, MV; Malzert-Fréon, A; Mansouri, E; Mao, C; Marcellin, E; Marchiori, PER; Marcotte, DJ; Maréchal, A; Maric, N; Maris, JM; Maron, L; Marti, CN; Martínez-Milla, J; Mateo, J; Mather, K; Mathison, CJN; Matthay, MA; Maxwell, CL; Mazier, D; Mazumder, D; Mazurkiewicz, M; Mazzucchelli, TG; McAuley, DF; Mccoy, K; McVicar, DW; Mebel, AM; Mech, A; Meester, EJ; Meiselbach, H; Melero, I; Ménard, G; Meng, X; Mengya, Y; Merle, G; Meunier, B; Mfarrej, B; Mi, K; Migueliz, I; Mikuška, P; Miladi, K; Miletich, R; Millar, JE; Mills, MR; Milne, R; Minute, L; Misiak, M; Mo, F; Modi, A; Mok, F; Molina, C; Mollen, CJ; Molteni, V; Montalto, M; Montet, D; Monti, MC; Moor, MB; Moravec, P; Morsiani, C; Murillo, E; Murugan, P; Muslem, R; Myers, RK; N'guessan, FK; Nabil, H; Nadal, J; Nadeem, M; Nafady, MM; Nafie, MS; Nair, HP; Nakano, R; Nance, J; Naren, N; Neil, CJ; Nelson, J; Nery, FC; Netsch, C; Nguyen, TH; Ni, L; Ni, YX; Nie, W; Nielsen, LK; Nigam, K; Nikolayev, AA; Nishiyama, M; Niu, LL; Niu, PP; Nock, BA; Noer, PR; Noll, G; Noll, S; Norenberg, JP; Nowicka, J; Nutho, B; O'Connor, M; Obonyo, NG; Ochiai, T; Ochoa, MC; Oh, BL; Oh, S; Olczak, J; Olivares, X; Ommurugan, B; Oosthuizen, MC; Operario, D; Orešič, M; Oshima, K; Otano, I; Ou, Y; Owen, TW; Oxvig, C; Pacey, V; Pai, M; Paik, H; Paiva, R; Palmieri, EM; Palpant, N; Pan, L; Pan, Q; Panahi, S; Pang, B; Pang, ZC; Pannecouque, C; Paris, L; Park, D; Park, DJ; Park, E; Park, EC; Park, IH; Park, JH; Park, JI; Park, S; Passmore, MR; Pattaranggoon, NC; Paun, M; Pedersen, S; Pedron, J; Peng, M; Peng, X; Penzhorn, BL; Pérez-Camargo, D; Perez-Maldonado, R; Pérez-Vicente, C; Pham, TD; Pickering, L; Pickersgill, NA; Pinault, E; Pinotsis, N; Plan, M; Pocino, K; Poh, CL; Pons, EDC; Popoff, MR; Porri, D; Pourmand, A; Pratviel, G; Prudente, DO; Qi, H; Qi, N; Qian, LY; Qiao, L; Qiao, Q; Qin, QP; Qiu, N; Qiu, SW; Qu, F; Quan, M; Quigg, A; Raee, E; Raibaud, P; Ramanitrahasimbola, D; Rapoport, L; Rasby, RJ; Rasoanirina, BNV; Raspini, B; Ratner, JR; Razafindrakoto, Z; Redd, MA; Ren, H; Ren, N; Rey, J; Reynolds, CP; Rich, PR; Richards, CJ; Rigol, M; Rimoldi, S; Robert, P; Rodrigues, AE; Roe, JH; Rohde, S; Rokita, JL; Roland, J; Rombaut, L; Ronkainen, J; Rothenberg, SM; Roy, SC; Ruan, Z; Rucker, PV; Rueda, D; Ruhwald, M; Rungrotmongkol, T; Rupert, AS; Rusjan, P; Ryabov, AD; Rysä, J; Saad, NES; Sabioni, P; Sadow, PM; Sahai, N; Salem, HF; Salinas, B; Salonurmi, T; Samé Guerra, D; Sánchez, J; Sanchez-González, J; Sanmamed, MF; Sansores-Peraza, P; Santoro, JC; Santschi, PH; Saritas, T; Sarkisova, Y; Savolainen, MJ; Scherberich, JE; Schlom, DG; Schmelz, EM; Schmid, MC; Schneider, MP; Schumacher, S; Schwartz, JC; Schwartzer, JJ; Schwehr, K; Schweitzer, DH; Scott, ME; Sedky, NK; See Hoe, L; Sejian, V; Selvaraju, S; Sen, SK; Seo, G; Šerý, O; Settles, JA; Sfar, S; Shaffer, J; Shan, GL; Shang, Q; Shannahan, JH; Shao, B; Shao, H; Shao, J; Shao, ZH; Shasha, Y; Shaw, K; Sheeba, V; Shekar, K; Shen, G; Shen, H; Shen, XD; Shen, Y; Sherrell, PC; Shete, PB; Shi, AX; Shi, J; Shi, JH; Shi, S; Shi, X; Shigeta, Y; Shimbo, A; Shin, E; Sikka, N; Silhavy, TJ; Simanon, N; Simard, S; Simon, J; Simon, M; Simpson, SD; Simundic, AM; Since, M; Singh, B; Singhroy, DN; Sinisterra, OT; Smith, EH; Sobreira, TJP; Solanes, N; Somasundar, Y; Sommerer, C; Sonei, A; Song, B; Song, E; Song, J; Song, M; Song, Y; Soo Lee, M; Sorensen, MD; Sournia-Saquet, A; Spaepen, E; Spirk, D; Srivastava, S; Stancill, JS; Stanczak, PS; Starenki, D; Starr, F; Step, DL; Steubl, D; Stigliani, JL; Stráská, J; Sträter, N; Su, ZZ; Sudano, I; Suen, JY; Suh, HJ; Sui, ZY; Suico, JG; Suleiman, K; Sumon, K; Sun, HB; Sun, J; Sun, L; Sun, LL; Sun, M; Sun, Q; Sun, W; Sun, X; Sun, XF; Sun, Y; Sun, YB; Sun, YH; Sun, YN; Sun, Z; Sunada, K; Suzuki, S; Sylvan, JB; Takala, J; Talla, D; Tamir, Z; Tan, SJ; Tanda, S; Tang, H; Tang, J; Tang, LF; Tang, SJ; Tang, Y; Tao, FB; Tappel, R; Taratkin, M; Teijeira, Á; Tellew, JE; Thomas, AM; Thomas, SG; Thomson, SR; Tian, J; Tie, Y; Tirado, JL; Tolonen, A; Tosato, G; Tronnet, A; Tsai, S; Turtoi, A; Turtoi, E; Tvrdoňová, M; Tyagi, A; Tzou, DT; Uddin Ahmad, Z; Urias, E; Usawachintachit, M; Ustriyana, P; Utsumi, F; Vacca, M; Vaculovič, T; Vaidya, SS; Valentin, A; Valgepea, K; van den Berg, P; van den Bergh, JP; van der Heiden, K; van Gaalen, K; Van Gemert, W; van Haard, PMM; van Hest, JCM; Vecchiarelli, E; Večeřa, Z; Venkatesh, R; Verhaeghe, P; Verhagen, HJ; Vetter, JM; Vieira, D; Vilchez-Tschischke, JP; Villena-Gutierrez, R; Villoslada Terrones, V; Vital-Jacome, M; Voelkl, J; Vogel, K; Vogrin, S; Volke, D; von Bahr, V; Vysloužil, J; Wade, TL; Wagner-Gillespie, M; Walsh, SW; Wan, LJ; Wan, SP; Wang, AL; Wang, B; Wang, BY; Wang, C; Wang, D; Wang, F; Wang, H; Wang, HR; Wang, HY; Wang, J; Wang, JY; Wang, K; Wang, L; Wang, LF; Wang, P; Wang, Q; Wang, R; Wang, SF; Wang, SP; Wang, SR; Wang, T; Wang, W; Wang, WP; Wang, X; Wang, XJ; Wang, Y; Wang, YL; Wang, YN; Wáng, YXJ; Wang, Z; Wang, ZF; Wang, ZY; Waning, B; Warner, JM; Washington, SL; Watson, AK; Wei, B; Wei, C; Wei, F; Wei, X; Wei, Y; Wemhoff, AP; Wen, Z; Weng, TT; Wesdemiotis, C; Wheeler, DA; Wildner, M; Wilson, BK; Wirth, LJ; Wissler, M; Wu, F; Wu, G; Wu, J; Wu, KH; Wu, MC; Wu, P; Wu, PK; Wu, S; Wu, W; Wu, X; Wu, XP; Wu, Y; Wyatt, E; Wyllie, S; Xia, Y; Xiao, BH; Xiao, SZ; Xiao, W; Xiao, X; Xiao, Z; Xie, D; Xie, K; Xie, X; Xie, Y; Xie, YF; Xin, S; Xin, Z; Xing, Q; Xing, WQ; Xiong, D; Xiong, X; Xu, C; Xu, D; Xu, F; Xu, G; Xu, H; Xu, J; Xu, JY; Xu, L; Xu, N; Xu, W; Xu, X; Xu, Y; Xu, YM; Xue, H; Xue, J; Xue, Z; Yan, R; Yan, SQ; Yan, W; Yan, X; Yan, Z; Yang, C; Yang, D; Yang, F; Yang, FC; Yang, G; Yang, J; Yang, M; Yang, P; Yang, Q; Yang, R; Yang, S; Yang, SJ; Yang, TWW; Yang, X; Yang, Y; Yang, Z; Yao, C; Yao, L; Yao, LP; Yao, M; Yao, T; Yao, W; Yao, Y; Yaseen, T; Yazdani, V; Ye, J; Ye, S; Yerys, BE; Yi, HWL; Yi, JL; Yin, F; Yin, J; Yin, Y; Yin, Z; Yong, ZP; Yongli, S; Yoo, JS; Yoshikawa, N; You, Q; Yu, B; Yu, CQ; Yu, H; Yu, HG; Yu, J; Yu, L; Yu, Q; Yu, X; Yu, Y; Yu, YK; Yu, Z; Yuan, Q; Yuan, R; Yuan, W; Yuan, X; Yuan, Y; Zager, RA; Zagozdzon, A; Zaller, N; Zang, YP; Zappi, ME; Zelikoff, JT; Zeman, T; Zhai, X; Zhan, P; Zhang, B; Zhang, C; Zhang, G; Zhang, H; Zhang, HB; Zhang, J; Zhang, JS; Zhang, L; Zhang, M; Zhang, Q; Zhang, RX; Zhang, S; Zhang, T; Zhang, W; Zhang, WH; Zhang, X; Zhang, XX; Zhang, Y; Zhang, YQ; Zhang, YW; Zhang, Z; Zhang, ZH; Zhao, D; Zhao, FL; Zhao, K; Zhao, L; Zhao, M; Zhao, R; Zhao, S; Zhao, W; Zhao, WG; Zhao, X; Zhao, Y; Zheng, G; Zheng, J; Zheng, S; Zheng, W; Zheng, Y; Zheng, YG; Zhong, Z; Zhou, C; Zhou, D; Zhou, H; Zhou, HY; Zhou, L; Zhou, Q; Zhou, X; Zhou, Y; Zhou, YL; Zhou, Z; Zhu, J; Zhu, L; Zhu, N; Zhu, X; Zhu, XF; Zhu, Y; Zhu, Z | 1 |
Blagden, SP; Kapacee, ZA; Knox, JJ; Lamarca, A; McNamara, MG; Palmer, D; Valle, JW | 1 |
Berjon, A; Brenes, J; Casado, G; Castelo, B; Espinosa, E; Feliu, J; Gallego, A; Hardisson, D; Hernandez, A; Mendiola, M; Ramon-Patino, J; Redondo, A | 1 |
Chung, H; Kim, HS; Kim, JW; Kim, SI; Lee, EJ; Lee, M; Park, NH; Song, YS | 1 |
Fujiwara, H; Koyanagi, T; Machida, S; Saga, Y; Takahashi, S; Takahashi, Y; Takei, Y; Tamura, K; Taneichi, A; Yoshiba, T | 1 |
Kato, K; Matsuoka, A; Nishikimi, K; Otsuka, S; Shozu, M; Takahashi, Y; Tate, S | 1 |
Blagden, SP; Nicum, S | 1 |
Bowering, V; Bruce, JP; Cabanero, M; Chen, E; Cristea, MC; Dhani, NC; Ellard, SL; Fleming, GF; Garg, S; Jenkins, S; Jones, GN; Karakasis, K; Kunos, CA; Lheureux, S; Mantia-Smaldone, G; Olawaiye, AB; Oza, AM; Pugh, TJ; Rath, P; Rodriguez-Canales, J; Stockley, T; Tan, Q; Tracy, M; Udagani, S; Wahner Hendrickson, AE; Wang, L; Weberpals, JI; Welch, S | 1 |
Eleraky, NE; Hasan, OA; Omar, MM; Zaki, RM | 1 |
Di Benedetto, L; Gozzi, E; Lazzeroni, R; Pietranera, M; Raimondi, FM; Raimondi, L; Rossi, L; Spinelli, GP | 1 |
Killock, D | 1 |
Curiel, TJ; Deng, Y; Gupta, HB; Kancharla, A; Kari, S; Kornepati, AVR; Li, R; Osta, E; Padron, AS; Reyes, RM; Sun, X; Svatek, RS; Vadlamudi, R; Wu, B; Zhang, D | 1 |
Goto, M; Hori, K; Ito, K; Nakagawa, M; Ono, H; Onoue, M; Shimoji, K; Shiomi, M; Suzuki, J; Tashima, L; Uragami, K; Yamashita, M; Yoshioka, E | 1 |
Agopsowicz, K; Burlot, C; Cardinal, O; Craig, M; Crosley, P; Farkkila, A; Fu, Y; Heikinheimo, M; Hitt, MM; Jenner, AL; Pihlajoki, M; Potts, KG | 1 |
Cass, I; Kamrava, M; Karlan, B; Kim, S; Li, A; Rimel, BJ; Rogatko, A; Walsh, CS | 1 |
Bartos, P; Bartunkova, J; Chovanec, J; Cibula, D; Fucikova, J; Galluzzi, L; Hassan, HIB; Hein, A; Hraska, M; Hrnciarova, T; Kieszko, D; Klat, J; Knapp, P; Madry, R; Mallmann, P; Markowska, J; Melichar, B; Minar, L; Pecen, L; Pluta, M; Rob, L; Spacek, J; Spisek, R; Streb, J; Valha, P; Wimberger, P | 1 |
Ariyoshi, K; Matsushita, S; Okadome, M; Saito, T; Shimada, T; Shimamoto, K; Shimokawa, M; Yamaguchi, S | 1 |
Blaydorn, L; Coats, J; Farley, JH; Khemka, V; Lynch, CA; McGahey, K; Niu, J; Sangal, A; Waypa, J; Weiss, GJ | 1 |
Bonnetain, F; de la Motte Rouge, T; Kalbacher, E; Lesoin, A; Pautier, P | 1 |
Fernandes Junior, HJ; Graziani, SR; Kalil Filho, R; Maranhão, RC; Morikawa, AT; Van Eyll, BM; Vital, CG | 1 |
Arenare, L; Bergamini, A; Bologna, A; Breda, E; Bryce, J; Cecere, SC; Cinieri, S; Cormio, G; Daniele, G; Di Napoli, M; Ferrandina, G; Gallo, C; Lorusso, D; Mangili, G; Murgia, V; Natale, D; Perrone, F; Piccirillo, MC; Pignata, S; Pisano, C; Raspagliesi, F; Sacco, C; Salutari, V; Scambia, G; Signoriello, S; Sorio, R; Vergote, IB; Wagner, U | 1 |
Gurunathan, S; Peng, QL; Yuan, YG | 1 |
Bonetti, A; Giuliani, J | 1 |
Bruckner, HW; Gurell, D; Hirschfeld, A | 1 |
Bell-McGuinn, K; Cristea, M; Fleming, GF; Gray, HJ; Luo, Y; Martin, LP; McKee, MD; Munasinghe, W; Sullivan, D; Xiong, H | 1 |
Farley, J; Kundranda, MN; Markman, M; Niu, J | 1 |
Chen, GP; Chen, YQ; Hu, JL; Liu, NF; Sun, HY; Yang, Y; Yu, H; Zhu, JQ; Zhu, T | 1 |
Chan, MW; Chang, CC; Chen, HJ; Chen, LY; Huang, RL; Lai, HC; Liew, PL; Su, PH; Wang, YC; Weng, YC | 1 |
Berkowitz, RS; Bonventre, JV; Crum, CP; D'Andrea, AD; Decker, B; Do, KT; Feltmate, CM; Hill, SJ; Horowitz, NS; Kochupurakkal, BS; Konstantinopoulos, PA; Liu, JF; Matulonis, UA; Morizane, R; Muto, MG; Nguyen, H; Nucci, MR; Roberts, EA; Shapiro, GI; Swisher, EM; Worley, MJ; Yang, C | 1 |
Chen, X; Shen, N; Tang, Z; Wang, G; Yang, S; Zhang, D | 1 |
Bryant, A; Gaitskell, K; Goodall, RJ; Lyons, TJ; Morrison, J; Thoma, C; Wiggans, AJ | 1 |
Benigno, BB; Clayton, EA; Huang, C; Matyunina, LV; McDonald, JF; McDonald, LD; Vannberg, F | 1 |
Garcia-Cremades, M; Iversen, PW; Pitou, C; Troconiz, IF | 1 |
Georgoulias, V; Hatzidaki, D; Kalbakis, K; Kentepozidis, N; Kontopodis, E; Kotsakis, A; Kouroussis, C; Polyzos, A; Syrios, J; Vardakis, N | 1 |
Hu, Y; Li, C; Xie, Y; Zeng, Q | 1 |
Burges, A; Colomban, O; Du Bois, A; Freyer, G; Hardy-Bessard, AC; Kurzeder, C; Leary, A; Lortholary, A; Péron, J; Pfisterer, J; Ray-Coquard, I; Tod, M; You, B | 1 |
Bré, J; Chan, TH; Harrison, DJ; Mullen, P; Reynolds, PA; Sarr, A; Um, IH | 1 |
Ahmad, M; Akhlaq, M; Danish, Z; Saeed, H; Saleem, Z; Sattar, S | 1 |
du Bois, A; Harter, P; Heitz, F; Kurzeder, C; Lubbe, D; Pfisterer, J; Plante, M; Vergote, I | 1 |
Dohrmann, T; Izbicki, JR; Jaenicke, F; Kutup, A; Mahner, S; Müller, V; Vashist, YK | 1 |
Altevogt, P; Bretz, NP; Fogel, M; Hazin, J; Herr, I; Keller, S; Moldenhauer, G; Perne, C; Salnikov, AV; Schlange, T | 1 |
Flatten, KS; Huehls, AM; Huntoon, CJ; Karnitz, LM; Kaufmann, SH; Sutor, SL; Wahner Hendrickson, AE | 1 |
Byun, HJ; Kim, BR; Park, SY; Rho, SB; Yoo, HJ | 1 |
Ikeda, Y; Kikuchi, Y; Kita, T; Kudoh, K; Sasaki, N; Takano, M | 1 |
Morishita, F; Okazawa, H; Orisaka, M; Tsuyoshi, H; Yoshida, Y | 1 |
Capellà, G; Casanovas, O; Ginestà, MM; Gracova, K; Graupera, M; Laquente, B; Serrano, T; Viñals, F; Vives, M | 1 |
Beijnen, JH; Huitema, AD; Leijen, S; Schellens, JH; van Werkhoven, E; Veltkamp, SA | 1 |
Lv, X; Pan, ZH; Su, A; Zhang, J; Zhou, QM | 1 |
Adam, J; Pinilla-Dominguez, P; Richardson, J; Robertson, J | 1 |
Khunnarong, J; Manusirivithaya, S; Pataradool, K; Pitakkarnkul, S; Prutthiphongsit, W; Srijaipracharoen, S; Tangjitgamol, S; Thavaramara, T | 1 |
Cheney, DL; Ghandehari, H; Kopeček, J; Larson, N; Ray, A; Yang, J | 1 |
Contreras-Steyls, M; Estrada, D; Gallego, E; Herrera, E; López-Navarro, N; Moyano, B | 1 |
Chen, WJ; Xiong, JP; Yuan, SF; Zhang, LP; Zheng, WE; Zhu, LJ | 1 |
Ariyoshi, K; Eto, T; Okadome, M; Saito, T; Shimamoto, K; Tomita, Y | 1 |
Arena, MG; Barba, M; Corrado, G; Di Lauro, L; Giannarelli, D; Mariani, L; Maugeri-Saccà, M; Paoletti, G; Pizzuti, L; Sergi, D; Tomao, F; Tomao, S; Vici, P; Vincenzoni, C; Vizza, E | 1 |
Bai, J; Fu, S; Guan, R; Huang, Y; Ji, W; Jin, Y; Meng, X; Quan, C; Sun, D; Sun, W; Yu, L; Yu, Y; Zhang, C; Zhao, Y; Zhu, J | 1 |
Abe, T; Fuga, M; Hasegawa, Y; Irie, K; Kawamura, D; Tanaka, T; Tochigi, S; Yanagisawa, T | 1 |
Asna, N; Grisaru, D; Inbar, M; Matcejevsky, D; Safra, T; Shpigel, S; Veizman, A | 1 |
Momeni, M; Veras, L; Zakashansky, K | 1 |
Clements, D; Dielschneider, R; Gujar, SA; Helson, E; Lee, PW; Marcato, P | 1 |
Baba, H; Iida, S; Ishiguro, M; Ishikawa, T; Iwata, N; Kikuchi, A; Kobayashi, H; Okazaki, S; Sugihara, K; Takahashi, H; Uetake, H | 1 |
Sinha, G | 1 |
Aghajanian, C; Blank, S; Goff, B; Husain, A; Nycum, LR; Wang, Y | 1 |
Chen, X; Dai, H; Qian, Z; Wang, Y; Xu, X; Zhao, Y | 1 |
Ashihara, K; Fujiwara, S; Kanemura, M; Kawaguchi, H; Ohmichi, M; Sasaki, H; Takai, M; Tanabe, A; Tanaka, T; Tanaka, Y; Terai, Y; Tsunetoh, S | 1 |
Callahan, MJ; Cobb, B; Cohn, DE; Copeland, LJ; Eisenhauer, EL; Fowler, JM; O'Malley, DM; Salani, R; Sutton, G; Zanagnolo, V | 1 |
Cheung, SS; Hasman, D; Tai, J | 1 |
Aghajanian, C; DeLair, D; Grisham, RN; Hyman, DM; Iasonos, A; Iyer, G; Sala, E; Zhou, Q | 1 |
Chanpanitkitchot, S; Khunnarong, J; Pataradool, K; Srijaipracharoen, S; Tangjitgamol, S; Thavaramara, T | 1 |
Kopeček, J; Sima, M; Yang, J; Zhang, R; Zhou, Y | 1 |
Bryant, C; Massey, AJ; Rawlinson, R | 1 |
Blanco-González, E; Espina, M; Iglesias, T; Montes-Bayón, M; Sierra, LM | 1 |
Liu, LH; Liu, YH; Xu, L; Yang, H | 1 |
Bosetti, R; Ferrandina, G; Marneffe, W; Scambia, G; Vereeck, L | 1 |
Byun, JH; Hong, SH; Jung, KH; Kim, HG; Kim, HY; Kim, KH; Lee, HJ; Lee, NR; Lee, S; Lee, SC; Park, KH; Rha, SY; Woo, IS; Yun, J | 1 |
Bhutia, YD; Cummins, S; Dhar, S; Govindarajan, R; Hooks, SB; Hung, SW; Marrache, S; Mody, H | 1 |
Barton, S; Edwards, SJ; Thurgar, E; Trevor, N | 1 |
Matsumoto, K; Onda, T; Yaegashi, N | 1 |
Ding, T; Liu, XH; Lv, QY; Song, J; Wang, SH; Wang, Y; Wei, MH; Wu, MD; Yang, QH; Zhou, J; Zhou, YF | 1 |
Li, Y; Shang, YM; Yang, Y; Zheng, H | 1 |
Alfredsson, J; Björklund, U; Bykov, VJ; Byström, S; Fransson, Å; Gullbo, J; Hallberg, A; Mohell, N; Uustalu, M; Wiman, KG | 1 |
Berlin, S; Campos, S; Horowitz, N; Krasner, C; Lee, H; Liu, J; Matulonis, U; Obermayer, E; Penson, R; Whalen, C | 1 |
Bevis, KS; Blansit, K; Chan, JK; ElNaggar, A; Fuh, KC; Huh, W; Kapp, DS; Previs, R; Secord, AA; Tillmanns, T | 1 |
Asami, Y; Iiba, M; Kitagawa, R; Kondo, K; Sato, N; Sugita, M; Tadauchi, K; Tsunoda, H; Uenoyama, A | 1 |
Aghajanian, C; Blank, SV; Goff, B; Husain, A; Nycum, LR; Wang, YV | 1 |
Daemen, TA; Dijkgraaf, EM; Goedemans, R; Kroep, JR; Melief, CJ; Nijman, HW; Reyners, AK; Santegoets, SJ; Smit, VT; van der Burg, SH; van der Hoeven, JJ; van Erkel, AR; van Poelgeest, MI; Welters, MJ | 1 |
Bradley, WH; Eng, KH; Hanlon, BM; Szender, JB | 1 |
Inatsu, H; Kondo, Y; Murata, T; Nyomura, S; Takahashi, N; Tokunaga, M; Tomita, K | 1 |
Bourade, V; Chen, E; Doyle, L; Goel, R; Halford, R; Jonker, D; Keller, D; Laurie, SA; Lheureux, S; Oza, AM; Siu, LL; Wang, L | 1 |
Alexandrov, VA; Belyaev, AM; Belyaeva, OA; Bespalov, VG; Kireeva, GS; Kopteva, OS; Krasilnikova, LA; Maidin, MA; Semenov, AL; Stukov, AN; Vasilieva, IN; Vyshinskaya, EA | 1 |
Chekerov, R; Ismaeel, F; Richter, R; Roots, I; Sehouli, J; Siepmann, T; Woopen, H | 1 |
Aftimos, P; Awada, A; Bahleda, R; Bourbouloux, E; Campone, M; Frenel, JS; Gombos, A; Soria, JC; Varga, A | 1 |
du Bois, A; Grabowski, JP; Harter, P; Heitz, F; Heitz, J; Kristensen, G; Pfisterer, J; Pujade-Lauraine, E; Ray-Coquard, I; Reuss, A; Traut, A | 1 |
Fujiwara, K; Hanaoka, T; Hasegawa, K; Iwasa, N; Kurosaki, A; Nagao, S; Nishikawa, T | 1 |
Hanvoravongchai, P; Havanond, P; Khempech, N; Luealon, P; Vasuratna, A | 1 |
Ben Shem, E; Ben Zvi, M; Levy, T; Menczer, J; Peled, O; Schreiber, L; Vaknine, H | 1 |
Adams, DJ; Bansal, V; Kota, R; Kulhari, H; Pooja, D; Reddy, TS; Shukla, R; Sistla, R; Tabor, RF | 1 |
Brody, JR; Daum, GS; DuHadaway, JB; Dunton, CJ; Furuuchi, N; Huang, YH; Jimbo, M; Leiby, BE; Peng, W; Pirritano, A; Sawicki, JA | 1 |
Aglietta, M; Calogero, R; De Simone, M; Di Renzo, MF; Erriquez, J; Katsaros, D; Mittica, G; Olivero, M; Ponzone, R; Scalzo, MS; Vaira, M; Valabrega, G | 1 |
Abramian, A; Arden, JM; Ayub, TH; Doeser, A; Hecking, T; Hoeller, T; Kaiser, C; Keyver-Paik, MD; Kuhn, W; Lüders, C; Thiesler, T | 1 |
Enas, NH; Friberg, LE; Gueorguieva, I; Zecchin, C | 1 |
Bastiere-Truchot, L; Berton-Rigaud, D; Colombo, N; Del Campo, JM; du Bois, A; Gadducci, A; García, Y; González-Martín, A; Kiermaier, A; Kurzeder, C; Mahner, S; Marmé, F; Martin, N; Ortega, E; Ottevanger, P; Pautier, P; Rau, J; Selle, F | 1 |
Almorsy, W; Elshebeiny, M | 1 |
Chan, C; Duan, X; Han, W; Lin, W; Poon, C | 1 |
Belau, AK; Bover-Barcelo, I; Canzler, U; Chekerov, R; Gonzalez-Martin, A; Hanker, LC; Harter, P; Hilpert, F; Keil, E; Klare, P; Kurzeder, C; Mahner, S; Meier, W; Petru, E; Reinthaller, A; Richter, R; Sehouli, J; Wimberger, P; Woopen, H; Zeimet, A | 1 |
Fujiwara, H; Machida, S; Matsubara, S; Morisawa, H; Nagashima, T; Saga, Y; Takahashi, S; Takahashi, Y; Takei, Y; Taneichi, A | 1 |
Du, X; Li, X; Liu, N; Sheng, X; Wang, F; Yu, H | 1 |
Chao, Y; Hou, MC; Lan, KH; Lee, SD; Lee, WP; Li, CP; Lin, HC | 1 |
Arenare, L; Bergamini, A; Cecere, SC; Della Pepa, C; Di Napoli, M; Facchini, G; Gargiulo, P; Mangili, G; Pignata, S; Pisano, C; Rossetti, S; Tambaro, R | 1 |
Fang, Y; Kopeček, J; Li, Y; Pan, H; Yang, J; Zhang, L; Zhang, R | 1 |
Doki, Y; Haraguchi, N; Hata, T; Kudo, T; Matsuda, C; Mizushima, T; Mori, M; Nishimura, J; Ohara, N; Satoh, T; Takahashi, H; Yamamoto, H | 1 |
Blackwood, E; Cao, Y; Evangelista, M; Klijn, C; Lee, HJ; Pham, V; Settleman, J; Stokoe, D; Wilson, C | 1 |
Bhosale, P; Dalton, HJ; Fleming, ND; Gershenson, DM; Schmeler, KM; Sun, CC | 1 |
Goff, BA; Holmberg, LA; Kurland, BF; Veljovich, D | 1 |
Camara, O; Keil, E; Klare, P; Lichtenegger, W; Oskay-Oezcelik, G; Paulenz, A; Sehouli, J; Sommer, H; Stauch, M; Stengel, D; Zeimet, AG | 1 |
Goodman, A; Ko, E; Lee, S | 1 |
Eisenkop, SM; McAlpine, JN; Spirtos, NM | 1 |
Etoh, T; Hoshiai, H; Koike, E; Nakai, H; Watanabe, Y | 1 |
Backes, FJ; Cohn, DE; Copeland, LJ; Fowler, JM; O'Malley, DM; Richardson, DL; Seamon, LG; Zanagnolo, V | 1 |
Aghajanian, CA; Fury, M; Gerst, S; Goss, TL; Hensley, ML; Konner, J; Larkin, J; Orlando, M; Sabbatini, P; Tai, DF | 1 |
Adrover Cebrian, E; Alonso Carrion, L; Arcusa Lanza, A; Bover Barcelo, I; Calvo Garcia, E; Casado Herraez, A; Churruca Galaz, C; Fabregat i Mayol, X; Gonzalez Martin, A; Herrero Ibañez, A; Mellado, B; Ojeda Gonzalez, B; Poveda Velasco, A; Rubio Perez, MJ | 1 |
Alberola Candel, V; Esteban González, E; Gasent Blesa, JM; Martín Algarra, S; Provencio Pulla, M | 1 |
Agostini, C; Aleba, A; Cretin, J; Dohollou, N; Ferrero, JM; Fric, D; Geay, JF; Gouttebel, MC; Haddad-Guichard, Z; Hardy-Bessard, AC; Lévy, E; Orfeuvre, H; Paraiso, D; Provencal, J; Pujade-Lauraine, E; Ray-Coquard, I; Salvat, J; Weber, B | 1 |
Hoskins, PJ | 1 |
Accario-Winslow, C; Alberts, DS; Argenta, PA; Bookman, MA; Brady, MF; Burger, RA; Colombo, N; De Geest, K; Fowler, JM; Friedlander, M; Harper, PG; McGuire, WP; Mutch, DG; Roth, LM; Swart, AM; Trimble, EL | 1 |
Apte, S; Boren, T; Chan, G; Chen, DT; Dressman, H; Hakam, A; Kamath, SG; Lancaster, JM; Wenham, R; Xiong, Y | 1 |
Beneduce, G; Breda, E; Di Maio, M; Forestieri, V; Gallo, C; Gebbia, V; Greggi, S; Lauria, R; Losito, S; Morabito, A; Pignata, S; Pisano, C; Scalone, S; Scaltriti, L; Sorio, R; Zagonel, V | 1 |
Brown, JV; Goldstein, BH; John, CR; Markman, M; Micha, JP; Rettenmaier, MA | 1 |
Chekerov, R; Fotopoulou, C; Karavas, A; Lichtenegger, W; Sehouli, J; Trappe, R | 1 |
Frumovitz, M; Han, LY; Rashid, A; Ricks, AM | 1 |
Adachi, S; Akiyama, M; Fujita, H; Hosokawa, K; Itani, Y; Ito, K; Tabata, T; Takeuchi, S; Tsubamoto, H | 1 |
Chovanec, J; Dorr, A; Habetinek, V; Helpianska, L; Horvathova, D; Jancokova, I; Koza, I; Kroslakova, D; Lalabova, R; Laluha, A; Magdin, D; Malec, V; Minarik, T; Packan, T; Rakicka, G; Sevcik, L; Spacek, J; Stresko, M; Sufliarsky, J; Svetlovska, D; Tkacova, V | 1 |
de la Peña, FA; Garcia-Martinez, E; Vicente, E; Zafra, M | 1 |
Emerich, J; Gołka, KA; Kobierski, J; Milczek, T | 1 |
Bernstein Molho, R; Grisaru, D; Inbar, M; Levy, T; Menzcher, J; Safra, T | 1 |
Alexandrescu, DT; Dasanu, CA; Herzog, TJ | 1 |
Felekouras, E; Giannakopoulos, K; Giannopoulos, A; Gogas, H; Karatzas, T; Lagadas, A; Papadopoulos, O; Polyzos, A; Polyzos, K; Tsavaris, N; Tsigris, C | 1 |
Danesi, R; Del Tacca, M; Ferlini, C; Ferrandina, G; Mey, V; Nannizzi, S; Petrillo, M; Ricciardi, S; Scambia, G | 1 |
Bourgeois, H; Chevalier-Place, A; Delva, R; Guardiola, E; Henry-Amar, M; Joly, F; Mayer, F; Pautier, P; Petit, T; Sevin, E | 1 |
Alvarez, RD; Gallion, HH; García, AA; Kilgore, LC; Lucci, J; Mannel, R; Numnum, TM; Orlando, M; Tai, DF; Zou, SX | 1 |
Amler, LC; Dizon, DS; Glenn, D; Gold, MA; Januario, T; Kelsey, S; Lin, CY; Makhija, S; Matulonis, U; Ng, K; Paton, V; Sliwkowski, MX; Strauss, A; Ueland, FR | 1 |
Auner, V; Horvat, R; Oskay-Oezcelik, G; Sehouli, J; Speiser, P; Zeillinger, R | 1 |
Daniele, A; Ferrero, A; Fuso, L; Logrippo, V; Perotto, S; Spanu, PG; Zola, P | 1 |
Groe, R; Grothey, A; Kantelhardt, EJ; Kegel, T; Koelbl, H; Mueller, LP; Schmoll, HJ; Seliger, G; Strauss, HG; Thomssen, C | 1 |
Besova, NS; Borisov, VI; Bychkov, MB; Chitiia, LV; Filatova, LV; Garin, AM; Gershanovich, ML; Gorbunova, VA; Gurov, SN; Makhnova, EV; Nebol'sin, VE; Raĭkhlin, NT; Sitdikova, SM; Topchieva, SV; Treshchalina, EM; Verebnikova, NV | 1 |
Amarantidis, K; Chamalidou, E; Chatzaki, E; Dimopoulos, P; Kakolyris, S; Karakitsos, P; Neanidis, K; Pitsiava, D; Tentes, A; Xenidis, N | 1 |
Agarwal, R; Carty, K; Gabra, H; Gore, ME; Gourley, C; Kaye, SB; Parkin, DE; Paul, J; Perren, TJ; Reed, N; Rustin, GJ | 1 |
Athanasas, G; Economopoulos, T; Koumarianou, A; Macheras, A; Papaxoinis, G; Pectasides, D; Pectasides, E; Pliarchopoulou, K; Psyrri, A; Xiros, N | 1 |
Bifulco, G; Carlomagno, C; De Placido, S; Insabato, L; Lauria, R | 1 |
Bertelsen, K; Christensen, RD; Keldsen, N; Lindegaard, JC; Lund, B; Mellemgaard, A; Mirza, MR | 1 |
Arcuri, C; Arisi, E; Caffo, O; Caldara, A; Ferro, A; Galligioni, E; Griso, C; Murgia, V; Scalone, S; Sorio, R | 1 |
Cree, IA; Gabriel, FG; Glaysher, S; Johnson, P; Knight, LA; Narayanan, A; Parker, K; Polak, M; Poole, M | 1 |
Gabra, H; Hartley, JA; James, LE; Jayson, GC; Jitlal, M; Ledermann, JA; Rustin, GJ; Spanswick, VJ | 1 |
Avall-Lundqvist, E; Burges, A; du Bois, A; Gropp, M; Hardy-Bessard, AC; Harter, P; Herrstedt, J; Huober, J; Jackisch, C; Jelic, S; Joly, F; Kristensen, G; Kurzeder, C; Müller, HH; Pfisterer, J; Pujade-Lauraine, E; Sehouli, J; Staehle, A; Weber, B; Wimberger, P | 1 |
Brigulová, K; Cervinka, M; Sedláková, I; Tošner, J | 1 |
Lin, YG; Matsuo, K; Roman, LD; Sood, AK | 1 |
Elit, L; Hirte, HW; Macalpine, K; Oza, AM; Schilder, RJ; Wang, L; Welch, SA; Wright, JJ | 1 |
Aneiros-Fernandez, J; Arias-Santiago, S; Husein-ElAhmed, H; Naranjo-Sintes, R | 1 |
Grendys, EC; Holloway, RW; Lefebvre, P; McMeekin, S; Vekeman, F | 1 |
Gupta, P; Khanna, AK; Khanna, R; Singh, S | 1 |
Jang, JS; Kim, HJ; Kim, KH; Kim, MC; Kim, SH; Kwon, HC; Kwon, KA; Lee, HS; Lee, S; Oh, SY | 1 |
Benz, M; Czernin, J; Fueger, B; Phelps, ME; Radu, CG; Satyamurthy, N; Schiepers, C; Schwarzenberg, J; Tran, AQ; Witte, ON | 1 |
Clamp, AR; Evans, S; Griffiths, RW; Hasan, J; Jayson, GC; Kumaran, GC; Mitchell, CL; Welch, RS; Zee, YK | 1 |
Hilpert, F; Jonat, W; Kuemper, C; Mundhenke, C; Schaefer, F; Strauss, A | 1 |
Chu, P; DU, XL; Li, DP; Liu, NF; Lu, CH; Sheng, XG; Zhou, CX | 1 |
Chang, QY; Li, M; Li, XG; Li, YF; Liu, J; Song, PP; Tian, HM; Wang, XB; Wu, LY; Zhang, W; Zhao, D | 1 |
Blomfield, P; Bohmer, R; Chan, WS; McIntosh, R | 1 |
Choi, YJ; Kim, JS; Kim, ST; Kim, YH; Oh, SC; Park, KH; Seo, JH; Shin, SW | 1 |
Berros, JP; Blay, P; Crespo, G; Esteban, E; Fernández, Y; Fonseca, PJ; Fra, J; Lacave, AJ; Losa, R; Luque, M; Muriel, C; Sanmamed, M; Sierra, M; Villanueva, N | 1 |
Al-Barrak, J; Gilks, CB; Hoskins, P; Lau, H; Santos, JL; Swenerton, KD; Tinker, A | 1 |
Ambrosone, CB; Bookman, M; Darcy, KM; Deloia, JA; Gallion, H; Krivak, TC; Tian, C | 1 |
Chen, DY; Qi, Q; Zhao, WY | 1 |
Aoki, D; Bartholomeusz, C; Ishihara, H; Itamochi, H; Kigawa, J; Suzuki, N; Terakawa, N; Ueno, NT; Walker, CL; Yoshida, T | 1 |
Brüning, A; Burger, P; Gingelmaier, A; Mylonas, I | 1 |
Bruzzone, M; Centurioni, MG; Cosso, M; Cristoforoni, P; Ferrarini, M; Giannelli, F; Giglione, P; Gualco, M; Merlo, DF; Miglietta, L | 1 |
Armstrong, DK; Bristow, RE; Diaz-Montes, TP; Giuntoli, RL | 1 |
Hatakeyama, K; Iiai, T; Kameyama, H; Nogami, H; Saitou, K; Umezu, H; Yagi, Y | 1 |
Lagerstedt, E; Mäenpää, J; Seppänen, J; Staff, S | 1 |
Bryant, A; Gaitskell, K; Haldar, K; Kehoe, S; Morrison, J; Nicum, S | 1 |
Burkholder, TL; Chen, MD; Gill, JF; Gordon, AN; Hines, J; Homesley, HD; Janicek, MF; Lim, PC; McMeekin, S; Obasaju, CK; Orlando, M; Tai, DF; Teneriello, M; Vaccarello, L; Wang, Y; Zhao, L | 1 |
Camoriano, JK; Colon-Otero, G; Erlichman, C; Glaser, G; Haluska, P; Hendrickson, AE; Ivy, SP; Karnitz, LM; Kaufmann, SH; Oberg, AL; Peethambaram, PP | 1 |
Eichler, K; Gruber-Rouh, T; Lehnert, T; Naguib, NN; Nour-Eldin, NE; Vogl, TJ; Zangos, S | 1 |
Ambrosone, CB; Armstrong, DK; Bookman, MA; Darcy, KM; Davis, W; DeLoia, JA; Gallion, H; Krivak, TC; Moysich, K; Tian, C; Zhao, H | 1 |
Enomoto, T; Fujita, M; Kimura, T; Kobayashi, E; Tsutsui, T; Ueda, Y; Yoshino, K | 1 |
Orlova, RV; Protasova, AE | 1 |
Altevogt, P; Dieckmann, C; Kiefel, H; Korniienko, O; Krüger, A; Moldenhauer, G; Salnikov, A; Schäfer, H; Sebens, S | 1 |
Dorigo, O; Eng, C; Fekete, M; Santiskulvong, C | 1 |
Belmont, LD; Fairbrother, WJ; Peale, FV; Tan, N; Wong, M; Yue, P; Zha, J | 1 |
Bookman, MA | 4 |
Thigpen, T | 3 |
Facio, G; Garcia, AA; Muderspach, L; Pham, H; Roman, L; Yessaian, A | 1 |
Cao, K; Dai, J; Li, L; Li, MY; Lin, C; Nie, CL; Wang, BN; Yang, J; Yang, Y; Yuan, Z; Zhang, J | 1 |
Cheewakriangkrai, C; Manopunya, M; Suprasert, P | 1 |
Furuya, K; Goto, T; Kato, M; Miyamoto, M; Sasaki, N; Takano, M | 1 |
Apte, SM; Bicaku, E; Bou Zgheib, N; Chen, DT; Chon, HS; Cubitt, CL; Gonzalez-Bosquet, J; Hakam, A; Judson, PL; Lancaster, JM; Marchion, DC; Sawah, EA; Stickles, XB; Wenham, RM; Xiong, Y | 1 |
Arsenijevic, L; Atanackovic, J; Jeftovic, M; Jeremic, K; Stefanovic, A; Stojnic, J; Zecevic, N | 1 |
Barash, I; Baumgartner, R; Blank, S; Curtin, JP; Gabizon, A; Kopolovic, J; Kwa, M; Michael, J; Muggia, F; Puzanov, I; Rosengarten, O; Shavit, L | 1 |
Basile, S; Bellati, F; Benedetti-Panici, P; Di Donato, V; Donfrancesco, C; Graziano, M; Marchetti, C; Palaia, I; Pernice, M; Perniola, G; Tomao, F | 1 |
Byun, HJ; Kim, BR; Park, SY; Rho, SB; Yoo, R | 1 |
Arcand, SL; Caceres, KY; Cyr, L; de Ladurantaye, M; Delvoye, N; Létourneau, IJ; Mes-Masson, AM; Meunier, L; Portelance, L; Provencher, DM; Quinn, MC; Shen, Z; Tonin, PN; Wang, LL | 1 |
Enomoto, T; Fujita, M; Hiramatsu, K; Kimura, T; Kiyohara, Y; Kobayashi, E; Tsutsui, T; Ueda, Y; Yoshino, K | 1 |
Bagnobianchi, A; Bingham, JP; Craddock, C; Hartley, JA; Hochhauser, D; Kiakos, K; Ledermann, JA; Lowe, HL; Newton, C; Spanswick, VJ | 1 |
Katsumata, N; Maejima, A | 1 |
Kitao, A; Matsumoto, K | 1 |
Chandran, S; Chennazhi, K; Lakshmanan, VK; Nair, SV; Pavithran, K; Praveen, G; Snima, KS | 1 |
Blackhurst, DW; Gill, SE; Puls, LE; Shrum, KJ; Thompson, LK | 1 |
Goto, T; Ikeda, Y; Kikuchi, Y; Kita, T; Kouta, H; Kudoh, K; Oda, K; Sasaki, N; Takano, M | 1 |
Cruickshank, S; Delmore, JE; diZerega, GS; Drummond, L; Peterson, KJ; Pham, H; Reed, E; Rodgers, KE; Schwartz, BM | 1 |
Allott, CP; Boxall, FE; Kelland, LR; Rogers, P; Stephens, TC | 1 |
Armand, JP; Faivre, S; Kayitalire, L; Le Chevalier, T; Lhommé, C; Lokiec, F; Monnerat, C; Novello, S; Pautier, P; Raymond, E; Ruffié, P; Taieb, J | 1 |
Joerger, M; Pestalozzi, BC; Walter, RB | 1 |
Fuxius, S; Mansouri, K; Mross, K; Unger, C | 1 |
Arcusa, A; Balil, A; Batiste-Alentorn, E; Carrasco, EM; Cirera, L; Font, A; Nogué, M; Perez-Gracia, JL; Tusquets, I | 1 |
Blohmer, J; Camara, O; Elling, D; Heinrich, G; Hindenburg, HJ; Klare, P; Ledwon, P; Lichtenegger, W; Oskay, G; Sehouli, J; Stengel, D | 1 |
Gutierrez, M; Lhomme, C; Pautier, P | 1 |
André, T; Culine, S; Epaud, C; Gligorov, J | 1 |
Bergman, AM; Peters, GJ; Pinedo, HM; Smid, K; Van Moorsel, CJ; Voorn, DA | 1 |
Eaton, S; Fusco, N; Mossbruger, K; Rodriguez, M; Rose, PG; Smrekar, M | 1 |
Brewer, CA; DiSaia, PJ; Evans, SS; Kidder, WA; Minor, DR; Nagourney, RA; Radecki, S; Sommers, BL | 1 |
Adachi, S; Iijima, T; Ito, K; Kimura, T; Nakatsuji, Y; Nobunaga, T | 1 |
Cullinane, C; Moufarij, MA; Phillips, DR | 1 |
Amant, F; Berteloot, P; D'Agostino, G; Scambia, G; Vergote, I | 1 |
Bilgin, T; Ozalp, S; Ozerkan, K; Vardar, MA; Yalçin, OT; Zorlu, G | 1 |
Makhnova, EV | 1 |
Gershanovich, ML; Makhnova, EV | 1 |
Berghe, KV; Berkenblit, A; Cannistra, SA; Feyler, H; Kim, Y; Niloff, J; Tung, N | 1 |
Goff, BA; Greer, BE; Jacobs, A; Storer, B; Thompson, T | 1 |
Heimans, JJ; Hoekman, K; Postma, TJ; Verstappen, CC | 1 |
Blohmer, J; Kaubitzsch, S; Lichtenegger, W; Oskay, G; Sehouli, J; Stengel, D | 2 |
Bookman, M; Copeland, LJ; Trimble, E | 1 |
Mutch, DG | 1 |
Fowler, WC; Van Le, L | 1 |
Belinson, J; Kulp, B; Markman, M; Peterson, G; Webster, K; Zanotti, K | 2 |
Breda, E; D'Agostino, G; Ferrandina, G; Gbaguidi, N; Lorusso, D; Ludovisi, M; Mancuso, S; Scambia, G; Testa, A | 1 |
Beauduin, M; Belpomme, D; Canon, JL; De Pauw, A; Gauthier, S; Janssens, J; Kayitalire, L; Krakowski, I; Moreau, V; Petit, T | 1 |
D'Agostino, G; Ferrandina, G; Fruscella, E; Gallo, D; Scambia, G | 1 |
Berkowitz, R; Campos, S; Colella, T; Duska, L; Fuller, A; Gore, S; Lee, H; Matulonis, U; Roche, M; Seiden, MV | 1 |
Kennedy, AW; Khuntia, D; Markman, M; Schwartz, BM | 1 |
Kaye, SB; McMahon, L; Paul, J; Reed, N; Vasey, PA | 1 |
Bookman, MA; Herzog, TJ; Look, KY; Rocereto, T; Schol, J; Vinters, J | 1 |
Aravantinos, G; Briassoulis, E; Dimopoulos, MA; Fountzilas, G; Gika, D; Kalofonos, C; Moulopoulos, LA; Papadimitriou, CA | 1 |
Geisler, JP; Manahan, KJ; Schraith, DF; Sorosky, JI | 1 |
Pfisterer, J | 1 |
Aghajanian, C; Ben-Porat, L; Chi, DS; Hensley, ML; Hoppe, B; Prasad, M; Sabbatini, P | 1 |
Barlow, C; Fennell, D; Gallagher, C; Ismay, J; Nystrom, M; Oesterling, C | 1 |
Friedlander, M; Harnett, P; Martin, A; Phillips, KA; Quinn, M; Richardson, G; Rischin, D | 1 |
Bahador, A; Facio, G; Garcia, AA; Jeffers, S; Kim, DY; O'Meara, A; Roman, L | 1 |
Aghajanian, C; Anderson, S; Bloss, J; Chi, D; Dizon, D; Dupont, J; Leitao, M; O'Flaherty, C; Sabbatini, P; Spriggs, D; Venkatraman, E | 1 |
A'Hern, R; Cole, C; Everard, M; Gibbens, I; Gore, M; Hall, G; Harries, M; Jenkins, A; Kaye, S; Moss, C; Perren, T; Pizzada, O; Shah, R | 1 |
Piura, B | 1 |
Al-Madhoun, AS; Eriksson, S; Loves, WJ; Padron, JM; Peters, GJ; Talianidis, I; van der Wilt, CL | 1 |
Piura, B; Rabinovich, A | 1 |
Burger, RA; Falkner, CA; Hunter, M; Monk, BJ; Tewari, D | 1 |
Cesák, T; Kohlová, T; Melichar, B; Nová, M; Urminská, H | 1 |
Ho, ES; Hung, MJ; Hwang, SF; Ke, YM; Liu, FS; Lu, CH | 1 |
Birk, CL; Brown, JV; Goldstein, BH; Graham, C; Mattison, J; Micha, JP; Rettenmaier, MA | 1 |
Hansen, SW; Larsen, FO | 1 |
Baba, T; Fujii, S; Mandai, M | 1 |
Cree, IA; Di Nicolantonio, F; Glaysher, S; Johnson, P; Knight, LA; Mercer, S; Sharma, S; Whitehouse, P | 1 |
Herzog, TJ | 1 |
Driscoll, DL; Lele, S; Marchetti, D; Odunsi, K; Rodabaugh, K; Villella, J | 1 |
Bader, K; Brown, JV; Goldstein, BH; Graham, C; Markman, M; Mattison, JA; Micha, JP; Rettenmaier, MA | 1 |
Aieta, M; De Giorgi, U; Fochessati, F; Marangolo, M; Paoluzzi, L; Papiani, G; Rosti, G; Valduga, F | 1 |
Akimoto, T; Hasegawa, K; Kishimoto, Y; Morimoto, Y; Sawai, T | 1 |
Choi, M; Fogoros, S; Griffith, KA; Hu, YY; Liu, JR; Lucas, PC; Williams, J | 1 |
Beslija, S; Fitzthum, E; Hayden, A; Kose, MF; Krejcy, K; Melemed, A; Minarik, T; Saip, P; Sufliarsky, J; Tulunay, G | 1 |
Belau, A; Burges, A; du Bois, A; Elser, G; Jackisch, C; Lueck, HJ; Olbricht, S; Pfisterer, J; Richter, B; Schmalfeldt, B; Schroeder, W; Staehle, A; Wagner, U | 1 |
Ditto, A; Fontanelli, R; Grijuela, B; Hanozet, F; Kusamura, S; Raspagliesi, F; Scibilia, G; Scollo, P; Solima, E; Spatti, G; Vecchione, F; Zanaboni, F | 1 |
Blessing, JA; Darcy, KM; Garcia, AA; Husseinzadeh, N; Lenz, HJ; Mannel, RS; Miller, DS | 1 |
Herzog, TJ; Lewin, SN; Liapis, H; Mutch, DG; Whitcomb, BP | 1 |
Chen, DT; Desmond, RA; Hemminki, A; Kanerva, A; Kangasniemi, L; Raki, M; Ranki, T; Ristimaki, A; Sarkioja, M | 1 |
Arora, R; Awasthy, BS; Fuloria, J; Ganesh, N; Gupta, SK; John, S; Naik, R; Selvamani, B | 1 |
Adamo, V; Breda, E; D'Agostino, G; Ferrandina, G; Lorusso, D; Ludovisi, M; Paris, I; Pezzella, G; Pisconti, S; Scambia, G; Testa, A; Zanghi, M | 1 |
Ozols, RF | 4 |
Chen, MD; Fleming, GF; Horowitz, I; Mitchell, S | 1 |
Duska, L; He, X; Klein, A; Mallett, A; Roche, M; Seiden, MV; Supko, JG | 1 |
Grénman, SE; Jalkanen, JT; Kuoppala, TA; Leminen, AO; Mäenpää, JU; Puistola, US; Vuolo-Merilä, PM; Yliskoski, MH | 1 |
Ahmad, T; Gibbens, I; Gore, M; Habeshaw, T; Hubner, R; Kaye, S; Keyzor, C; Rothermundt, C | 1 |
Brown, S; Chen, EX; Chin, SF; Duran, I; Nottage, M; Oza, AM; Pond, GR; Siu, LL; Sturgeon, J | 1 |
Comijn, EC; Lakerveld, B; Noordhuis, P; Peters, GJ; Pinedo, HM; Smid, K; Van der Vijgh, WJ; Van Moorsel, CJ; Voorn, D; Weaver, D; Willey, JC | 1 |
Poveda, A | 1 |
Lehoczky, O | 1 |
Markman, M | 2 |
Alvero, AB; Brown, D; Chen, W; Garg, M; Kelly, G; Mor, G; O'Malley, D; Rutherford, T | 1 |
Altevogt, P; Debatin, KM; Edler, L; Gutwein, P; Herr, I; Marmé, A; Mattern, J; Rittgen, W; Wenger, T; Zhang, C | 1 |
Atkinson, R; Coleman, R; Kaye, S; Lewsley, L; Osborne, R; Parkin, D; Paul, J; Reed, NS; Rustin, GJ; Symonds, R; Vasey, PA | 1 |
Angleitner-Boubenizek, L; Deibl, M; Marth, C; Petru, E; Reinthaller, A; Stempfl, A; Volgger, B; Zeimet, AG | 1 |
Aghajanian, C; Chi, DS; Correa, DD; Dupont, J; Hensley, ML; Sabbatini, P; Spriggs, D; Thaler, H; Venkatraman, E; Wilton, A | 1 |
Kose, MF; Meydanli, MM; Tulunay, G | 1 |
Atkinson, N; Bodurka, DC; Branham, D; Gershenson, DM; Jenkins, AD; Sun, CC; Verschraegen, C; Wolf, JK | 1 |
Alexandre, J; Chapron, C; Chopin, N; Goldwasser, F; Moachon, L | 1 |
Bartolini, S; Cappuzzo, F; Finocchiaro, G; Gioia, V; Toschi, L | 1 |
Baek, JH; Chae, YS; Cho, GJ; Choi, YJ; Chung, JS; Jeon, SB; Jung, HY; Kim, DH; Kim, JG; Lee, KB; Shin, HJ; Sohn, SK; Yu, W | 1 |
Cheong, KA; Chrystal, K; Galani, E; Gallagher, C; Harper, PG; Lofts, F; Marx, GM; Steer, CB; Strickland, AH; Thomas, H; Yip, D | 1 |
Blessing, JA; Brewer, CA; Hanjani, P; Morgan, M; Nagourney, RA | 1 |
Odicino, F; Pasinetti, B; Pecorelli, S; Tisi, G | 1 |
Ledermann, JA; Pfisterer, J | 1 |
Economopoulos, T; Pectasides, D; Pectasides, M; Psyrri, A | 1 |
Buesa, JM; Esteban, E; Gión, MO; Losa, R; Sierra, MI | 1 |
Neale, G; Qureshi, F | 1 |
Gibb, RK; Hagemann, A; Mutch, DG; Norris, L; Powell, MA; Rader, JS; Viviano, D; Wright, JD | 1 |
Boaz, M; Brenner, J; Golan, A; Grisaru, D; Hayat, H; Inbar, M; Levy, T; Menczer, J; Ron, I; Safra, T | 1 |
Case, AS; Estes, JM; Partridge, EE; Rocconi, RP; Straughn, JM | 1 |
Campos, S; Duska, LR; Falke, R; Krasner, CN; Lee, H; Matulonis, UA; Penson, RT; Roche, M; Seiden, MV; Smith, LM | 1 |
Di Stefano, A; Fanfani, F; Lorusso, D; Scambia, G | 1 |
Arcuri, C; Galligioni, E; Griso, C; Sorio, R | 1 |
Götz, C; Harlozinska, A; Kartarius, S; Montenarh, M; Touma, R | 1 |
Fan, W; Kraft, AS; Sui, M; Xiong, X | 1 |
Akel, A; Bachmann, C; Dreischer, P; Eisele, K; Gulbins, E; Huober, J; Kempe, DS; Klarl, BA; Lang, F; Lang, PA; Niemoeller, OM; Sobiesiak, M; Wieder, T | 1 |
Bentley, J; du Bois, A; Eisenhauer, E; Emerich, J; Hirte, H; Jackisch, C; Kimmig, R; Kuhn, W; Lacave, AJ; Le, T; Lück, HJ; Olbricht, S; Pfisterer, J; Plante, M; Rochon, J; Stähle, A; Stuart, G; Vergote, I; Wagner, U; Zimmermann, AH | 1 |
Lehoczky, O; Pulay, T | 1 |
Bamias, A; Bozas, G; Dimopoulos, MA; Efstathiou, E; Gika, D; Koutsoukou, V; Papadimitriou, CA | 1 |
Ilanchadran, A; Tan, TY; Tay, SK | 1 |
DeVita, VT | 1 |
Meerum Terwogt, JM; Rodenhuis, S; Schellens, JH; van Boven, HH; van den Heuvel, MM; Veltkamp, SA | 1 |
Brames, MJ; Einhorn, LH; Juliar, B; Williams, SD | 1 |
Aghajanian, C; Chi, DS; Colevas, AD; Derosa, F; Dizon, D; Dupont, J; Hensley, ML; Sabbatini, P; Spriggs, D; Venkatraman, E | 1 |
Brown, JV; Goldstein, BH; Graham, C; Hu, JC; Markman, M; Micha, JP; Rettenmaier, MA | 1 |
Corrado, G; Ferrandina, G; Legge, F; Mey, V; Nannizzi, S; Petrillo, M; Ricciardi, S; Scambia, G | 1 |
Komiyama, S; Kurahashi, T; Kuwabara, Y; Mikami, M; Murakami, I; Nakamura, M; Tanaka, K | 1 |
Gordon, AN; Goss, T; Marciniack, M; McMeekin, SD; Mutch, DG; Naumann, RW; Orlando, M; Scribner, DR; Secord, AA; Teneriello, MG; Wang, Y | 1 |
Havrilesky, LJ; Kulasingam, S; Myers, E; Secord, AA | 1 |
Aravantinos, G; Economopoulos, T; Gaglia, A; Gouveris, P; Koumarianou, A; Papaxoinis, G; Pectasides, D; Pectasides, E; Psyrri, A; Sykiotis, C; Xiros, N | 1 |
Kad, R; Kalra, N; Osama, S | 1 |
Bützow, R; Chen, DT; Desmond, RA; Hemminki, A; Kanerva, A; Raki, M; Särkioja, M | 1 |
Huang, HF; Lang, JH; Pan, LY; Peng, P; Shen, K; Wu, M; Yang, JX | 1 |
Germano, D; Manzione, L; Rosati, G | 1 |
Fujiwara, S; Ino, K; Kajiyama, H; Kato, S; Kikkawa, F; Nakamura, S; Nawa, A; Shibata, K; Suzuki, K | 1 |
Breda, E; Del Medico, P; Ferrandina, G; Katsaros, D; Lorusso, D; Ludovisi, M; Pignata, S; Priolo, D; Savarese, A; Scaltriti, L; Scambia, G | 1 |
Carone, V; Corrado, G; Ferrandina, G; Ludovisi, M; Petrillo, M; Scambia, G | 1 |
Behne, MJ; Brüllke, N; Hauswirth, U; Menz, A; Moll, I; Müllerleile, U | 1 |
Choi, SH; Han, SS; Kang, SB; Kim, JW; Lee, HP; Lee, YK; Park, NH; Song, YS | 1 |
Aydiner, A; Derin, D; Guney, N; Tas, F; Topuz, E | 1 |
Eriksson, S; Peters, GJ; Ruiz van Haperen, VW; Stegmann, AP; Veerman, G | 1 |
Boven, E; Braakhuis, BJ; Peters, GJ; Ruiz van Haperen, VW; Veerman, G | 1 |
Bergman, AM; Braakhuis, BJ; Kuiper, CM; Peters, GJ; Ruiz van Haperen, VW; Veerman, G | 1 |
Neijt, JP | 1 |
Bergman, AM; Kuiper, CM; Peters, GJ; Ruiz van Haperen, VW; Veerman, G | 1 |
Eisenhauer, EA; Hansen, HH; Hansen, M; Neijt, JP; Piccart, MJ; Sessa, C; Thigpen, JT | 1 |
Hansen, M; Hansen, OP; Lund, B; Neijt, JP; Theilade, K | 2 |
Boven, E; Noordhuis, P; Peters, GJ; Ruiz van Haperen, VW; Veerman, G; Vermorken, JB | 1 |
Boven, E; Eriksson, S; Hermsen, M; Peters, GJ; Pinedo, HM; Ruiz van Haperen, VW; Stegmann, AP; Veerman, G; Vermorken, JB | 1 |
Boven, E; Erkelens, CA; Hatty, SA; Pinedo, HM; Schipper, H | 1 |
Fields, AL; Goldberg, GL; Runowicz, CD | 1 |
Peters, G; Pinedo, HM; van Haperen, VW; Veerman, G; Vermorken, JB | 1 |
Bokemeyer, C; Daikeler, T; Kanz, L; Maas, K | 1 |
Lund, B; Neijt, JP | 1 |
Francis, PA; Michael, M; Millward, MJ; Rischin, D; Shapiro, JD; Toner, GC; Walcher, V | 1 |
Eisenhauer, EA; Vermorken, JB | 1 |
Fukuoka, M; Furuse, K; Hasegawa, K; Hirabayashi, K; Nakajima, H; Niitani, H; Noda, K; Ogura, T; Taguchi, T | 1 |
Von Hoff, DD | 1 |
Kaufmann, M; von Minckwitz, G | 1 |
Pedersen, AG | 1 |
Bell, DR; Levi, JA; Millward, MJ; Pavlakis, N | 1 |
Awada, A; Klastersky, J | 1 |
Cartee, L; Kucera, GL | 1 |
Bergman, AM; Kroep, JR; Peters, GJ; Pinedo, HM; van Moorsel, CJ; Veerman, G; Vermorken, JB; Voorn, DA | 1 |
Bergman, AM; Kuiper, CM; Peters, GJ; Pinedo, HM; Ruiz van Haperen, VW; Veerman, G | 1 |
Brandner, G; Hess, RD; Merlin, T | 1 |
Augustine, K; Benjapibal, M; Edwards, CL; Kavanagh, JJ; Kudelka, AP; Vasuratna, A; Verschraegen, CF | 1 |
Peters, GJ; Pinedo, HM; Ruiz van Haperen, VW; Smitskamp-Wilms, E; Veerman, G | 1 |
Bell, D; Bugat, R; Campbell, L; Friedlander, M; Harnett, P; Kayitalire, L; Millward, MJ; Moreno, JA; Ripoche, V; Varette, C | 1 |
Guechev, A; Loves, WJ; Peters, GJ; Pinedo, HM; Postmus, PE; Smid, K; van Moorsel, CJ; Veerman, G; Vermorken, JB | 1 |
Cartee, L; Kucera, GL; Nixon, JB | 1 |
Einhorn, LH; Stender, MJ; Williams, SD | 1 |
Brady, MF; McGuire, WP; Ozols, RF | 1 |
Hansen, SW; Sessa, C; Tuxen, MK | 1 |
Bergman, AM; Kuiper, CM; Peters, GJ; Pinedo, HM; van der Vijgh, WJ; van Moorsel, CJ; Veerman, G; Vermorken, JB | 1 |
Bauknecht, T; Neijt, JP; Visseren-Grul, CM; von Minckwitz, G | 1 |
Piver, MS; Silver, DF | 1 |
Cianci, C; Conte, PF; Gadducci, A | 1 |
Catik, A; Kroep, JR; Peters, GJ; Pinedo, HM; van Groeningen, CJ; van Moorsel, CJ; Vermorken, JB | 1 |
Bergman, AM; Kroep, JR; Peters, GJ; Pinedo, HM; Ruiz van Haperen, VW; van Moorsel, CJ; Veerman, G; Voorn, DA | 1 |
Goldwasser, F; Gross, M; Hiesse, C; Kriaa, F | 1 |
Casella, G; Costanzo, R; De Placido, G; De Vivo, R; Iodice, F; Perrone, F; Pignata, S; Ricchi, P; Tramontana, F; Tramontana, S; Varriale, E; Vernaglia, A | 1 |
Bergman, AM; Giaccone, G; Mauritz, R; Noordhuis, P; Peters, GJ; Pinedo, HM; van Moorsel, CJ | 1 |
Barbarisi, A; Benassai, G; Carbone, I; Ciccarelli, PD; Crovella, F; De Rosa, P; Frattolillo, A; Iaffaioli, RV; Libutti, M; Santangelo, M; Tortoriello, A; Turitto, G | 1 |
Lambrou, N; Trimble, EL | 1 |
Abu-Rustum, N; Barakat, RR; Brown, CL; Chi, DS; Curtin, JP; Hoskins, WJ; Husain, A; Poynor, EA; Prasad, M | 1 |
Cree, IA; Hindley, A; Kurbacher, CM; Lamont, A; Neale, MH | 1 |
D'Agostino, G; Ferrandina, G; Greggi, S; Lorusso, D; Mancuso, S; Manzione, L; Salerno, MG; Scambia, G | 1 |
Banzato, F; Cappella, P; D'Incalci, M; Faretta, M; Lupi, M; Montalenti, F; Tomasoni, D; Ubezio, P; Viale, F | 1 |
Hansen, SW | 2 |
Mandachain, M; Orlando, M | 1 |
Chalas, E; Hindenburg, A; Jeyakumar, A | 1 |
Blohmer, JU; du Bois, A; Kimmig, R; Lück, HJ; Moebus, V; Pfisterer, J; Quaas, J; Schroeder, W | 1 |
Twelves, C | 1 |
Ahern, J; Carmichael, J; Dombernowsky, P; Hansen, H; Hansen, M; Harper, PG; Highley, MS; Hirsch, F; Lund, B; Parnis, FX; Underhill, CR; Williams, C | 1 |
De Vincenzo, R; Distefano, M; Ferlini, C; Gaggini, C; Mancuso, S; Scambia, G | 1 |
du Bois, A | 1 |
Breidenbach, M; Kurbacher, CM; Mallmann, P; Rein, DT | 1 |
D'Agostino, G; Farnetano, MG; Ferrandina, G; Garganese, G; Lorusso, D; Mancuso, S; Salerno, MG; Scambia, G | 1 |
Catalano, P; Einhorn, LH; Hinton, S; Kuzel, T; Loehrer, PJ; Vaughn, D; Wilding, G | 1 |
Fujiwaki, R; Hata, K; Iwanari, O; Katabuchi, H; Miyazaki, K; Moriyama, M; Nakayama, K; Okamura, H; Sakai, E | 1 |
Hensley, ML | 1 |
Ban, J; Weber, G | 1 |
Bhalla, K; Bullock, G; Holladay, C; Ibrado, AM; Jasiok, M; Lutzky, J; Singh, S | 1 |
Noordhuis, P; Peters, GJ; Ruiz van Haperen, VW; Veerman, G; Vermorken, JB | 1 |
Reviews
55 review(s) available for deoxycytidine and Ovarian Neoplasms
Article | Year |
---|---|
Gemcitabine for recurrent ovarian cancer - a systematic review and meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Randomized Controlled Trials as Topic | 2019 |
Precision medicine for ovarian clear cell carcinoma based on gene alterations.
Topics: Adenocarcinoma, Clear Cell; Antimetabolites, Antineoplastic; Class I Phosphatidylinositol 3-Kinases; Deoxycytidine; DNA-Binding Proteins; Enhancer of Zeste Homolog 2 Protein; Female; Gemcitabine; Gene Dosage; Glutathione; Humans; Molecular Targeted Therapy; Mutation; Ovarian Neoplasms; Precision Medicine; Transcription Factors | 2020 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor Proteins, Signal Transducing; Adenine; Adenocarcinoma; Adipogenesis; Administration, Cutaneous; Administration, Ophthalmic; Adolescent; Adsorption; Adult; Aeromonas hydrophila; Aerosols; Aged; Aged, 80 and over; Aging; Agriculture; Air Pollutants; Air Pollution; Airway Remodeling; Alanine Transaminase; Albuminuria; Aldehyde Dehydrogenase 1 Family; Algorithms; AlkB Homolog 2, Alpha-Ketoglutarate-Dependent Dioxygenase; Alzheimer Disease; Amino Acid Sequence; Ammonia; Ammonium Compounds; Anaerobiosis; Anesthetics, Dissociative; Anesthetics, Inhalation; Animals; Anti-Bacterial Agents; Anti-HIV Agents; Anti-Infective Agents; Anti-Inflammatory Agents; Antibiotics, Antineoplastic; Antibodies, Antineutrophil Cytoplasmic; Antibodies, Monoclonal, Humanized; Antifungal Agents; Antigens, Bacterial; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Antitubercular Agents; Antiviral Agents; Apolipoproteins E; Apoptosis; Arabidopsis; Arabidopsis Proteins; Arsenic; Arthritis, Rheumatoid; Asthma; Atherosclerosis; ATP-Dependent Proteases; Attitude of Health Personnel; Australia; Austria; Autophagy; Axitinib; Bacteria; Bacterial Outer Membrane Proteins; Bacterial Proteins; Bacterial Toxins; Bacterial Typing Techniques; Bariatric Surgery; Base Composition; Bayes Theorem; Benzoxazoles; Benzylamines; beta Catenin; Betacoronavirus; Betula; Binding Sites; Biological Availability; Biological Oxygen Demand Analysis; Biomarkers; Biomarkers, Tumor; Biopsy; Bioreactors; Biosensing Techniques; Birth Weight; Blindness; Blood Chemical Analysis; Blood Gas Analysis; Blood Glucose; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Blood-Brain Barrier; Blotting, Western; Body Mass Index; Body Weight; Bone and Bones; Bone Density; Bone Resorption; Borates; Brain; Brain Infarction; Brain Injuries, Traumatic; Brain Neoplasms; Breakfast; Breast Milk Expression; Breast Neoplasms; Bronchi; Bronchoalveolar Lavage Fluid; Buffaloes; Cadherins; Calcification, Physiologic; Calcium Compounds; Calcium, Dietary; Cannula; Caprolactam; Carbon; Carbon Dioxide; Carboplatin; Carcinogenesis; Carcinoma, Ductal; Carcinoma, Ehrlich Tumor; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Carcinoma, Renal Cell; Cardiovascular Diseases; Carps; Carrageenan; Case-Control Studies; Catalysis; Catalytic Domain; Cattle; CD8-Positive T-Lymphocytes; Cell Adhesion; Cell Cycle Proteins; Cell Death; Cell Differentiation; Cell Line; Cell Line, Tumor; Cell Movement; Cell Nucleus; Cell Phone Use; Cell Proliferation; Cell Survival; Cell Transformation, Neoplastic; Cell Transformation, Viral; Cells, Cultured; Cellulose; Chemical Phenomena; Chemoradiotherapy; Child; Child Development; Child, Preschool; China; Chitosan; Chlorocebus aethiops; Cholecalciferol; Chromatography, Liquid; Circadian Clocks; Circadian Rhythm; Circular Dichroism; Cisplatin; Citric Acid; Clinical Competence; Clinical Laboratory Techniques; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clostridioides difficile; Clostridium Infections; Coculture Techniques; Cohort Studies; Cold Temperature; Colitis; Collagen Type I; Collagen Type I, alpha 1 Chain; Collagen Type XI; Color; Connective Tissue Diseases; Copper; Coronary Angiography; Coronavirus 3C Proteases; Coronavirus Infections; Cost of Illness; Counselors; COVID-19; COVID-19 Testing; Creatine Kinase; Creatinine; Cross-Over Studies; Cross-Sectional Studies; Cryoelectron Microscopy; Cryosurgery; Crystallography, X-Ray; Cues; Cultural Competency; Cultural Diversity; Curriculum; Cyclic AMP Response Element-Binding Protein; Cyclin-Dependent Kinase Inhibitor p21; Cycloparaffins; Cysteine Endopeptidases; Cytokines; Cytoplasm; Cytoprotection; Databases, Factual; Denitrification; Deoxycytidine; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diagnosis, Differential; Diatoms; Diet; Diet, High-Fat; Dietary Exposure; Diffusion Magnetic Resonance Imaging; Diketopiperazines; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Disease Progression; Disease-Free Survival; DNA; DNA Damage; DNA Glycosylases; DNA Repair; DNA-Binding Proteins; DNA, Bacterial; DNA, Viral; Docetaxel; Dose Fractionation, Radiation; Dose-Response Relationship, Drug; Down-Regulation; Doxorubicin; Drosophila; Drosophila melanogaster; Drug Carriers; Drug Delivery Systems; Drug Liberation; Drug Repositioning; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Drug Therapy, Combination; Edema; Edible Grain; Education, Graduate; Education, Medical, Graduate; Education, Pharmacy; Ehlers-Danlos Syndrome; Electron Transport Complex III; Electron Transport Complex IV; Electronic Nicotine Delivery Systems; Emergency Service, Hospital; Empathy; Emulsions; Endothelial Cells; Endurance Training; Energy Intake; Enterovirus A, Human; Environment; Environmental Monitoring; Enzyme Assays; Enzyme Inhibitors; Epithelial Cells; Epithelial-Mesenchymal Transition; Epoxide Hydrolases; Epoxy Compounds; Erythrocyte Count; Erythrocytes; Escherichia coli; Escherichia coli Infections; Escherichia coli Proteins; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Estrogens; Etanercept; Ethiopia; Ethnicity; Ethylenes; Exanthema; Exercise; Exercise Test; Exercise Tolerance; Extracellular Matrix; Extracorporeal Membrane Oxygenation; Eye Infections, Fungal; False Negative Reactions; Fatty Acids; Fecal Microbiota Transplantation; Feces; Female; Femur Neck; Fermentation; Ferritins; Fetal Development; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Fibroblasts; Fibroins; Fish Proteins; Flavanones; Flavonoids; Focus Groups; Follow-Up Studies; Food Handling; Food Supply; Food, Formulated; Forced Expiratory Volume; Forests; Fractures, Bone; Fruit and Vegetable Juices; Fusobacteria; G1 Phase Cell Cycle Checkpoints; G2 Phase Cell Cycle Checkpoints; Gamma Rays; Gastrectomy; Gastrointestinal Microbiome; Gastrointestinal Stromal Tumors; Gefitinib; Gels; Gemcitabine; Gene Amplification; Gene Expression; Gene Expression Regulation; Gene Expression Regulation, Bacterial; Gene Expression Regulation, Neoplastic; Gene Expression Regulation, Plant; Gene Knockdown Techniques; Gene-Environment Interaction; Genotype; Germany; Glioma; Glomerular Filtration Rate; Glucagon; Glucocorticoids; Glycemic Control; Glycerol; Glycogen Synthase Kinase 3 beta; Glycolipids; Glycolysis; Goblet Cells; Gram-Negative Bacterial Infections; Granulocyte Colony-Stimulating Factor; Graphite; Greenhouse Effect; Guanidines; Haemophilus influenzae; HCT116 Cells; Health Knowledge, Attitudes, Practice; Health Personnel; Health Services Accessibility; Health Services Needs and Demand; Health Status Disparities; Healthy Volunteers; Heart Failure; Heart Rate; Heart Transplantation; Heart-Assist Devices; HEK293 Cells; Heme; Heme Oxygenase-1; Hemolysis; Hemorrhage; Hepatitis B; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Hepatocytes; Hexoses; High-Throughput Nucleotide Sequencing; Hippo Signaling Pathway; Histamine; Histamine Agonists; Histidine; Histone Deacetylase 2; HIV Infections; HIV Reverse Transcriptase; HIV-1; Homebound Persons; Homeodomain Proteins; Homosexuality, Male; Hospice and Palliative Care Nursing; HSP70 Heat-Shock Proteins; Humans; Hyaluronan Receptors; Hydrogen; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydrolysis; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemia; Hypoglycemic Agents; Hypoxia; Idiopathic Interstitial Pneumonias; Imaging, Three-Dimensional; Imatinib Mesylate; Immunotherapy; Implementation Science; Incidence; INDEL Mutation; Induced Pluripotent Stem Cells; Industrial Waste; Infant; Infant, Newborn; Inflammation; Inflammation Mediators; Infliximab; Infusions, Intravenous; Inhibitory Concentration 50; Injections; Insecticides; Insulin-Like Growth Factor Binding Protein 5; Insulin-Secreting Cells; Interleukin-1; Interleukin-17; Interleukin-8; Internship and Residency; Intestines; Intracellular Signaling Peptides and Proteins; Ion Transport; Iridaceae; Iridoid Glucosides; Islets of Langerhans Transplantation; Isodon; Isoflurane; Isotopes; Italy; Joint Instability; Ketamine; Kidney; Kidney Failure, Chronic; Kidney Function Tests; Kidney Neoplasms; Kinetics; Klebsiella pneumoniae; Knee Joint; Kruppel-Like Factor 4; Kruppel-Like Transcription Factors; Lactate Dehydrogenase 5; Laparoscopy; Laser Therapy; Lasers, Semiconductor; Lasers, Solid-State; Laurates; Lead; Leukocyte L1 Antigen Complex; Leukocytes, Mononuclear; Light; Lipid Peroxidation; Lipopolysaccharides; Liposomes; Liver; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Locomotion; Longitudinal Studies; Lopinavir; Lower Urinary Tract Symptoms; Lubricants; Lung; Lung Diseases, Interstitial; Lung Neoplasms; Lymphocyte Activation; Lymphocytes, Tumor-Infiltrating; Lymphoma, Mantle-Cell; Lysosomes; Macrophages; Male; Manganese Compounds; MAP Kinase Kinase 4; Mass Screening; Maternal Health; Medicine, Chinese Traditional; Melanoma, Experimental; Memantine; Membrane Glycoproteins; Membrane Proteins; Mesenchymal Stem Cell Transplantation; Metal Nanoparticles; Metalloendopeptidases; Metalloporphyrins; Methadone; Methane; Methicillin-Resistant Staphylococcus aureus; Mexico; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Inbred ICR; Mice, Knockout; Mice, Nude; Mice, SCID; Mice, Transgenic; Microarray Analysis; Microbial Sensitivity Tests; Microbiota; Micronutrients; MicroRNAs; Microscopy, Confocal; Microsomes, Liver; Middle Aged; Milk; Milk, Human; Minority Groups; Mitochondria; Mitochondrial Membranes; Mitochondrial Proteins; Models, Animal; Models, Molecular; Molecular Conformation; Molecular Docking Simulation; Molecular Dynamics Simulation; Molecular Epidemiology; Molecular Structure; Molecular Weight; Multilocus Sequence Typing; Multimodal Imaging; Muscle Strength; Muscle, Skeletal; Muscular Diseases; Mutation; Mycobacterium tuberculosis; Myocardial Stunning; Myristates; NAD(P)H Dehydrogenase (Quinone); Nanocomposites; Nanogels; Nanoparticles; Nanotechnology; Naphthalenes; Nasal Cavity; National Health Programs; Necrosis; Needs Assessment; Neoadjuvant Therapy; Neonicotinoids; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Proteins; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm Transplantation; Neoplasms; Neoplastic Stem Cells; Netherlands; Neuroblastoma; Neuroprotective Agents; Neutrophils; NF-kappa B; NFATC Transcription Factors; Nicotiana; Nicotine; Nitrates; Nitrification; Nitrites; Nitro Compounds; Nitrogen; Nitrogen Dioxide; North Carolina; Nuclear Magnetic Resonance, Biomolecular; Nuclear Proteins; Nucleic Acid Hybridization; Nucleosomes; Nutrients; Obesity; Obesity, Morbid; Oceans and Seas; Oncogene Protein v-akt; Oncogenes; Oocytes; Open Reading Frames; Osteoclasts; Osteogenesis; Osteoporosis; Osteoporosis, Postmenopausal; Outpatients; Ovarian Neoplasms; Ovariectomy; Overweight; Oxazines; Oxidants; Oxidation-Reduction; Oxidative Stress; Oxides; Oxidoreductases; Oxygen; Oxygen Inhalation Therapy; Oxygenators, Membrane; Ozone; Paclitaxel; Paenibacillus; Pain Measurement; Palliative Care; Pancreatic Neoplasms; Pandemics; Parasympathetic Nervous System; Particulate Matter; Pasteurization; Patient Preference; Patient Satisfaction; Pediatric Obesity; Permeability; Peroxiredoxins; Peroxynitrous Acid; Pharmaceutical Services; Pharmacists; Pharmacy; Phaseolus; Phenotype; Phoeniceae; Phosphates; Phosphatidylinositol 3-Kinases; Phospholipid Transfer Proteins; Phospholipids; Phosphorus; Phosphorylation; Photoperiod; Photosynthesis; Phylogeny; Physical Endurance; Physicians; Pilot Projects; Piperidines; Pituitary Adenylate Cyclase-Activating Polypeptide; Plant Extracts; Plant Leaves; Plant Proteins; Plant Roots; Plaque, Atherosclerotic; Pneumonia; Pneumonia, Viral; Point-of-Care Testing; Polyethylene Glycols; Polymers; Polysorbates; Pore Forming Cytotoxic Proteins; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Postprandial Period; Poverty; Pre-Exposure Prophylaxis; Prediabetic State; Predictive Value of Tests; Pregnancy; Pregnancy Trimester, First; Pregnancy, High-Risk; Prenatal Exposure Delayed Effects; Pressure; Prevalence; Primary Graft Dysfunction; Primary Health Care; Professional Role; Professionalism; Prognosis; Progression-Free Survival; Prolactin; Promoter Regions, Genetic; Proof of Concept Study; Proportional Hazards Models; Propylene Glycol; Prospective Studies; Prostate; Protein Binding; Protein Biosynthesis; Protein Isoforms; Protein Kinase Inhibitors; Protein Phosphatase 2; Protein Processing, Post-Translational; Protein Serine-Threonine Kinases; Protein Structure, Tertiary; Protein Transport; Proteoglycans; Proteome; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-myc; Proto-Oncogene Proteins c-ret; Proto-Oncogene Proteins p21(ras); Proton Pumps; Protons; Protoporphyrins; Pseudomonas aeruginosa; Pseudomonas fluorescens; Pulmonary Artery; Pulmonary Disease, Chronic Obstructive; Pulmonary Gas Exchange; Pulmonary Veins; Pyrazoles; Pyridines; Pyrimidines; Qualitative Research; Quinoxalines; Rabbits; Random Allocation; Rats; Rats, Sprague-Dawley; Rats, Wistar; Receptors, Histamine H3; Receptors, Immunologic; Receptors, Transferrin; Recombinant Proteins; Recurrence; Reference Values; Referral and Consultation; Regional Blood Flow; Registries; Regulon; Renal Insufficiency, Chronic; Reperfusion Injury; Repressor Proteins; Reproducibility of Results; Republic of Korea; Research Design; Resistance Training; Respiration, Artificial; Respiratory Distress Syndrome; Respiratory Insufficiency; Resuscitation; Retinal Dehydrogenase; Retreatment; Retrospective Studies; Reverse Transcriptase Inhibitors; Rhinitis, Allergic; Ribosomal Proteins; Ribosomes; Risk Assessment; Risk Factors; Ritonavir; Rivers; RNA Interference; RNA-Seq; RNA, Messenger; RNA, Ribosomal, 16S; RNA, Small Interfering; Rosuvastatin Calcium; Rural Population; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Salivary Ducts; Salivary Gland Neoplasms; San Francisco; SARS-CoV-2; Satiation; Satiety Response; Schools; Schools, Pharmacy; Seasons; Seawater; Selection, Genetic; Sequence Analysis, DNA; Serine-Threonine Kinase 3; Sewage; Sheep; Sheep, Domestic; Shock, Hemorrhagic; Signal Transduction; Silver; Silymarin; Single Photon Emission Computed Tomography Computed Tomography; Sirolimus; Sirtuin 1; Skin; Skin Neoplasms; Skin Physiological Phenomena; Sleep Initiation and Maintenance Disorders; Social Class; Social Participation; Social Support; Soil; Soil Microbiology; Solutions; Somatomedins; Soot; Specimen Handling; Spectrophotometry, Ultraviolet; Spectroscopy, Fourier Transform Infrared; Spectrum Analysis; Spinal Fractures; Spirometry; Staphylococcus aureus; STAT1 Transcription Factor; STAT3 Transcription Factor; Streptomyces coelicolor; Stress, Psychological; Stroke; Stroke Volume; Structure-Activity Relationship; Students, Medical; Students, Pharmacy; Substance Abuse Treatment Centers; Sulfur Dioxide; Surface Properties; Surface-Active Agents; Surveys and Questionnaires; Survival Analysis; Survival Rate; Survivin; Sweden; Swine; Swine, Miniature; Sympathetic Nervous System; T-Lymphocytes, Regulatory; Talaromyces; Tandem Mass Spectrometry; tau Proteins; Telemedicine; Telomerase; Telomere; Telomere Homeostasis; Temperature; Terminally Ill; Th1 Cells; Thiamethoxam; Thiazoles; Thiophenes; Thioredoxin Reductase 1; Thrombosis; Thulium; Thyroid Cancer, Papillary; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms; Time Factors; Titanium; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases; Transcription Factor AP-1; Transcription Factors; Transcription, Genetic; Transcriptional Activation; Transcriptome; Transforming Growth Factor beta1; Transistors, Electronic; Translational Research, Biomedical; Transplantation Tolerance; Transplantation, Homologous; Transportation; Treatment Outcome; Tretinoin; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary; Tubulin Modulators; Tumor Microenvironment; Tumor Necrosis Factor Inhibitors; Tumor Necrosis Factor-alpha; Twins; Ultrasonic Therapy; Ultrasonography; Ultraviolet Rays; United States; Up-Regulation; Uranium; Urethra; Urinary Bladder; Urodynamics; Uromodulin; Uveitis; Vasoconstrictor Agents; Ventricular Function, Left; Vero Cells; Vesicular Transport Proteins; Viral Nonstructural Proteins; Visual Acuity; Vital Capacity; Vitamin D; Vitamin D Deficiency; Vitamin K 2; Vitamins; Volatilization; Voriconazole; Waiting Lists; Waste Disposal, Fluid; Wastewater; Water Pollutants, Chemical; Whole Genome Sequencing; Wine; Wnt Signaling Pathway; Wound Healing; Wounds and Injuries; WW Domains; X-linked Nuclear Protein; X-Ray Diffraction; Xanthines; Xenograft Model Antitumor Assays; YAP-Signaling Proteins; Yogurt; Young Adult; Zebrafish; Zebrafish Proteins; Ziziphus | 2016 |
NUC-1031, use of ProTide technology to circumvent gemcitabine resistance: current status in clinical trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Clinical Trials as Topic; Cytidine Monophosphate; Deoxycytidine; Drug Resistance, Neoplasm; Drug Synergism; Female; Gemcitabine; Humans; Ovarian Neoplasms; Pancreatic Neoplasms; Randomized Controlled Trials as Topic; Treatment Outcome | 2020 |
Gemcitabine-induced dilated-cardiomyopathy in patient with platinum-refractory ovarian-cancer: A case report and literature review.
Topics: Adult; Cardiomyopathy, Dilated; Deoxycytidine; Female; Gemcitabine; Humans; Ovarian Neoplasms; Stroke Volume; Ventricular Function, Left | 2021 |
Epidermal growth factor receptor blockers for the treatment of ovarian cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Piperidines; Progression-Free Survival; Quality of Life; Quinazolines; Randomized Controlled Trials as Topic | 2018 |
Slow progression of calcified cerebellar metastasis from ovarian cancer: a case report and review of the literature.
Topics: Adenocarcinoma, Mucinous; Adult; Antimetabolites, Antineoplastic; Calcinosis; Cerebellar Neoplasms; Combined Modality Therapy; Cranial Irradiation; Craniotomy; Deoxycytidine; Disease Progression; Encephalocele; Female; Gemcitabine; Humans; Hydrocephalus; Hysterectomy; Magnetic Resonance Imaging; Ovarian Neoplasms; Ovariectomy; Tomography, X-Ray Computed | 2013 |
Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for advanced recurrent or refractory ovarian cancer: a systematic review and economic evaluation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cost-Benefit Analysis; Deoxycytidine; Dioxoles; Disease-Free Survival; Double-Blind Method; Doxorubicin; Female; Gemcitabine; Health Care Costs; Humans; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Polyethylene Glycols; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Risk Assessment; Survival Analysis; Tetrahydroisoquinolines; Topotecan; Trabectedin; Treatment Outcome; United Kingdom | 2015 |
Pharmacotherapy for recurrent ovarian cancer: current status and future perspectives.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carboplatin; Carcinoma, Ovarian Epithelial; Deoxycytidine; Doxorubicin; Everolimus; Female; Folic Acid; Gemcitabine; Humans; Indazoles; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Nivolumab; Ovarian Neoplasms; Paclitaxel; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Polyethylene Glycols; Pyrimidines; Quinazolines; Recombinant Fusion Proteins; Sirolimus; Sulfonamides; Topotecan; TOR Serine-Threonine Kinases; Vinca Alkaloids | 2015 |
[LEIOMYOSARCOMA ARISING FROM OVARIAN VEIN WITH RIGHT HYDRONEPHROSIS: A CASE REPORT].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Hydronephrosis; Leiomyosarcoma; Ovarian Neoplasms; Taxoids; Tomography, X-Ray Computed; Vena Cava, Inferior | 2015 |
The influence of polypharmacy on grade III/IV toxicity, prior discontinuation of chemotherapy and overall survival in ovarian cancer.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Deoxycytidine; Disease-Free Survival; Etoposide; Female; Gemcitabine; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Polypharmacy; Randomized Controlled Trials as Topic; Survival Rate; Topotecan; Withholding Treatment; Young Adult | 2016 |
Overcoming platinum resistance in ovarian carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Organoplatinum Compounds; Ovarian Neoplasms | 2010 |
Tolerability, efficacy, and safety of pegylated liposomal Doxorubicin in combination with Carboplatin versus gemcitabine-Carboplatin for the treatment of platinum-sensitive recurrent ovarian cancer: a systematic review.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Disease-Free Survival; Doxorubicin; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Polyethylene Glycols | 2010 |
Epidermal growth factor receptor blockers for the treatment of ovarian cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Deoxycytidine; Disease-Free Survival; ErbB Receptors; Female; Gemcitabine; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Randomized Controlled Trials as Topic | 2011 |
First-line chemotherapy in epithelial ovarian cancer.
Topics: Adenocarcinoma, Mucinous; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Cisplatin; Clinical Trials as Topic; Cystadenocarcinoma, Serous; Deoxycytidine; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Gemcitabine; Humans; Neoplasms, Glandular and Epithelial; Neovascularization, Pathologic; Ovarian Neoplasms; Paclitaxel; Poly(ADP-ribose) Polymerase Inhibitors; Receptors, Vascular Endothelial Growth Factor; Topotecan; Vascular Endothelial Growth Factor A | 2012 |
A rational approach to the management of recurrent or persistent ovarian carcinoma.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Chemotherapy, Cancer, Regional Perfusion; Decision Making; Deoxycytidine; Disease Progression; Doxorubicin; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Ovary; Paclitaxel; Polyethylene Glycols; Quality of Life; Randomized Controlled Trials as Topic | 2012 |
Gemcitabine-associated hemolytic-uremic syndrome.
Topics: Antimetabolites, Antineoplastic; Deoxycytidine; Female; Gemcitabine; Hemolytic-Uremic Syndrome; Humans; Male; Middle Aged; Ovarian Neoplasms; Ribonucleotide Reductases | 2002 |
[Gemicitabine in the treatment of epithelial ovarian cancer].
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Hematologic Diseases; Humans; Multicenter Studies as Topic; Organoplatinum Compounds; Ovarian Neoplasms; Paclitaxel; Palliative Care; Prodrugs; Remission Induction; Topotecan; Treatment Outcome; Vinblastine; Vinorelbine | 2002 |
Gemcitabine combination chemotherapy of ovarian cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Drug Synergism; Female; Gemcitabine; Humans; Ovarian Neoplasms; Paclitaxel; Salvage Therapy | 2003 |
Gemcitabine as a single-agent treatment for ovarian cancer.
Topics: Antimetabolites, Antineoplastic; Clinical Trials as Topic; Deoxycytidine; Female; Gemcitabine; Humans; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms | 2003 |
Gemcitabine: current role and future options in the treatment of ovarian cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Ovarian Neoplasms; Treatment Outcome | 2003 |
Brain metastases of epithelial ovarian carcinoma responding to cisplatin and gemcitabine combination chemotherapy: a case report and review of the literature.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cisplatin; Deoxycytidine; Epithelial Cells; Female; Fluorouracil; Gemcitabine; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms | 2004 |
[Peritoneal dissemination of ovarian cancer and tumor angiogenesis].
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Bevacizumab; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Neovascularization, Pathologic; Ovarian Neoplasms; Peritoneal Neoplasms; Vascular Endothelial Growth Factor A | 2004 |
Recurrent ovarian cancer: how important is it to treat to disease progression?
Topics: Altretamine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Deoxycytidine; Disease Progression; Docetaxel; Doxorubicin; Etoposide; Female; Gemcitabine; Humans; Ovarian Neoplasms; Paclitaxel; Recurrence; Risk; Taxoids; Time Factors; Topotecan | 2004 |
Gemcitabine and carboplatin in second-line ovarian cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Survival Rate | 2005 |
Gemcitabine in patients with ovarian cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Resistance, Neoplasm; Drug Synergism; Female; Gemcitabine; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Prognosis; Quality of Life; Remission Induction | 2005 |
[Review of effectiveness of chemotherapy with gemcitabine in ovarian cancer].
Topics: Antimetabolites, Antineoplastic; Deoxycytidine; Female; Gemcitabine; Humans; Neutropenia; Ovarian Neoplasms; Thrombocytopenia; Treatment Outcome | 2005 |
Gemcitabine plus carboplatin in platinum-sensitive recurrent ovarian carcinoma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Prognosis; Quality of Life; Survival | 2006 |
Role of gemcitabine in cancer therapy.
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Interactions; Female; Gemcitabine; Humans; Lung Neoplasms; Neoplasms; Ovarian Neoplasms; Pancreatic Neoplasms; Urinary Bladder Neoplasms | 2005 |
Optimizing gemcitabine regimens in ovarian cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Decision Trees; Deoxycytidine; Female; Gemcitabine; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic | 2006 |
Management of platinum-sensitive recurrent ovarian cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel | 2006 |
The role of gemcitabine in first-line treatment of advanced ovarian carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Clinical Trials, Phase III as Topic; Deoxycytidine; Female; Gemcitabine; Humans; Neoplasm Metastasis; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic | 2006 |
Optimal therapy for platinum-resistant recurrent ovarian cancer: doxorubicin, gemcitabine or topotecan?
Topics: Antineoplastic Agents; Carboplatin; Deoxycytidine; Doxorubicin; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Topotecan | 2006 |
Role of gemcitabine in ovarian cancer treatment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum Compounds; Survival Analysis; Treatment Outcome | 2006 |
New cytostatic drugs in ovarian cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Female; Gemcitabine; Humans; Ovarian Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic | 1993 |
Promising new therapies in the treatment of advanced ovarian cancer.
Topics: Antineoplastic Agents; Camptothecin; Clinical Trials as Topic; Deoxycytidine; Drug Resistance; Female; Gemcitabine; Humans; Ovarian Neoplasms; Paclitaxel; Topoisomerase I Inhibitors; Topotecan | 1995 |
Gemcitabine in cisplatin-resistant ovarian cancer.
Topics: Antineoplastic Agents; Cisplatin; Clinical Trials, Phase II as Topic; Deoxycytidine; Drug Resistance; Female; Gemcitabine; Humans; Ovarian Neoplasms | 1996 |
New drugs in gynecologic oncology.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Squamous Cell; Clinical Trials as Topic; Deoxycytidine; Endometrial Neoplasms; Female; Gemcitabine; Genital Neoplasms, Female; Humans; Ovarian Neoplasms; Platinum Compounds; Uterine Cervical Neoplasms | 1996 |
Gemcitabine in ovarian cancer: an overview of safety and efficacy.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Deoxycytidine; Female; Gemcitabine; Humans; Middle Aged; Ovarian Neoplasms | 1997 |
Future directions in the chemotherapy of ovarian cancer.
Topics: Administration, Oral; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Clinical Trials as Topic; Cyclophosphamide; Deoxycytidine; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Etoposide; Europe; Female; Forecasting; Gemcitabine; Humans; Injections, Intraperitoneal; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Time Factors; Topotecan; Vinblastine; Vinorelbine | 1997 |
[Gemcitabine: a new chemotherapy agent for solid cancers].
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Cisplatin; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Hematologic Diseases; Humans; Lung Neoplasms; Neoplasms; Ovarian Neoplasms; Palliative Care; Pancreatic Neoplasms; Radiation-Sensitizing Agents | 1997 |
Gemcitabine in the treatment of ovarian cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Ovarian Neoplasms; Paclitaxel; Treatment Outcome | 1999 |
Up date in the management of advanced ovarian carcinoma.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Clinical Trials as Topic; Deoxycytidine; Female; Gemcitabine; Humans; Ovarian Neoplasms; Topotecan | 1999 |
The role of gemcitabine in the treatment of ovarian cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Deoxycytidine; Female; Gemcitabine; Humans; Ovarian Neoplasms; Prognosis | 2000 |
Dose-intensive approaches to ovarian cancer.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Cyclophosphamide; Deoxycytidine; Dose-Response Relationship, Drug; Etoposide; Female; Gemcitabine; Humans; Ovarian Neoplasms; Prognosis; Survival Analysis; Topotecan | 1999 |
The current role of gemcitabine in ovarian cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Deoxycytidine; Female; Gemcitabine; Humans; Ovarian Neoplasms | 2001 |
Developmental chemotherapy in advanced ovarian cancer: incorporation of topoisomerase-I inhibitors and perspective of the Gynecologic Oncology Group.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Deoxycytidine; DNA Adducts; Female; Gemcitabine; Humans; Immunologic Factors; Liposomes; Ovarian Neoplasms; Paclitaxel; Prognosis; Randomized Controlled Trials as Topic; Survival Analysis; Topoisomerase I Inhibitors; Topotecan | 2001 |
Gemcitabine in ovarian cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Ovarian Neoplasms | 2001 |
Vision of the future: capecitabine.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Kidney Neoplasms; Male; Ovarian Neoplasms; Pancreatic Neoplasms | 2001 |
Treatment of advanced ovarian cancer.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Deoxycytidine; Doxorubicin; Etoposide; Female; Gemcitabine; Humans; Liposomes; Ovarian Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic; Topotecan | 2001 |
Second-line treatment of ovarian cancer with single-agent gemcitabine.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Cisplatin; Clinical Trials, Phase II as Topic; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms | 2002 |
The role of gemcitabine-based doublets in the management of ovarian carcinoma.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carboplatin; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Doxorubicin; Etoposide; Female; Gemcitabine; Humans; Ovarian Neoplasms; Paclitaxel; Topotecan; Vinblastine; Vinorelbine | 2002 |
Gemcitabine, platinum, and paclitaxel regimens in patients with advanced ovarian carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Female; Gemcitabine; Humans; Ovarian Neoplasms; Paclitaxel | 2002 |
Developmental chemotherapy in advanced ovarian cancer: incorporation of newer cytotoxic agents in a phase III randomized trial of the Gynecologic Oncology Group (GOG-0182).
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Clinical Trials as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Doxorubicin; Etoposide; Female; Gemcitabine; Humans; Ovarian Neoplasms; Paclitaxel; Topotecan | 2002 |
Epithelial ovarian cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Combined Modality Therapy; Deoxycytidine; Docetaxel; Doxorubicin; Etoposide; Female; Gemcitabine; Humans; Ifosfamide; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Platinum Compounds; Practice Guidelines as Topic; Tamoxifen; Taxoids; Topotecan; Vinblastine; Vinorelbine | 2002 |
Trials
147 trial(s) available for deoxycytidine and Ovarian Neoplasms
Article | Year |
---|---|
A Replication stress biomarker is associated with response to gemcitabine versus combined gemcitabine and ATR inhibitor therapy in ovarian cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Ataxia Telangiectasia Mutated Proteins; Biomarkers, Tumor; Deoxycytidine; DNA Replication; Female; Gemcitabine; Humans; Isoxazoles; Mutation; Oncogenes; Ovarian Neoplasms; Progression-Free Survival; Protein Kinase Inhibitors; Pyrazines; Recombinational DNA Repair; Retinoblastoma Binding Proteins | 2021 |
Phase II study of gemcitabine, cisplatin, and bevacizumab for first recurrent and refractory ovarian clear cell carcinoma Kansai Clinical Oncology Group-G1601.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma; Carcinoma, Ovarian Epithelial; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Middle Aged; Ovarian Neoplasms | 2023 |
Patient-reported outcomes and final overall survival results from the randomized phase 3 PENELOPE trial evaluating pertuzumab in low tumor human epidermal growth factor receptor 3 (HER3) mRNA-expressing platinum-resistant ovarian cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Deoxycytidine; Double-Blind Method; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Patient Reported Outcome Measures; Progression-Free Survival; Receptor, ErbB-3; RNA, Messenger; Topotecan | 2019 |
A randomized, double-blind, placebo-controlled phase 1b/2 study of ralimetinib, a p38 MAPK inhibitor, plus gemcitabine and carboplatin versus gemcitabine and carboplatin for women with recurrent platinum-sensitive ovarian cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Deoxycytidine; Double-Blind Method; Female; Gemcitabine; Humans; Imidazoles; Maintenance Chemotherapy; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; p38 Mitogen-Activated Protein Kinases; Progression-Free Survival; Pyridines; Young Adult | 2020 |
A Randomized Phase II Trial of Epigenetic Priming with Guadecitabine and Carboplatin in Platinum-resistant, Recurrent Ovarian Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Carboplatin; Deoxycytidine; Doxorubicin; Drug Resistance, Neoplasm; Epigenesis, Genetic; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Patient Safety; Polyethylene Glycols; Survival Rate; Topotecan; Treatment Outcome | 2020 |
A phase II study of the combination chemotherapy of bevacizumab and gemcitabine in women with platinum-resistant recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Deoxycytidine; Fallopian Tube Neoplasms; Female; Gemcitabine; Humans; Middle Aged; Ovarian Neoplasms; Peritoneal Neoplasms | 2020 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor Proteins, Signal Transducing; Adenine; Adenocarcinoma; Adipogenesis; Administration, Cutaneous; Administration, Ophthalmic; Adolescent; Adsorption; Adult; Aeromonas hydrophila; Aerosols; Aged; Aged, 80 and over; Aging; Agriculture; Air Pollutants; Air Pollution; Airway Remodeling; Alanine Transaminase; Albuminuria; Aldehyde Dehydrogenase 1 Family; Algorithms; AlkB Homolog 2, Alpha-Ketoglutarate-Dependent Dioxygenase; Alzheimer Disease; Amino Acid Sequence; Ammonia; Ammonium Compounds; Anaerobiosis; Anesthetics, Dissociative; Anesthetics, Inhalation; Animals; Anti-Bacterial Agents; Anti-HIV Agents; Anti-Infective Agents; Anti-Inflammatory Agents; Antibiotics, Antineoplastic; Antibodies, Antineutrophil Cytoplasmic; Antibodies, Monoclonal, Humanized; Antifungal Agents; Antigens, Bacterial; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Antitubercular Agents; Antiviral Agents; Apolipoproteins E; Apoptosis; Arabidopsis; Arabidopsis Proteins; Arsenic; Arthritis, Rheumatoid; Asthma; Atherosclerosis; ATP-Dependent Proteases; Attitude of Health Personnel; Australia; Austria; Autophagy; Axitinib; Bacteria; Bacterial Outer Membrane Proteins; Bacterial Proteins; Bacterial Toxins; Bacterial Typing Techniques; Bariatric Surgery; Base Composition; Bayes Theorem; Benzoxazoles; Benzylamines; beta Catenin; Betacoronavirus; Betula; Binding Sites; Biological Availability; Biological Oxygen Demand Analysis; Biomarkers; Biomarkers, Tumor; Biopsy; Bioreactors; Biosensing Techniques; Birth Weight; Blindness; Blood Chemical Analysis; Blood Gas Analysis; Blood Glucose; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Blood-Brain Barrier; Blotting, Western; Body Mass Index; Body Weight; Bone and Bones; Bone Density; Bone Resorption; Borates; Brain; Brain Infarction; Brain Injuries, Traumatic; Brain Neoplasms; Breakfast; Breast Milk Expression; Breast Neoplasms; Bronchi; Bronchoalveolar Lavage Fluid; Buffaloes; Cadherins; Calcification, Physiologic; Calcium Compounds; Calcium, Dietary; Cannula; Caprolactam; Carbon; Carbon Dioxide; Carboplatin; Carcinogenesis; Carcinoma, Ductal; Carcinoma, Ehrlich Tumor; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Carcinoma, Renal Cell; Cardiovascular Diseases; Carps; Carrageenan; Case-Control Studies; Catalysis; Catalytic Domain; Cattle; CD8-Positive T-Lymphocytes; Cell Adhesion; Cell Cycle Proteins; Cell Death; Cell Differentiation; Cell Line; Cell Line, Tumor; Cell Movement; Cell Nucleus; Cell Phone Use; Cell Proliferation; Cell Survival; Cell Transformation, Neoplastic; Cell Transformation, Viral; Cells, Cultured; Cellulose; Chemical Phenomena; Chemoradiotherapy; Child; Child Development; Child, Preschool; China; Chitosan; Chlorocebus aethiops; Cholecalciferol; Chromatography, Liquid; Circadian Clocks; Circadian Rhythm; Circular Dichroism; Cisplatin; Citric Acid; Clinical Competence; Clinical Laboratory Techniques; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clostridioides difficile; Clostridium Infections; Coculture Techniques; Cohort Studies; Cold Temperature; Colitis; Collagen Type I; Collagen Type I, alpha 1 Chain; Collagen Type XI; Color; Connective Tissue Diseases; Copper; Coronary Angiography; Coronavirus 3C Proteases; Coronavirus Infections; Cost of Illness; Counselors; COVID-19; COVID-19 Testing; Creatine Kinase; Creatinine; Cross-Over Studies; Cross-Sectional Studies; Cryoelectron Microscopy; Cryosurgery; Crystallography, X-Ray; Cues; Cultural Competency; Cultural Diversity; Curriculum; Cyclic AMP Response Element-Binding Protein; Cyclin-Dependent Kinase Inhibitor p21; Cycloparaffins; Cysteine Endopeptidases; Cytokines; Cytoplasm; Cytoprotection; Databases, Factual; Denitrification; Deoxycytidine; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diagnosis, Differential; Diatoms; Diet; Diet, High-Fat; Dietary Exposure; Diffusion Magnetic Resonance Imaging; Diketopiperazines; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Disease Progression; Disease-Free Survival; DNA; DNA Damage; DNA Glycosylases; DNA Repair; DNA-Binding Proteins; DNA, Bacterial; DNA, Viral; Docetaxel; Dose Fractionation, Radiation; Dose-Response Relationship, Drug; Down-Regulation; Doxorubicin; Drosophila; Drosophila melanogaster; Drug Carriers; Drug Delivery Systems; Drug Liberation; Drug Repositioning; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Drug Therapy, Combination; Edema; Edible Grain; Education, Graduate; Education, Medical, Graduate; Education, Pharmacy; Ehlers-Danlos Syndrome; Electron Transport Complex III; Electron Transport Complex IV; Electronic Nicotine Delivery Systems; Emergency Service, Hospital; Empathy; Emulsions; Endothelial Cells; Endurance Training; Energy Intake; Enterovirus A, Human; Environment; Environmental Monitoring; Enzyme Assays; Enzyme Inhibitors; Epithelial Cells; Epithelial-Mesenchymal Transition; Epoxide Hydrolases; Epoxy Compounds; Erythrocyte Count; Erythrocytes; Escherichia coli; Escherichia coli Infections; Escherichia coli Proteins; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Estrogens; Etanercept; Ethiopia; Ethnicity; Ethylenes; Exanthema; Exercise; Exercise Test; Exercise Tolerance; Extracellular Matrix; Extracorporeal Membrane Oxygenation; Eye Infections, Fungal; False Negative Reactions; Fatty Acids; Fecal Microbiota Transplantation; Feces; Female; Femur Neck; Fermentation; Ferritins; Fetal Development; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Fibroblasts; Fibroins; Fish Proteins; Flavanones; Flavonoids; Focus Groups; Follow-Up Studies; Food Handling; Food Supply; Food, Formulated; Forced Expiratory Volume; Forests; Fractures, Bone; Fruit and Vegetable Juices; Fusobacteria; G1 Phase Cell Cycle Checkpoints; G2 Phase Cell Cycle Checkpoints; Gamma Rays; Gastrectomy; Gastrointestinal Microbiome; Gastrointestinal Stromal Tumors; Gefitinib; Gels; Gemcitabine; Gene Amplification; Gene Expression; Gene Expression Regulation; Gene Expression Regulation, Bacterial; Gene Expression Regulation, Neoplastic; Gene Expression Regulation, Plant; Gene Knockdown Techniques; Gene-Environment Interaction; Genotype; Germany; Glioma; Glomerular Filtration Rate; Glucagon; Glucocorticoids; Glycemic Control; Glycerol; Glycogen Synthase Kinase 3 beta; Glycolipids; Glycolysis; Goblet Cells; Gram-Negative Bacterial Infections; Granulocyte Colony-Stimulating Factor; Graphite; Greenhouse Effect; Guanidines; Haemophilus influenzae; HCT116 Cells; Health Knowledge, Attitudes, Practice; Health Personnel; Health Services Accessibility; Health Services Needs and Demand; Health Status Disparities; Healthy Volunteers; Heart Failure; Heart Rate; Heart Transplantation; Heart-Assist Devices; HEK293 Cells; Heme; Heme Oxygenase-1; Hemolysis; Hemorrhage; Hepatitis B; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Hepatocytes; Hexoses; High-Throughput Nucleotide Sequencing; Hippo Signaling Pathway; Histamine; Histamine Agonists; Histidine; Histone Deacetylase 2; HIV Infections; HIV Reverse Transcriptase; HIV-1; Homebound Persons; Homeodomain Proteins; Homosexuality, Male; Hospice and Palliative Care Nursing; HSP70 Heat-Shock Proteins; Humans; Hyaluronan Receptors; Hydrogen; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydrolysis; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemia; Hypoglycemic Agents; Hypoxia; Idiopathic Interstitial Pneumonias; Imaging, Three-Dimensional; Imatinib Mesylate; Immunotherapy; Implementation Science; Incidence; INDEL Mutation; Induced Pluripotent Stem Cells; Industrial Waste; Infant; Infant, Newborn; Inflammation; Inflammation Mediators; Infliximab; Infusions, Intravenous; Inhibitory Concentration 50; Injections; Insecticides; Insulin-Like Growth Factor Binding Protein 5; Insulin-Secreting Cells; Interleukin-1; Interleukin-17; Interleukin-8; Internship and Residency; Intestines; Intracellular Signaling Peptides and Proteins; Ion Transport; Iridaceae; Iridoid Glucosides; Islets of Langerhans Transplantation; Isodon; Isoflurane; Isotopes; Italy; Joint Instability; Ketamine; Kidney; Kidney Failure, Chronic; Kidney Function Tests; Kidney Neoplasms; Kinetics; Klebsiella pneumoniae; Knee Joint; Kruppel-Like Factor 4; Kruppel-Like Transcription Factors; Lactate Dehydrogenase 5; Laparoscopy; Laser Therapy; Lasers, Semiconductor; Lasers, Solid-State; Laurates; Lead; Leukocyte L1 Antigen Complex; Leukocytes, Mononuclear; Light; Lipid Peroxidation; Lipopolysaccharides; Liposomes; Liver; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Locomotion; Longitudinal Studies; Lopinavir; Lower Urinary Tract Symptoms; Lubricants; Lung; Lung Diseases, Interstitial; Lung Neoplasms; Lymphocyte Activation; Lymphocytes, Tumor-Infiltrating; Lymphoma, Mantle-Cell; Lysosomes; Macrophages; Male; Manganese Compounds; MAP Kinase Kinase 4; Mass Screening; Maternal Health; Medicine, Chinese Traditional; Melanoma, Experimental; Memantine; Membrane Glycoproteins; Membrane Proteins; Mesenchymal Stem Cell Transplantation; Metal Nanoparticles; Metalloendopeptidases; Metalloporphyrins; Methadone; Methane; Methicillin-Resistant Staphylococcus aureus; Mexico; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Inbred ICR; Mice, Knockout; Mice, Nude; Mice, SCID; Mice, Transgenic; Microarray Analysis; Microbial Sensitivity Tests; Microbiota; Micronutrients; MicroRNAs; Microscopy, Confocal; Microsomes, Liver; Middle Aged; Milk; Milk, Human; Minority Groups; Mitochondria; Mitochondrial Membranes; Mitochondrial Proteins; Models, Animal; Models, Molecular; Molecular Conformation; Molecular Docking Simulation; Molecular Dynamics Simulation; Molecular Epidemiology; Molecular Structure; Molecular Weight; Multilocus Sequence Typing; Multimodal Imaging; Muscle Strength; Muscle, Skeletal; Muscular Diseases; Mutation; Mycobacterium tuberculosis; Myocardial Stunning; Myristates; NAD(P)H Dehydrogenase (Quinone); Nanocomposites; Nanogels; Nanoparticles; Nanotechnology; Naphthalenes; Nasal Cavity; National Health Programs; Necrosis; Needs Assessment; Neoadjuvant Therapy; Neonicotinoids; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Proteins; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm Transplantation; Neoplasms; Neoplastic Stem Cells; Netherlands; Neuroblastoma; Neuroprotective Agents; Neutrophils; NF-kappa B; NFATC Transcription Factors; Nicotiana; Nicotine; Nitrates; Nitrification; Nitrites; Nitro Compounds; Nitrogen; Nitrogen Dioxide; North Carolina; Nuclear Magnetic Resonance, Biomolecular; Nuclear Proteins; Nucleic Acid Hybridization; Nucleosomes; Nutrients; Obesity; Obesity, Morbid; Oceans and Seas; Oncogene Protein v-akt; Oncogenes; Oocytes; Open Reading Frames; Osteoclasts; Osteogenesis; Osteoporosis; Osteoporosis, Postmenopausal; Outpatients; Ovarian Neoplasms; Ovariectomy; Overweight; Oxazines; Oxidants; Oxidation-Reduction; Oxidative Stress; Oxides; Oxidoreductases; Oxygen; Oxygen Inhalation Therapy; Oxygenators, Membrane; Ozone; Paclitaxel; Paenibacillus; Pain Measurement; Palliative Care; Pancreatic Neoplasms; Pandemics; Parasympathetic Nervous System; Particulate Matter; Pasteurization; Patient Preference; Patient Satisfaction; Pediatric Obesity; Permeability; Peroxiredoxins; Peroxynitrous Acid; Pharmaceutical Services; Pharmacists; Pharmacy; Phaseolus; Phenotype; Phoeniceae; Phosphates; Phosphatidylinositol 3-Kinases; Phospholipid Transfer Proteins; Phospholipids; Phosphorus; Phosphorylation; Photoperiod; Photosynthesis; Phylogeny; Physical Endurance; Physicians; Pilot Projects; Piperidines; Pituitary Adenylate Cyclase-Activating Polypeptide; Plant Extracts; Plant Leaves; Plant Proteins; Plant Roots; Plaque, Atherosclerotic; Pneumonia; Pneumonia, Viral; Point-of-Care Testing; Polyethylene Glycols; Polymers; Polysorbates; Pore Forming Cytotoxic Proteins; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Postprandial Period; Poverty; Pre-Exposure Prophylaxis; Prediabetic State; Predictive Value of Tests; Pregnancy; Pregnancy Trimester, First; Pregnancy, High-Risk; Prenatal Exposure Delayed Effects; Pressure; Prevalence; Primary Graft Dysfunction; Primary Health Care; Professional Role; Professionalism; Prognosis; Progression-Free Survival; Prolactin; Promoter Regions, Genetic; Proof of Concept Study; Proportional Hazards Models; Propylene Glycol; Prospective Studies; Prostate; Protein Binding; Protein Biosynthesis; Protein Isoforms; Protein Kinase Inhibitors; Protein Phosphatase 2; Protein Processing, Post-Translational; Protein Serine-Threonine Kinases; Protein Structure, Tertiary; Protein Transport; Proteoglycans; Proteome; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-myc; Proto-Oncogene Proteins c-ret; Proto-Oncogene Proteins p21(ras); Proton Pumps; Protons; Protoporphyrins; Pseudomonas aeruginosa; Pseudomonas fluorescens; Pulmonary Artery; Pulmonary Disease, Chronic Obstructive; Pulmonary Gas Exchange; Pulmonary Veins; Pyrazoles; Pyridines; Pyrimidines; Qualitative Research; Quinoxalines; Rabbits; Random Allocation; Rats; Rats, Sprague-Dawley; Rats, Wistar; Receptors, Histamine H3; Receptors, Immunologic; Receptors, Transferrin; Recombinant Proteins; Recurrence; Reference Values; Referral and Consultation; Regional Blood Flow; Registries; Regulon; Renal Insufficiency, Chronic; Reperfusion Injury; Repressor Proteins; Reproducibility of Results; Republic of Korea; Research Design; Resistance Training; Respiration, Artificial; Respiratory Distress Syndrome; Respiratory Insufficiency; Resuscitation; Retinal Dehydrogenase; Retreatment; Retrospective Studies; Reverse Transcriptase Inhibitors; Rhinitis, Allergic; Ribosomal Proteins; Ribosomes; Risk Assessment; Risk Factors; Ritonavir; Rivers; RNA Interference; RNA-Seq; RNA, Messenger; RNA, Ribosomal, 16S; RNA, Small Interfering; Rosuvastatin Calcium; Rural Population; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Salivary Ducts; Salivary Gland Neoplasms; San Francisco; SARS-CoV-2; Satiation; Satiety Response; Schools; Schools, Pharmacy; Seasons; Seawater; Selection, Genetic; Sequence Analysis, DNA; Serine-Threonine Kinase 3; Sewage; Sheep; Sheep, Domestic; Shock, Hemorrhagic; Signal Transduction; Silver; Silymarin; Single Photon Emission Computed Tomography Computed Tomography; Sirolimus; Sirtuin 1; Skin; Skin Neoplasms; Skin Physiological Phenomena; Sleep Initiation and Maintenance Disorders; Social Class; Social Participation; Social Support; Soil; Soil Microbiology; Solutions; Somatomedins; Soot; Specimen Handling; Spectrophotometry, Ultraviolet; Spectroscopy, Fourier Transform Infrared; Spectrum Analysis; Spinal Fractures; Spirometry; Staphylococcus aureus; STAT1 Transcription Factor; STAT3 Transcription Factor; Streptomyces coelicolor; Stress, Psychological; Stroke; Stroke Volume; Structure-Activity Relationship; Students, Medical; Students, Pharmacy; Substance Abuse Treatment Centers; Sulfur Dioxide; Surface Properties; Surface-Active Agents; Surveys and Questionnaires; Survival Analysis; Survival Rate; Survivin; Sweden; Swine; Swine, Miniature; Sympathetic Nervous System; T-Lymphocytes, Regulatory; Talaromyces; Tandem Mass Spectrometry; tau Proteins; Telemedicine; Telomerase; Telomere; Telomere Homeostasis; Temperature; Terminally Ill; Th1 Cells; Thiamethoxam; Thiazoles; Thiophenes; Thioredoxin Reductase 1; Thrombosis; Thulium; Thyroid Cancer, Papillary; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms; Time Factors; Titanium; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases; Transcription Factor AP-1; Transcription Factors; Transcription, Genetic; Transcriptional Activation; Transcriptome; Transforming Growth Factor beta1; Transistors, Electronic; Translational Research, Biomedical; Transplantation Tolerance; Transplantation, Homologous; Transportation; Treatment Outcome; Tretinoin; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary; Tubulin Modulators; Tumor Microenvironment; Tumor Necrosis Factor Inhibitors; Tumor Necrosis Factor-alpha; Twins; Ultrasonic Therapy; Ultrasonography; Ultraviolet Rays; United States; Up-Regulation; Uranium; Urethra; Urinary Bladder; Urodynamics; Uromodulin; Uveitis; Vasoconstrictor Agents; Ventricular Function, Left; Vero Cells; Vesicular Transport Proteins; Viral Nonstructural Proteins; Visual Acuity; Vital Capacity; Vitamin D; Vitamin D Deficiency; Vitamin K 2; Vitamins; Volatilization; Voriconazole; Waiting Lists; Waste Disposal, Fluid; Wastewater; Water Pollutants, Chemical; Whole Genome Sequencing; Wine; Wnt Signaling Pathway; Wound Healing; Wounds and Injuries; WW Domains; X-linked Nuclear Protein; X-Ray Diffraction; Xanthines; Xenograft Model Antitumor Assays; YAP-Signaling Proteins; Yogurt; Young Adult; Zebrafish; Zebrafish Proteins; Ziziphus | 2016 |
Tailored-dose chemotherapy with gemcitabine and irinotecan in patients with platinum-refractory/resistant ovarian or primary peritoneal cancer: a phase II trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Irinotecan; Ovarian Neoplasms; Platinum | 2021 |
Adavosertib plus gemcitabine for platinum-resistant or platinum-refractory recurrent ovarian cancer: a double-blind, randomised, placebo-controlled, phase 2 trial.
Topics: Antimetabolites, Antineoplastic; Canada; Deoxycytidine; Double-Blind Method; Enzyme Inhibitors; Female; Gemcitabine; Humans; Middle Aged; Ovarian Neoplasms; Pyrazoles; Pyrimidinones; Survival; United States | 2021 |
Phase II trial of cisplatin, gemcitabine and pembrolizumab for platinum-resistant ovarian cancer.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; CA-125 Antigen; Cisplatin; Deoxycytidine; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Platinum; Progression-Free Survival; Survival Rate; Treatment Outcome | 2021 |
Dendritic cell-based immunotherapy (DCVAC/OvCa) combined with second-line chemotherapy in platinum-sensitive ovarian cancer (SOV02): A randomized, open-label, phase 2 trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Combined Modality Therapy; Dendritic Cells; Deoxycytidine; Female; Gemcitabine; Humans; Immunotherapy, Adoptive; Middle Aged; Neoplasm Staging; Ovarian Neoplasms | 2021 |
A phase Ib study of pembrolizumab plus chemotherapy in patients with advanced cancer (PembroPlus).
Topics: Adenocarcinoma; Adult; Aged; Albumins; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Diarrhea; Docetaxel; Doxorubicin; Drug Eruptions; Fatigue; Female; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Nausea; Neoplasms; Ovarian Neoplasms; Paclitaxel; Pancreatic Neoplasms; Polyethylene Glycols; Sarcoma; Small Cell Lung Carcinoma; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine; Vomiting | 2017 |
Phase II study of paclitaxel associated with lipid core nanoparticles (LDE) as third-line treatment of patients with epithelial ovarian carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Deoxycytidine; Disease Progression; Disease-Free Survival; Doxorubicin; Female; Gemcitabine; Humans; Lipids; Nanoparticles; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Polyethylene Glycols | 2017 |
Randomized Controlled Trial Testing the Efficacy of Platinum-Free Interval Prolongation in Advanced Ovarian Cancer: The MITO-8, MaNGO, BGOG-Ov1, AGO-Ovar2.16, ENGOT-Ov1, GCIG Study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Dioxoles; Disease Progression; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Early Termination of Clinical Trials; Europe; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Polyethylene Glycols; Prospective Studies; Tetrahydroisoquinolines; Time Factors; Topotecan; Trabectedin; Treatment Outcome | 2017 |
Phase I combination study of the PARP inhibitor veliparib plus carboplatin and gemcitabine in patients with advanced ovarian cancer and other solid malignancies.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Bayes Theorem; Benzimidazoles; Bile Duct Neoplasms; Breast Neoplasms; Carboplatin; Carcinoma, Basal Cell; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Cholangiocarcinoma; Deoxycytidine; Female; Gallbladder Neoplasms; Gemcitabine; Genes, BRCA1; Genes, BRCA2; Germ-Line Mutation; Humans; Induction Chemotherapy; Kidney Neoplasms; Kidney Pelvis; Liver Neoplasms; Lung Neoplasms; Maintenance Chemotherapy; Male; Maximum Tolerated Dose; Mesothelioma; Middle Aged; Nausea; Neoplasm Metastasis; Neutropenia; Ovarian Neoplasms; Poly(ADP-ribose) Polymerase Inhibitors; Prostatic Neoplasms; Skin Neoplasms; Thrombocytopenia; Treatment Outcome | 2018 |
Combination of weekly topotecan and gemcitabine as a salvage treatment in patients with recurrent ovarian cancer: a phase I study.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Drug Administration Schedule; Drug Combinations; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Salvage Therapy; Topotecan | 2019 |
Impact of beta blocker medication in patients with platinum sensitive recurrent ovarian cancer-a combined analysis of 2 prospective multicenter trials by the AGO Study Group, NCIC-CTG and EORTC-GCG.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Disease-Free Survival; Female; Follow-Up Studies; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Young Adult | 2013 |
Phase I dose-escalation study and population pharmacokinetic analysis of fixed dose rate gemcitabine plus carboplatin as second-line therapy in patients with ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma; Deoxycytidine; Female; Gemcitabine; Humans; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Ovarian Neoplasms; Thrombocytopenia | 2013 |
Treatment outcomes of paclitaxel for refractory or recurrent epithelial ovarian cancer patients in Thailand.
Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Carboplatin; Carcinoma, Transitional Cell; Cisplatin; Cyclophosphamide; Cystadenocarcinoma, Serous; Deoxycytidine; Drug Resistance, Neoplasm; Endometrial Neoplasms; Etoposide; Female; Follow-Up Studies; Gemcitabine; Humans; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Prognosis; Survival Rate | 2013 |
Phase II clinical study on the GEMOX regimen as second- line therapy for advanced ovarian cancer.
Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Case-Control Studies; Cystadenocarcinoma, Serous; Deoxycytidine; Endometrial Neoplasms; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Ovarian Neoplasms; Prognosis; Quality of Life; Survival Rate | 2013 |
Gemcitabine-oxaliplatin (GEMOX) as salvage treatment in pretreated epithelial ovarian cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Cohort Studies; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin; Salvage Therapy | 2013 |
Independent radiologic review: bevacizumab in combination with gemcitabine and carboplatin in recurrent ovarian cancer.
Topics: Adult; Advisory Committees; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Radiology; Tomography, X-Ray Computed | 2014 |
A phase II study of gemcitabine, carboplatin and bevacizumab for the treatment of platinum-sensitive recurrent ovarian cancer.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Deoxycytidine; Drug Therapy, Combination; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms | 2014 |
Bevacizumab shows activity in patients with low-grade serous ovarian and primary peritoneal cancer.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Ovarian Epithelial; Cyclophosphamide; Cystadenocarcinoma, Serous; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Prognosis; Retrospective Studies; Survival Rate; Topotecan; Young Adult | 2014 |
Phase II study of gemcitabine and vinorelbine as second- or third-line therapy in patients with primary refractory or platinum-resistant recurrent ovarian and primary peritoneal cancer by the Korean Cancer Study Group (KCSG)_KCSG GY10-10.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Organoplatinum Compounds; Ovarian Neoplasms; Peritoneal Neoplasms; Republic of Korea; Vinblastine; Vinorelbine | 2015 |
Phase I study of combination of vorinostat, carboplatin, and gemcitabine in women with recurrent, platinum-sensitive epithelial ovarian, fallopian tube, or peritoneal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Fallopian Tube Neoplasms; Female; Gemcitabine; Humans; Hydroxamic Acids; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Peritoneal Neoplasms; Vorinostat | 2015 |
Final overall survival and safety analysis of OCEANS, a phase 3 trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent ovarian cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Ovarian Epithelial; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Survival Rate | 2015 |
A phase 1/2 study combining gemcitabine, Pegintron and p53 SLP vaccine in patients with platinum-resistant ovarian cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cancer Vaccines; Cells, Cultured; Deoxycytidine; Drug Administration Schedule; Drug Resistance, Neoplasm; Feasibility Studies; Female; Gemcitabine; Humans; Interferon alpha-2; Interferon-alpha; Lymphocytes, Tumor-Infiltrating; Middle Aged; Netherlands; Ovarian Neoplasms; Platinum Compounds; Polyethylene Glycols; Recombinant Proteins; T-Lymphocytes; Time Factors; Treatment Outcome; Tumor Suppressor Protein p53 | 2015 |
A phase I combination dose-escalation study of eribulin mesylate and gemcitabine in patients with advanced solid tumours: a study of the Princess Margaret Consortium.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Endometrial Neoplasms; Female; Furans; Gemcitabine; Humans; Ketones; Male; Middle Aged; Neoplasm Metastasis; Neoplasms; Neutropenia; Ontario; Ovarian Neoplasms; Response Evaluation Criteria in Solid Tumors; Treatment Outcome | 2015 |
Impact of Chemotherapy on Retroperitoneal Lymph Nodes in Ovarian Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Carboplatin; Deoxycytidine; Female; Fibrosis; Gemcitabine; Humans; Lymph Node Excision; Lymph Nodes; Lymphatic Metastasis; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Ovarian Neoplasms; Prognosis; Retroperitoneal Space; Taxoids | 2016 |
Models for change in tumour size, appearance of new lesions and survival probability in patients with advanced epithelial ovarian cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Deoxycytidine; Gemcitabine; Humans; Models, Biological; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Survival Analysis | 2016 |
Pertuzumab Plus Chemotherapy for Platinum-Resistant Ovarian Cancer: Safety Run-in Results of the PENELOPE Trial.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Middle Aged; Organoplatinum Compounds; Ovarian Neoplasms; Paclitaxel; Topotecan | 2016 |
Topotecan plus carboplatin versus standard therapy with paclitaxel plus carboplatin (PC) or gemcitabine plus carboplatin (GC) or pegylated liposomal doxorubicin plus carboplatin (PLDC): a randomized phase III trial of the NOGGO-AGO-Study Group-AGO Austria
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Austria; Carboplatin; Deoxycytidine; Disease-Free Survival; Doxorubicin; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Polyethylene Glycols; Quality of Life; Topotecan | 2016 |
Treatment of recurrent or persistent platinum-refractory ovarian, fallopian tube or primary peritoneal cancer with gemcitabine and topotecan: a phase II trial of the Puget Sound Oncology Consortium.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; Fallopian Tube Neoplasms; Female; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Peritoneal Neoplasms; Quality of Life; Topotecan | 2008 |
Nonplatinum topotecan combinations versus topotecan alone for recurrent ovarian cancer: results of a phase III study of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group.
Topics: Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Chi-Square Distribution; Deoxycytidine; Etoposide; Female; Gemcitabine; Germany; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Proportional Hazards Models; Quality of Life; Survival Rate; Topotecan; Treatment Outcome | 2008 |
Phase II study of single-agent gemcitabine in heavily pretreated Japanese patients with recurrent ovarian cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Salvage Therapy | 2008 |
A phase I trial of pemetrexed plus gemcitabine given biweekly with B-vitamin support in solid tumor malignancies or advanced epithelial ovarian cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Deoxycytidine; Dietary Supplements; Drug Administration Schedule; Female; Folic Acid; Gemcitabine; Glutamates; Guanine; Humans; Maximum Tolerated Dose; Neoplasms; Neutropenia; Ovarian Neoplasms; Pemetrexed; Treatment Outcome; Vitamin B Complex | 2008 |
A phase II trial of fixed-dosed rate gemcitabine in platinum-resistant ovarian cancer: a GEICO (Grupo Español de Investigación en Cáncer de Ovario) Trial.
Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Endometrioid; Cystadenocarcinoma, Serous; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Infusions, Intravenous; Middle Aged; Organoplatinum Compounds; Ovarian Neoplasms; Peritoneal Neoplasms; Prognosis; Ribonucleotide Reductases; Survival Rate | 2008 |
Management of platinum-resistant ovarian cancer with the combination of pemetrexed and gemcitabine.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Gemcitabine; Glutamates; Guanine; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Pemetrexed; Platinum Compounds; Salvage Therapy; Survival Analysis; Treatment Outcome | 2009 |
Gemcitabine-oxaliplatin combination for ovarian cancer resistant to taxane-platinum treatment: a phase II study from the GINECO group.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Deoxycytidine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Middle Aged; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin; Platinum; Taxoids | 2009 |
Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Disease-Free Survival; Doxorubicin; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Polyethylene Glycols; Topotecan | 2009 |
A phase II study of capecitabine in the treatment of ovarian cancer resistant or refractory to platinum therapy: a multicentre Italian trial in ovarian cancer (MITO-6) trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Middle Aged; Organoplatinum Compounds; Ovarian Neoplasms; Patient Compliance; Survival Analysis | 2009 |
Venous thromboembolism in recurrent ovarian cancer-patients: A systematic evaluation of the North-Eastern German Society of Gynaecologic Oncology Ovarian Cancer Study Group (NOGGO).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cohort Studies; Deoxycytidine; Disease-Free Survival; Etoposide; Female; Gemcitabine; Germany; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Prognosis; Retrospective Studies; Survival Rate; Topotecan; Venous Thromboembolism | 2009 |
A phase I/II study of docetaxel and gemcitabine combination for chemotherapy-resistant ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Middle Aged; Ovarian Neoplasms; Taxoids | 2009 |
A feasibility study of weekly docetaxel with capecitabine in ovarian cancer: a promising combination of two active drugs with a potential for synergism.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Docetaxel; Drug Administration Schedule; Drug Synergism; Feasibility Studies; Female; Fluorouracil; Humans; Middle Aged; Ovarian Neoplasms; Taxoids | 2009 |
Weekly combination of topotecan and gemcitabine in early recurrent ovarian cancer patients: a French multicenter phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intravenous; Middle Aged; Ovarian Neoplasms; Quality of Life; Topotecan; Treatment Outcome | 2009 |
Fixed-dose rate gemcitabine plus carboplatin in relapsed, platinum-sensitive ovarian cancer patients: results of a three-arm Phase I study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cohort Studies; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Middle Aged; Ovarian Neoplasms | 2009 |
Clinical activity of gemcitabine plus pertuzumab in platinum-resistant ovarian cancer, fallopian tube cancer, or primary peritoneal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Double-Blind Method; Fallopian Tube Neoplasms; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Ovarian Neoplasms; Peritoneal Neoplasms; Receptor, ErbB-2; Receptor, ErbB-3; RNA, Messenger | 2010 |
Gemcitabine and vinorelbine combination in platinum-sensitive recurrent ovarian cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Papillary; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Feasibility Studies; Female; Gemcitabine; Humans; Middle Aged; Ovarian Neoplasms; Platinum Compounds; Recurrence; Survival Analysis; Vinblastine; Vinorelbine | 2009 |
Phase 2 trial of docetaxel, gemcitabine, and oxaliplatin combination chemotherapy in platinum- and paclitaxel-pretreated epithelial ovarian cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Fallopian Tube Neoplasms; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin; Paclitaxel; Peritoneal Neoplasms; Prognosis; Prospective Studies; Risk Factors; Taxoids; Treatment Outcome; Young Adult | 2009 |
[Final results of cooperative studies of dicarbamine used as a hemoprotector in combination chemotherapy for cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Caproates; Cyclophosphamide; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Hematinics; Humans; Imidazoles; Leukopenia; Middle Aged; Neutropenia; Ovarian Neoplasms; Treatment Outcome | 2009 |
Biweekly vinorelbine and gemcitabine as second-line and beyond treatment in ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Drug Administration Schedule; Female; Gemcitabine; Humans; Middle Aged; Ovarian Neoplasms; Prospective Studies; Treatment Outcome; Vinblastine; Vinorelbine | 2011 |
First-line therapy for ovarian cancer with carboplatin followed by paclitaxel-gemcitabine (SCOTROC5): a feasibility study and comparative analysis of the SCOTROC series.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Disease-Free Survival; Feasibility Studies; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Middle Aged; Ovarian Neoplasms; Paclitaxel; Treatment Outcome | 2010 |
Carboplatin/gemcitabine alternating with carboplatin/pegylated liposomal doxorubicin and carboplatin/cyclophosphamide in platinum-refractory/resistant paclitaxel - pretreated ovarian carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cyclophosphamide; Deoxycytidine; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Middle Aged; Ovarian Neoplasms; Polyethylene Glycols; Prospective Studies; Survival Rate | 2010 |
A phase II study of combination chemotherapy in early relapsed epithelial ovarian cancer using gemcitabine and pegylated liposomal doxorubicin.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cystadenocarcinoma, Serous; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Doxorubicin; Female; Gemcitabine; Humans; Middle Aged; Ovarian Neoplasms; Polyethylene Glycols; Survival Rate | 2010 |
Multicenter phase 2 study of combined gemcitabine and epirubicin as second-line treatment for patients with advanced ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Epirubicin; Female; Follow-Up Studies; Gemcitabine; Humans; Infusions, Intravenous; Italy; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Remission Induction; Survival Analysis; Treatment Outcome | 2010 |
Inhibition of carboplatin-induced DNA interstrand cross-link repair by gemcitabine in patients receiving these drugs for platinum-resistant ovarian cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carboplatin; Deoxycytidine; DNA Damage; DNA Repair; DNA, Neoplasm; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Middle Aged; Ovarian Neoplasms; Platinum Compounds; Time Factors; Treatment Outcome | 2010 |
Phase III trial of carboplatin plus paclitaxel with or without gemcitabine in first-line treatment of epithelial ovarian cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Europe; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Middle Aged; Ovarian Neoplasms; Paclitaxel; Proportional Hazards Models; Prospective Studies; Quality of Life; Time Factors; Treatment Outcome; Young Adult | 2010 |
Sorafenib in combination with gemcitabine in recurrent epithelial ovarian cancer: a study of the Princess Margaret Hospital Phase II Consortium.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Deoxycytidine; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Ovarian Neoplasms; Phenylurea Compounds; Pyridines; Sorafenib; Survival Analysis; Treatment Outcome | 2010 |
Adjuvant chemoradiation versus chemotherapy in completely resected advanced gastric cancer with D2 nodal dissection.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gastrectomy; Humans; Liver Neoplasms; Lymph Node Excision; Male; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Peritoneal Neoplasms; Radiotherapy, Adjuvant; Stomach Neoplasms; Survival Rate; Treatment Outcome | 2010 |
Human biodistribution and radiation dosimetry of novel PET probes targeting the deoxyribonucleoside salvage pathway.
Topics: Adult; Deoxycytidine; Deoxyribonucleosides; Female; Humans; Lymphoma; Male; Metabolic Networks and Pathways; Ovarian Neoplasms; Positron-Emission Tomography; Radiometry; Young Adult | 2011 |
[Gemcitabine based combination chemotherapy, a new salvage regimen for recurrent platinum resistant epithelial ovarian cancer].
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Resistance, Neoplasm; Epirubicin; Female; Gemcitabine; Humans; Ifosfamide; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neutropenia; Ovarian Neoplasms; Platinum Compounds; Prognosis; Retrospective Studies; Salvage Therapy; Survival Rate; Treatment Outcome | 2010 |
Pegylated liposomal doxorubicin and gemcitabine in a fixed dose rate infusion for the treatment of patients with poor prognosis of recurrent ovarian cancer: a phase Ib study.
Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cystadenocarcinoma, Serous; Deoxycytidine; Doxorubicin; Endometrial Neoplasms; Female; Gemcitabine; Humans; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Polyethylene Glycols; Survival Rate; Tissue Distribution; Treatment Outcome | 2011 |
[Comparison between the effects of irinotecan or oxaliplatin combined with capecitabine in the treatment of advanced gastric cancer].
Topics: Adenocarcinoma; Adult; Aged; Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Deoxycytidine; Diarrhea; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Liver Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Neuritis; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin; Remission Induction; Stomach Neoplasms; Young Adult | 2011 |
Second-line treatment with intravenous gemcitabine and oral etoposide in platinum-resistant advanced ovarian cancer patients: results of a phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; Deoxycytidine; Drug Resistance, Neoplasm; Etoposide; Female; Gemcitabine; Humans; Middle Aged; Ovarian Neoplasms; Platinum; Survival Analysis; Treatment Outcome | 2011 |
Phase III trial of induction gemcitabine or paclitaxel plus carboplatin followed by paclitaxel consolidation in ovarian cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Deoxycytidine; Disease-Free Survival; Fallopian Tube Neoplasms; Female; Gemcitabine; Humans; Induction Chemotherapy; Middle Aged; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Survival Rate; Young Adult | 2011 |
A phase II study of gemcitabine in combination with tanespimycin in advanced epithelial ovarian and primary peritoneal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzoquinones; Biomarkers, Tumor; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cohort Studies; Deoxycytidine; Female; Gemcitabine; HSP70 Heat-Shock Proteins; HSP90 Heat-Shock Proteins; Humans; Lactams, Macrocyclic; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Peritoneal Neoplasms; Survival Rate | 2012 |
Common variants in ABCB1, ABCC2 and ABCG2 genes and clinical outcomes among women with advanced stage ovarian cancer treated with platinum and taxane-based chemotherapy: a Gynecologic Oncology Group study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Carboplatin; Cisplatin; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Humans; Middle Aged; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Ovarian Neoplasms; Paclitaxel; Polymorphism, Genetic; Topotecan; Young Adult | 2012 |
Phase II study of gemcitabine and docetaxel in recurrent platinum resistant ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Taxoids | 2012 |
Intraperitoneal chemotherapy by ultrasound-guided direct puncture in recurrent ovarian cancer: feasibility, compliance, and complications.
Topics: Adult; Aged; Antineoplastic Agents; Cisplatin; Deoxycytidine; Feasibility Studies; Female; Gemcitabine; Humans; Injections, Intraperitoneal; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Patient Compliance; Pilot Projects; Prospective Studies; Ultrasonography, Interventional | 2012 |
New-onset congestive heart failure with gemcitabine in ovarian and other solid cancers.
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Coronary Artery Disease; Deoxycytidine; Diabetes Mellitus; Female; Gemcitabine; Heart Failure; Humans; Lung Neoplasms; Middle Aged; Ovarian Neoplasms; Pancreatic Neoplasms; Retrospective Studies; Urinary Bladder Neoplasms | 2014 |
Weekly administration of bevacizumab, gemcitabine, and oxaliplatin in patients with recurrent and refractory ovarian cancer: a preliminary result of 19 cases.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma; Deoxycytidine; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Organoplatinum Compounds; Ovarian Neoplasms; Pilot Projects; Recurrence; Treatment Outcome | 2013 |
Pharmacodynamic stimulation of thrombogenesis by angiotensin (1-7) in recurrent ovarian cancer patients receiving gemcitabine and platinum-based chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Angiotensin I; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carboplatin; Cisplatin; Deoxycytidine; Double-Blind Method; Female; Gemcitabine; Humans; Middle Aged; Ovarian Neoplasms; Peptide Fragments; Thrombocytopenia | 2013 |
Phase I-II and pharmacokinetic study of gemcitabine combined with oxaliplatin in patients with advanced non-small-cell lung cancer and ovarian carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Confidence Intervals; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; France; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin; Probability; Prognosis; Risk Assessment; Severity of Illness Index; Survival Analysis; Treatment Outcome | 2002 |
Gemcitabine and interferon-alpha 2b in solid tumors: a phase I study in patients with advanced or metastatic non-small cell lung, ovarian, pancreatic or renal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Infusions, Intravenous; Injections, Subcutaneous; Interferon alpha-2; Interferon-alpha; Karnofsky Performance Status; Kidney Neoplasms; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Ovarian Neoplasms; Pancreatic Neoplasms; Recombinant Proteins; Treatment Outcome | 2002 |
Phase II study of gemcitabine and cisplatin in chemonaive patients with advanced epithelial ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms | 2002 |
A phase II study of topotecan plus gemcitabine in the treatment of patients with relapsed ovarian cancer after failure of first-line chemotherapy.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Confidence Intervals; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Ovariectomy; Probability; Survival Analysis; Topotecan; Treatment Failure; Treatment Outcome | 2002 |
Gemcitabine reverses cisplatin resistance: demonstration of activity in platinum- and multidrug-resistant ovarian and peritoneal carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Drug Administration Schedule; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Synergism; Female; Gemcitabine; Humans; Infusions, Intravenous; Middle Aged; Ovarian Neoplasms; Peritoneal Neoplasms | 2003 |
Phase II trial of gemcitabine plus cisplatin repeating doublet therapy in previously treated, relapsed ovarian cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Middle Aged; Ovarian Neoplasms; Receptor, ErbB-2 | 2003 |
Phase II study of gemcitabine in recurrent platinum-and paclitaxel-resistant ovarian cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Deoxycytidine; Drug Administration Schedule; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Infusions, Intravenous; Middle Aged; Organoplatinum Compounds; Ovarian Neoplasms; Paclitaxel; Salvage Therapy | 2003 |
Phase I trial of docetaxel, carboplatin, and gemcitabine as first-line therapy for patients with high-risk epithelial tumors of müllerian origin.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Epithelial Cells; Female; Gemcitabine; Humans; Middle Aged; Mullerian Ducts; Ovarian Neoplasms; Paclitaxel; Taxoids | 2003 |
Treatment of recurrent platinum resistant ovarian or peritoneal cancer with gemcitabine and doxorubicin: A phase I/II trial of the Puget Sound Oncology Consortium (PSOC 1602).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Doxorubicin; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Peritoneal Neoplasms; Platinum; Prospective Studies; Quality of Life; Survival Analysis; Treatment Outcome; Washington | 2003 |
Clinical trials of newer regimens for treating ovarian cancer: the rationale for Gynecologic Oncology Group Protocol GOG 182-ICON5.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Humans; Liposomes; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Topotecan | 2003 |
Phase 2 trial of single-agent gemcitabine in platinum-paclitaxel refractory ovarian cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Fallopian Tube Neoplasms; Female; Gemcitabine; Humans; Middle Aged; Organoplatinum Compounds; Ovarian Neoplasms; Paclitaxel | 2003 |
Phase II study of liposomal doxorubicin and gemcitabine in the salvage treatment of ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Humans; Infusions, Intravenous; Liposomes; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Salvage Therapy; Treatment Outcome | 2003 |
Gemcitabine combined with cisplatin as first-line treatment in patients with epithelial ovarian cancer: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intravenous; Middle Aged; Ovarian Neoplasms; Survival Rate | 2003 |
A phase II trial of three sequential doublets for the treatment of advanced müllerian malignancies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; Cystadenocarcinoma, Papillary; Cystadenocarcinoma, Serous; Deoxycytidine; Doxorubicin; Drug Administration Schedule; Endometrial Neoplasms; Fallopian Tube Neoplasms; Female; Gemcitabine; Genital Neoplasms, Female; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Mixed Tumor, Mullerian; Ovarian Neoplasms; Peritoneal Neoplasms; Topotecan | 2003 |
A phase II trial of capecitabine (Xeloda) in recurrent ovarian cancer.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Capecitabine; Cisplatin; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Quality of Life | 2003 |
Phase I feasibility trial of carboplatin, paclitaxel, and gemcitabine in patients with previously untreated epithelial ovarian or primary peritoneal cancer: a Gynecologic Oncology Group study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Drug Administration Schedule; Epithelial Cells; Female; Gemcitabine; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms | 2004 |
Second-line chemotherapy with gemcitabine and carboplatin in paclitaxel-pretreated, platinum-sensitive ovarian cancer patients. A Hellenic Cooperative Oncology Group Study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Prospective Studies | 2004 |
Dose finding study for combination treatment with topotecan and gemcitabine of patients with recurrent ovarian cancer after failure of first-line chemotherapy with Paclitaxel and platinum.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Retreatment; Topotecan; Treatment Failure | 2004 |
Dose intense triplet chemotherapy with gemcitabine, carboplatin, paclitaxel with peripheral blood progenitor cell support for six cycles in advanced epithelial ovarian cancer.
Topics: Adolescent; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Female; Gemcitabine; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Maximum Tolerated Dose; Middle Aged; Ovarian Neoplasms; Paclitaxel; Transplantation, Autologous | 2004 |
A phase II trial of capecitabine in heavily pre-treated platinum-resistant ovarian cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Drug Resistance, Neoplasm; Fallopian Tube Neoplasms; Female; Fluorouracil; Humans; Middle Aged; Organoplatinum Compounds; Ovarian Neoplasms; Peritoneal Neoplasms | 2004 |
Phase II study of gemcitabine and weekly paclitaxel in recurrent platinum-resistant ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Middle Aged; Organoplatinum Compounds; Ovarian Neoplasms; Paclitaxel | 2004 |
Intraperitoneal cisplatin with intraperitoneal gemcitabine in patients with epithelial ovarian cancer: results of a phase I/II Trial.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Cisplatin; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Injections, Intraperitoneal; Middle Aged; Nausea; Neutropenia; Ovarian Neoplasms; Survival Analysis; Thrombocytopenia; Treatment Outcome; Vomiting | 2004 |
A phase II feasibility study of carboplatin followed by sequential weekly paclitaxel and gemcitabine as first-line treatment for ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Fallopian Tube Neoplasms; Female; Gemcitabine; Humans; Lung; Middle Aged; Neutropenia; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Treatment Outcome | 2004 |
Triplet combination of gemcitabine, carboplatin, and paclitaxel in previously treated, relapsed ovarian and peritoneal carcinoma: an experience in Taiwan.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Salvage Therapy | 2004 |
Pilot study of outpatient paclitaxel, carboplatin and gemcitabine for advanced stage epithelial ovarian, peritoneal, and fallopian tube cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Fallopian Tube Neoplasms; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Pilot Projects | 2004 |
Experience with single-agent paclitaxel consolidation following primary chemotherapy with carboplatin, paclitaxel, and gemcitabine in advanced ovarian cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel | 2005 |
Weekly gemcitabine, paclitaxel, oxaliplatin combination chemotherapy in patients with Cisplatin-refractory germ cell tumor: preliminary experience.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Germinoma; Humans; Male; Mediastinal Neoplasms; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin; Paclitaxel; Survival Analysis; Testicular Neoplasms | 2004 |
A phase II study of gemcitabine plus carboplatin in platinum-sensitive, recurrent ovarian carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms | 2005 |
A phase II study of paclitaxel, carboplatin, and gemcitabine in previously untreated patients with epithelial ovarian cancer FIGO stage IC-IV (AGO-OVAR protocol OVAR-8).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Disease-Free Survival; Epithelial Cells; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel | 2005 |
Gemcitabine combined with oxaliplatin (GEMOX) as second-line chemotherapy in patients with advanced ovarian cancer refractory or resistant to platinum and taxane.
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Administration Schedule; Drug Resistance, Neoplasm; Feasibility Studies; Female; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Maximum Tolerated Dose; Middle Aged; Neutropenia; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin; Platinum Compounds; Severity of Illness Index; Taxoids; Thrombocytopenia; Treatment Outcome | 2004 |
Phase II clinical trial of capecitabine in ovarian carcinoma recurrent 6-12 months after completion of primary chemotherapy, with exploratory TS, DPD, and TP correlates: a Gynecologic Oncology Group study.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); Drug Screening Assays, Antitumor; Female; Fluorouracil; Gene Expression; Humans; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Ovarian Neoplasms; Peritoneal Neoplasms; Thymidine Phosphorylase; Thymidylate Synthase | 2005 |
A multicenter phase II study of gemcitabine, paclitaxel, and cisplatin in chemonaïve advanced ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel | 2005 |
Gemcitabine and liposomal doxorubicin in the salvage treatment of ovarian cancer: updated results and long-term survival.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Doxorubicin; Drug Administration Schedule; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Salvage Therapy; Survival Rate | 2005 |
A phase I trial of gemcitabine and topotecan in previously treated ovarian or peritoneal cancer: a Gynecologic Oncology Group study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Dose-Response Relationship, Drug; Fallopian Tube Neoplasms; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Peritoneal Neoplasms; Topotecan | 2006 |
Sequential gemcitabine-carboplatin followed by paclitaxel-carboplatin in the first-line treatment of advanced ovarian cancer: A phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; Carboplatin; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Staging; Neutropenia; Ovarian Neoplasms; Paclitaxel | 2006 |
Combination chemotherapy with carboplatin, capecitabine and epirubicin (ECarboX) as second- or third-line treatment in patients with relapsed ovarian cancer: a phase I/II trial.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Deoxycytidine; Epirubicin; Female; Humans; Infusions, Intravenous; Injections, Intravenous; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Treatment Outcome | 2006 |
Phase I trial of gemcitabine, doxorubicin and cisplatin (GAP) in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Doxorubicin; Endometrial Neoplasms; Female; Gemcitabine; Humans; Male; Middle Aged; Nasopharyngeal Neoplasms; Neoplasms; Ovarian Neoplasms | 2006 |
SCOTROC 2A: carboplatin followed by docetaxel or docetaxel-gemcitabine as first-line chemotherapy for ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Deoxycytidine; Disease Progression; Docetaxel; Drug Administration Schedule; Dyspnea; Fallopian Tube Neoplasms; Female; Gemcitabine; Humans; Infusions, Intravenous; Middle Aged; Ovarian Neoplasms; Peritoneal Neoplasms; Survival Analysis; Taxoids; Treatment Outcome | 2006 |
Combined PEG liposomal doxorubicin and gemcitabine are active and have acceptable toxicity in patients with platinum-refractory and -resistant ovarian cancer after previous platinum-taxane therapy: a phase II Austrian AGO study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Doxorubicin; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Polyethylene Glycols; Quality of Life | 2006 |
Phase I/II study of weekly paclitaxel plus carboplatin and gemcitabine as first-line treatment of advanced-stage ovarian cancer: pathologic complete response and longitudinal assessment of impact on cognitive functioning.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cognition; Cognition Disorders; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Longitudinal Studies; Middle Aged; Ovarian Neoplasms; Paclitaxel; Quality of Life | 2006 |
A phase II trial of oral capecitabine in patients with platinum--and taxane--refractory ovarian, fallopian tube, or peritoneal cancer.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Bridged-Ring Compounds; Capecitabine; Deoxycytidine; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Middle Aged; Ovarian Neoplasms; Peritoneal Neoplasms; Platinum Compounds; Taxoids | 2006 |
Phase II study of capecitabine and irinotecan combination chemotherapy in patients with advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Deoxycytidine; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Irinotecan; Liver Neoplasms; Male; Middle Aged; Ovarian Neoplasms; Peritoneal Neoplasms; Stomach Neoplasms; Survival Rate | 2006 |
Gemcitabine and oxaliplatin followed by paclitaxel and carboplatin as first line therapy for patients with suboptimally debulked, advanced epithelial ovarian cancer. A phase II trial of sequential doublets. The GO-First Study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Middle Aged; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin; Paclitaxel; Survival Rate | 2006 |
Cisplatin plus gemcitabine in platinum-refractory ovarian or primary peritoneal cancer: a phase II study of the Gynecologic Oncology Group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Peritoneal Neoplasms | 2006 |
Three sequential chemotherapy doublets for the treatment of newly diagnosed advanced müllerian malignancies: the modified triple doublet regimen.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Doxorubicin; Drug Administration Schedule; Fallopian Tube Neoplasms; Female; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Mixed Tumor, Mullerian; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Topotecan | 2006 |
Gemcitabine and anthracyclines in platinum-resistant ovarian cancer.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Middle Aged; Ovarian Neoplasms; Platinum Compounds; Treatment Outcome | 2006 |
Stimulation of erythrocyte phosphatidylserine exposure by paclitaxel.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Calcium; Carboplatin; Cell Size; Ceramides; Deoxycytidine; Endometrial Neoplasms; Erythrocytes; Female; Gemcitabine; Hematocrit; Humans; Mice; Mice, Inbred C57BL; Osmotic Pressure; Ovarian Neoplasms; Paclitaxel; Phosphatidylserines; Protein Binding; Sphingomyelin Phosphodiesterase; Time Factors | 2006 |
Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Quality of Life; Survival Analysis; Treatment Outcome | 2006 |
Biweekly gemcitabine and cisplatin in platinum-resistant/refractory, paclitaxel-pretreated, ovarian and peritoneal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Prospective Studies | 2007 |
First-line gemcitabine and carboplatin in advanced ovarian carcinoma: a phase II study.
Topics: Anemia; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Female; Gemcitabine; Humans; Middle Aged; Ovarian Neoplasms; Survival Analysis; Thrombocytopenia; Treatment Outcome | 2006 |
Phase II study of paclitaxel plus gemcitabine salvage chemotherapy for germ cell tumors after progression following high-dose chemotherapy with tandem transplant.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Follow-Up Studies; Gemcitabine; Humans; Indiana; Kaplan-Meier Estimate; Male; Neoplasms, Germ Cell and Embryonal; Ovarian Neoplasms; Paclitaxel; Retrospective Studies; Salvage Therapy; Testicular Neoplasms; Time Factors; Treatment Failure; Treatment Outcome | 2007 |
A phase I trial of BMS-247550 (NSC# 710428) and gemcitabine in patients with advanced solid tumors.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cohort Studies; Deoxycytidine; Dose-Response Relationship, Drug; Epothilones; Female; Gemcitabine; Humans; Kidney Neoplasms; Leukopenia; Lung Neoplasms; Male; Melanoma; Middle Aged; Neoplasms; Ovarian Neoplasms; Sarcoma; Urinary Bladder Neoplasms; Uterine Neoplasms; Water-Electrolyte Imbalance | 2007 |
Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Cisplatin; Deoxycytidine; Disease-Free Survival; Doxorubicin; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Middle Aged; Ovarian Neoplasms; Polyethylene Glycols; Treatment Outcome | 2007 |
Gemcitabine and pegylated liposomal doxorubicin alternating with cisplatin plus cyclophosphamide in platinum refractory/resistant, paclitaxel-pretreated, ovarian carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Cyclophosphamide; Deoxycytidine; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Drug Resistance, Neoplasm; Epithelial Cells; Female; Gemcitabine; Humans; Infusions, Intravenous; Middle Aged; Ovarian Neoplasms; Paclitaxel; Polyethylene Glycols | 2008 |
Phase II study of gemcitabine combined with platinum chemotherapy for recurrent epithelial ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Platinum Compounds | 2007 |
Gemcitabine combined with oxaliplatin (GEMOX) as salvage treatment in elderly patients with advanced ovarian cancer refractory or resistant to platinum: a single institution experience.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin; Platinum Compounds; Salvage Therapy | 2007 |
Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Deoxycytidine; Disease Progression; Doxorubicin; Drug Administration Schedule; Female; Gemcitabine; Humans; Italy; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Polyethylene Glycols; Quality of Life; Treatment Outcome | 2008 |
Prognostic role of Ca125 response criteria and RECIST criteria: analysis of results from the MITO-3 phase III trial of gemcitabine versus pegylated liposomal doxorubicin in recurrent ovarian cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; CA-125 Antigen; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Polyethylene Glycols; Predictive Value of Tests; Prognosis; Survival Analysis | 2008 |
Phase II study of gemcitabine (2',2'-difluorodeoxycytidine) in previously treated ovarian cancer patients.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Deoxycytidine; Drug Administration Schedule; Drug Resistance, Multiple; Female; Gemcitabine; Humans; Infusions, Intravenous; Middle Aged; Ovarian Neoplasms; Survival Analysis; Treatment Outcome | 1994 |
Phase II study of gemcitabine in previously platinum-treated ovarian cancer patients.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Deoxycytidine; Drug Administration Schedule; Female; Follow-Up Studies; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Platinum Compounds; Survival Rate; Time Factors | 1995 |
Activity of gemcitabine in patients with advanced ovarian cancer: responses seen following platinum and paclitaxel.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Deoxycytidine; Female; Gemcitabine; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Platinum; Treatment Outcome | 1996 |
[An early phase II study of gemcitabine hydrochloride (LY 188011). Gemcitabine Cooperative Study Group for Early Phase II].
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Breast Neoplasms; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intravenous; Leukopenia; Lung Neoplasms; Male; Middle Aged; Neoplasms; Neutropenia; Ovarian Neoplasms; Stomach Neoplasms; Uterine Cervical Neoplasms | 1996 |
Phase I studies of gemcitabine combined with carboplatin or paclitaxel.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Ovarian Neoplasms; Paclitaxel; Ribonucleotide Reductases | 1997 |
Mechanisms of synergism between gemcitabine and cisplatin.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; DNA, Neoplasm; Drug Synergism; Female; Gemcitabine; Humans; Ovarian Neoplasms; RNA, Neoplasm; Tumor Cells, Cultured | 1998 |
A phase II study of gemcitabine in platinum pre-treated patients with advanced epithelial ovarian cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Combined Modality Therapy; Deoxycytidine; Drug Resistance, Neoplasm; Female; Fever; Gemcitabine; Humans; Middle Aged; Nausea; Neutropenia; Ovarian Neoplasms; Quality of Life; Remission Induction; Salvage Therapy; Survival Rate; Treatment Outcome | 1998 |
Phase II trial of gemcitabine in refractory germ cell tumors.
Topics: Adolescent; Adult; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Gemcitabine; Germinoma; Humans; Male; Middle Aged; Ovarian Neoplasms; Testicular Neoplasms | 1999 |
Phase II study of gemcitabine in ovarian cancer.
Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intravenous; Middle Aged; Ovarian Neoplasms; Quality of Life | 1999 |
Gemcitabine-cisplatin: a schedule finding study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cross-Over Studies; Deoxycytidine; Drug Administration Schedule; Esophageal Neoplasms; Female; Gemcitabine; Humans; Leukopenia; Linear Models; Lung Neoplasms; Male; Middle Aged; Ovarian Neoplasms; Thrombocytopenia | 1999 |
A phase I study of gemcitabine and epirubicin for the treatment of platinum-resistant or refractory advanced ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Deoxycytidine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Epirubicin; Female; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neutropenia; Ovarian Neoplasms; Treatment Outcome | 2000 |
Phase I dose escalation study of gemcitabine and paclitaxel plus colony-stimulating factors in previously treated patients with advanced breast and ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neutropenia; Ovarian Neoplasms; Paclitaxel; Thrombocytopenia | 2000 |
Topotecan and gemcitabine in platinum/paclitaxel-resistant ovarian cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Cisplatin; Deoxycytidine; Disease Progression; Drug Administration Schedule; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Gemcitabine; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Recurrence; Topotecan; Treatment Outcome | 2001 |
Multicenter phase II study of gemcitabine in previously untreated patients with advanced epithelial ovarian cancer.
Topics: Adult; Aged; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Middle Aged; Neutropenia; Ovarian Neoplasms; Thrombocytopenia; Treatment Outcome | 2001 |
Phase I study of gemcitabine and liposomal doxorubicin in relapsed ovarian cancer.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Blood Platelets; Deoxycytidine; Doxorubicin; Drug Administration Schedule; Female; Gemcitabine; Hemoglobins; Humans; Infusions, Intravenous; Leukocytes; Liposomes; Middle Aged; Ovarian Neoplasms; Treatment Outcome | 2002 |
Phase II study of paclitaxel plus gemcitabine in refractory germ cell tumors (E9897): a trial of the Eastern Cooperative Oncology Group.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Germinoma; Humans; Infusions, Intravenous; Male; Ovarian Neoplasms; Paclitaxel; Seminoma; Testicular Neoplasms; Treatment Outcome; United States | 2002 |
Other Studies
232 other study(ies) available for deoxycytidine and Ovarian Neoplasms
Article | Year |
---|---|
Nivolumab Versus Gemcitabine or Pegylated Liposomal Doxorubicin in Patients With Platinum-Resistant Ovarian Cancer.
Topics: Deoxycytidine; Doxorubicin; Gemcitabine; Humans; Nivolumab; Ovarian Neoplasms; Polyethylene Glycols | 2022 |
Platinum rechallenge treatment using gemcitabine plus carboplatin with or without bevacizumab for platinum-resistant ovarian cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Deoxycytidine; Gemcitabine; Humans; Ovarian Neoplasms; Platinum | 2022 |
MiR-624-5p enhances NLRP3 augmented gemcitabine resistance via EMT/IL-1β/Wnt/β-catenin signaling pathway in ovarian cancer.
Topics: beta Catenin; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; MicroRNAs; NLR Family, Pyrin Domain-Containing 3 Protein; Ovarian Neoplasms; Wnt Signaling Pathway | 2022 |
Gemcitabine cationic polymeric nanoparticles against ovarian cancer: formulation, characterization, and targeted drug delivery.
Topics: Chitosan; Deoxycytidine; Drug Carriers; Gemcitabine; Humans; Nanoparticles; Ovarian Neoplasms | 2022 |
Antitumour effects of a solid lipid nanoparticle loaded with gemcitabine and oxaliplatin on the viability, apoptosis, autophagy, and Hsp90 of ovarian cancer cells.
Topics: Apoptosis; Autophagy; Cell Line, Tumor; Deoxycytidine; Female; Gemcitabine; Humans; Liposomes; Nanoparticles; Ovarian Neoplasms; Oxaliplatin | 2022 |
Efficacy of gemcitabine in combination with nanoparticle albumin-bound paclitaxel in the treatment of recurrent ovarian cancer: A retrospective single institution review.
Topics: Albumin-Bound Paclitaxel; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Nanoparticles; Ovarian Neoplasms; Paclitaxel; Retrospective Studies; Treatment Outcome | 2023 |
Gemcitabine-loaded RGD modified liposome for ovarian cancer: preparation, characterization and pharmacodynamic studies.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Cell Survival; China; Deoxycytidine; Drug Delivery Systems; Drug Liberation; Female; Gemcitabine; Humans; Liposomes; Mice; Mice, Inbred BALB C; Nanoparticles; Oligopeptides; Ovarian Neoplasms; Particle Size; Rats | 2019 |
Therapeutic preferability of gemcitabine for ARID1A-deficient ovarian clear cell carcinoma.
Topics: Adenocarcinoma, Clear Cell; Adult; Aged; Animals; Antimetabolites, Antineoplastic; Apoptosis; Cell Line, Tumor; Deoxycytidine; DNA-Binding Proteins; Female; Gemcitabine; Gene Knockout Techniques; HCT116 Cells; HEK293 Cells; Humans; Immunohistochemistry; Mice; Mice, Inbred BALB C; Middle Aged; Nuclear Proteins; Ovarian Neoplasms; Random Allocation; Transcription Factors; Xenograft Model Antitumor Assays | 2019 |
Secondary cytoreductive surgery in platinum-sensitive recurrent ovarian cancer before olaparib maintenance: Still getting any benefit? A case-control study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Case-Control Studies; Cystadenocarcinoma, Serous; Cytoreduction Surgical Procedures; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Genes, BRCA1; Genes, BRCA2; Germ-Line Mutation; Humans; Maintenance Chemotherapy; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Phthalazines; Piperazines | 2019 |
Treatment strategies for recurrent ovarian cancer in older adult patients in Japan: a study based on real-world data.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Deoxycytidine; Drug Resistance, Neoplasm; Evidence-Based Medicine; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Ovarian Neoplasms; Paclitaxel; Survival Rate | 2020 |
Rapid decrease in serum VEGF-A levels may be a worse prognostic biomarker for patients with platinum-resistant recurrent ovarian cancer treated with bevacizumab and gemcitabine.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Pharmacological; Biomarkers, Tumor; Cisplatin; Deoxycytidine; Disease Progression; Drug Monitoring; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Predictive Value of Tests; Prognosis; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor B | 2020 |
Bevacizumab in recurrent ovarian cancer: could it be particularly effective in patients with clear cell carcinoma?
Topics: Adenocarcinoma, Clear Cell; Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Confidence Intervals; Cystadenocarcinoma, Serous; Deoxycytidine; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Odds Ratio; Ovarian Neoplasms; Paclitaxel; Progression-Free Survival; Retrospective Studies | 2021 |
Recurrence patterns after bevacizumab in platinum-sensitive, recurrent epithelial ovarian cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Carboplatin; Carcinoma, Ovarian Epithelial; Cisplatin; Cohort Studies; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Retrospective Studies; Topotecan | 2020 |
Efficacy and toxicity of pegylated liposomal doxorubicin as therapy for recurrent ovarian cancer in relation to the number of previous chemotherapy regimens: Comparison with gemcitabine.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Polyethylene Glycols; Retrospective Studies | 2021 |
A source of hope for platinum-resistant ovarian cancer?
Topics: Deoxycytidine; Double-Blind Method; Female; Gemcitabine; Humans; Ovarian Neoplasms; Platinum; Pyrazoles; Pyrimidinones | 2021 |
Externally Triggered Novel Rapid-Release Sonosensitive Folate-Modified Liposomes for Gemcitabine: Development and Characteristics.
Topics: Animals; Antineoplastic Agents; Cell Death; Cell Line, Tumor; Deoxycytidine; Drug Delivery Systems; Drug Liberation; Endocytosis; Female; Folic Acid; Gemcitabine; Humans; Liposomes; Ovarian Neoplasms; Particle Size; Rats, Sprague-Dawley; Tissue Distribution; Ultrasonics | 2021 |
WEE1 inhibition after platinum resistance.
Topics: Cell Cycle Proteins; Deoxycytidine; Double-Blind Method; Female; Gemcitabine; Humans; Ovarian Neoplasms; Platinum; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidinones | 2021 |
Bladder cancer cell-intrinsic PD-L1 signals promote mTOR and autophagy activation that can be inhibited to improve cytotoxic chemotherapy.
Topics: Animals; Antibiotics, Antineoplastic; Autophagy; B7-H1 Antigen; Cell Line, Tumor; Cell Proliferation; Chloroquine; Cisplatin; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Gene Expression; Humans; Mechanistic Target of Rapamycin Complex 1; Melanoma; Mice; Mice, Inbred C57BL; Mice, Inbred NOD; Mice, SCID; Neoplasm Metastasis; Ovarian Neoplasms; Phosphorylation; Proto-Oncogene Proteins c-akt; Sirolimus; Urinary Bladder Neoplasms | 2021 |
[Clinical Application of Gemcitabine plus Cisplatin plus Bevacizumab Combination Chemotherapy for Ovarian Clear Cell Carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms | 2021 |
Procaspase-Activating Compound-1 Synergizes with TRAIL to Induce Apoptosis in Established Granulosa Cell Tumor Cell Line (KGN) and Explanted Patient Granulosa Cell Tumor Cells In Vitro.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzoquinones; Carboplatin; Caspase 3; Cell Line, Tumor; Deoxycytidine; Dose-Response Relationship, Drug; Drug Synergism; Enzyme Activation; Female; Gemcitabine; Granulosa Cell Tumor; Humans; Hydrazones; In Vitro Techniques; Mathematical Concepts; Models, Biological; Ovarian Neoplasms; Piperazines; TNF-Related Apoptosis-Inducing Ligand | 2021 |
Improvement in the prognosis of ovarian cancer in the era before addition of molecular targeting therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Demography; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Humans; Middle Aged; Molecular Targeted Therapy; Multivariate Analysis; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Polyethylene Glycols; Prognosis | 2017 |
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Topotecan | 2017 |
Silver nanoparticles enhance the apoptotic potential of gemcitabine in human ovarian cancer cells: combination therapy for effective cancer treatment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Delivery Systems; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Metal Nanoparticles; Ovarian Neoplasms; Resveratrol; Silver; Stilbenes | 2017 |
The Pharmacological Costs of Second-Line Treatments for Recurrent Ovarian Cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Clinical Trials, Phase III as Topic; Cost-Benefit Analysis; Deoxycytidine; Dioxoles; Disease-Free Survival; Doxorubicin; Drug Costs; European Union; Female; Gemcitabine; Humans; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Polyethylene Glycols; Randomized Controlled Trials as Topic; Survival Rate; Tetrahydroisoquinolines; Trabectedin | 2017 |
Bevacizumab Added to Moderate-dose Chemotherapy for Refractory Uterine Cancer.
Topics: Adenocarcinoma; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bile Duct Neoplasms; Camptothecin; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Docetaxel; Endometrial Neoplasms; Female; Fluorouracil; Gemcitabine; Humans; Induction Chemotherapy; Irinotecan; Leucovorin; Middle Aged; Ovarian Neoplasms; Retrospective Studies; Taxoids | 2018 |
Platinum-Gemcitabine-Avastin (PGA) for platinum-resistant/refractory ovarian cancer.
Topics: Adult; Aged; Antineoplastic Agents; Bevacizumab; Deoxycytidine; Drug Therapy, Combination; Female; Gemcitabine; Humans; Middle Aged; Ovarian Neoplasms; Platinum Compounds; Retrospective Studies | 2017 |
Role and timing of second-line therapies for patients with recurrent platinum-resistant ovarian epithelial cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Cisplatin; Cytoreduction Surgical Procedures; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Response Evaluation Criteria in Solid Tumors; Retreatment; Retrospective Studies; Survival Rate; Topotecan | 2017 |
GATA3 as a master regulator and therapeutic target in ovarian high-grade serous carcinoma stem cells.
Topics: Alkaline Phosphatase; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cadherins; Cell Differentiation; Cell Line, Tumor; Cell Lineage; Deoxycytidine; Female; GATA3 Transcription Factor; Gemcitabine; Histone Demethylases; Humans; Neoplastic Stem Cells; Nuclear Proteins; Ovarian Neoplasms; Paclitaxel; Prognosis; Protein Binding; Spheroids, Cellular | 2018 |
Prediction of DNA Repair Inhibitor Response in Short-Term Patient-Derived Ovarian Cancer Organoids.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Cystadenocarcinoma, Serous; Deoxycytidine; DNA Repair; DNA Replication; Female; Follow-Up Studies; Gemcitabine; Humans; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Organ Culture Techniques; Organoids; Ovarian Neoplasms; Prognosis; Pyrazines; Pyrazoles | 2018 |
Dihydroartemisinin increases gemcitabine therapeutic efficacy in ovarian cancer by inducing reactive oxygen species.
Topics: Animals; Antimetabolites, Antineoplastic; Artemisinins; Cell Line, Tumor; Cytidine Deaminase; Deoxycytidine; Drug Synergism; Drug Therapy, Combination; Female; Gemcitabine; Heme Oxygenase-1; Humans; Inhibitory Concentration 50; Mice; Mice, Inbred BALB C; Mice, Nude; Ovarian Neoplasms; Reactive Oxygen Species; Signal Transduction; Treatment Outcome; Tumor Burden; Xenograft Model Antitumor Assays | 2019 |
Machine learning predicts individual cancer patient responses to therapeutic drugs with high accuracy.
Topics: Algorithms; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Computational Biology; Databases, Factual; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Genome, Human; Humans; Machine Learning; Neoplasms; Ovarian Neoplasms; Precision Medicine; Predictive Value of Tests; Support Vector Machine; Transcriptome | 2018 |
Translational Framework Predicting Tumour Response in Gemcitabine-Treated Patients with Advanced Pancreatic and Ovarian Cancer from Xenograft Studies.
Topics: Animals; Antimetabolites, Antineoplastic; Data Interpretation, Statistical; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Mice; Models, Biological; Ovarian Neoplasms; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Survival Analysis; Treatment Outcome; Tumor Burden; Xenograft Model Antitumor Assays | 2019 |
Expression profile and prognostic value of SFN in human ovarian cancer.
Topics: 14-3-3 Proteins; Aged; Aged, 80 and over; Biomarkers, Tumor; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Exoribonucleases; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Prognosis; RNA, Messenger | 2019 |
Early Modeled Longitudinal CA-125 Kinetics and Survival of Ovarian Cancer Patients: A GINECO AGO MRC CTU Study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CA-125 Antigen; Carboplatin; Clinical Trials, Phase III as Topic; Deoxycytidine; Female; Gemcitabine; Humans; Longitudinal Studies; Models, Statistical; Multicenter Studies as Topic; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic; Retrospective Studies; Survival Rate | 2019 |
Genome-scale CRISPR/Cas9 screen determines factors modulating sensitivity to ProTide NUC-1031.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Clinical Trials, Phase I as Topic; CRISPR-Cas Systems; Cytidine Monophosphate; Deoxycytidine; Deoxycytidine Kinase; Drug Resistance, Neoplasm; Female; Gemcitabine; HEK293 Cells; Humans; Ovarian Neoplasms; Pancreatic Neoplasms | 2019 |
Comparison of clinico-pathological characteristics and survival of recurrent ovarian cancer patients on seven different chemo-protocols.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Progression-Free Survival; Topotecan; Treatment Outcome; Young Adult | 2019 |
Gastropleural fistula in a patient with recurrent ovarian cancer receiving combination therapy with Carboplatin, gemcitabine, and bevacizumab.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Ovarian Epithelial; Deoxycytidine; Female; Gastric Fistula; Gemcitabine; Humans; Intestinal Fistula; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms | 2013 |
Antibody targeting of CD24 efficiently retards growth and influences cytokine milieu in experimental carcinomas.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; CD24 Antigen; Cell Growth Processes; Cell Line, Tumor; Cell Proliferation; Cytokines; Deoxycytidine; Disease Models, Animal; Female; Gemcitabine; Humans; Immunohistochemistry; Lung Neoplasms; Macrophages; Mice; Mice, SCID; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Transplantation, Heterologous; Xenograft Model Antitumor Assays | 2013 |
ATR inhibition broadly sensitizes ovarian cancer cells to chemotherapy independent of BRCA status.
Topics: Antineoplastic Agents; Ataxia Telangiectasia Mutated Proteins; Benzimidazoles; BRCA1 Protein; BRCA2 Protein; cdc25 Phosphatases; Cell Cycle Proteins; Cell Line, Tumor; Cell Survival; Checkpoint Kinase 1; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Immunoblotting; Ovarian Neoplasms; Phosphorylation; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Protein Kinases; Protein Serine-Threonine Kinases; Pyrazines; Pyrazoles; Pyrimidines; RNA Interference; Signal Transduction; Sulfones; Topotecan | 2013 |
BLU enhances the effects of anti-angiogenic activity in combination with gemcitabine-based chemotherapeutic agents.
Topics: 3-Phosphoinositide-Dependent Protein Kinases; Antimetabolites, Antineoplastic; Apoptosis; bcl-2-Associated X Protein; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cytoskeletal Proteins; Deoxycytidine; Female; G1 Phase Cell Cycle Checkpoints; Gemcitabine; Human Umbilical Vein Endothelial Cells; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Neovascularization, Pathologic; NF-kappa B; Ovarian Neoplasms; Phosphorylation; Proto-Oncogene Proteins c-akt; rho GTP-Binding Proteins; TOR Serine-Threonine Kinases; Tumor Suppressor Protein p53; Tumor Suppressor Proteins; Up-Regulation; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2013 |
Complete remission of recurrent and refractory ovarian cancers using weekly administration of bevacizumab and gemcitabine/oxaliplatin: report of two cases.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Deoxycytidine; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin | 2013 |
18F-fluorothymidine PET is a potential predictive imaging biomarker of the response to gemcitabine-based chemotherapeutic treatment for recurrent ovarian cancer: preliminary results in three patients.
Topics: Aged; Biomarkers, Tumor; Deoxycytidine; Dideoxynucleosides; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Positron-Emission Tomography; Recurrence; Tomography, X-Ray Computed | 2013 |
Metronomic chemotherapy following the maximum tolerated dose is an effective anti-tumour therapy affecting angiogenesis, tumour dissemination and cancer stem cells.
Topics: Adenocarcinoma; Administration, Metronomic; Animals; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Deoxycytidine; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Mice; Mice, Nude; Neoplasms; Neoplastic Stem Cells; Neovascularization, Pathologic; Ovarian Neoplasms; Pancreatic Neoplasms; Random Allocation; Thrombospondin 1; Xenograft Model Antitumor Assays | 2013 |
Salvage therapy of gemcitabine plus endostar significantly improves progression-free survival (PFS) with platinum-resistant recurrent epithelial ovarian cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cystadenocarcinoma, Serous; Deoxycytidine; Drug Resistance, Neoplasm; Endostatins; Female; Follow-Up Studies; Gemcitabine; Humans; Middle Aged; Neoplasm Grading; Neoplasm Metastasis; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum; Prognosis; Recombinant Proteins; Retrospective Studies; Salvage Therapy; Survival Rate | 2013 |
NICE guidance on bevacizumab in combination with gemcitabine and carboplatin for treating the first recurrence of platinum-sensitive advanced ovarian cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Cost-Benefit Analysis; Deoxycytidine; Drug Costs; Female; Gemcitabine; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Practice Guidelines as Topic; Quality-Adjusted Life Years; Survival Analysis; Time Factors; Treatment Outcome | 2013 |
Biodegradable multiblock poly(N-2-hydroxypropyl)methacrylamide gemcitabine and paclitaxel conjugates for ovarian cancer cell combination treatment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cathepsin B; Cell Line, Tumor; Cell Survival; Chemistry, Pharmaceutical; Deoxycytidine; Drug Carriers; Drug Stability; Drug Synergism; Female; Gemcitabine; Humans; Hydrogen-Ion Concentration; Hydrolysis; Kinetics; Male; Molecular Weight; Ovarian Neoplasms; Paclitaxel; Polymerization; Polymethacrylic Acids; Solubility; Technology, Pharmaceutical | 2013 |
Gemcitabine therapy-associated cutaneous vasculitis with a polyarteritis nodosa-like pattern.
Topics: Adenocarcinoma; Adult; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Gemcitabine; Humans; Ovarian Neoplasms; Polyarteritis Nodosa; Vasculitis, Leukocytoclastic, Cutaneous | 2013 |
The safety and efficacy of cisplatin plus gemcitabine in recurrent ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Drug-Related Side Effects and Adverse Reactions; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms | 2014 |
Gemcitabine eliminates double minute chromosomes from human ovarian cancer cells.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; DNA Damage; DNA, Neoplasm; Eukaryotic Translation Initiation Factor 5A; Female; Gemcitabine; Gene Amplification; Histones; Humans; Hydroxyurea; In Situ Hybridization, Fluorescence; Micronuclei, Chromosome-Defective; Myeloid Cell Leukemia Sequence 1 Protein; N-Myc Proto-Oncogene Protein; Nuclear Proteins; Oncogene Proteins; Ovarian Neoplasms; Peptide Initiation Factors; Real-Time Polymerase Chain Reaction; RNA-Binding Proteins | 2013 |
The combination of gemcitabine and carboplatin shows similar efficacy in the treatment of platinum-resistant and platinum-sensitive recurrent epithelial ovarian cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Endometrioid; Carcinoma, Ovarian Epithelial; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Fallopian Tube Neoplasms; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Peritoneal Neoplasms; Retrospective Studies | 2014 |
Bevacizumab-induced transient sixth nerve palsy in ovarian cancer: A case report.
Topics: Abducens Nerve Diseases; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Deoxycytidine; Female; Gemcitabine; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms | 2016 |
Gemcitabine enhances the efficacy of reovirus-based oncotherapy through anti-tumour immunological mechanisms.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Mice; Mice, Inbred C57BL; Oncolytic Virotherapy; Ovarian Neoplasms; Reoviridae; T-Lymphocytes; Virus Replication | 2014 |
[Resection for the treatment of bleeding caused by ovarian metastasis after hepatectomy for metachronous liver metastasis from sigmoid colon cancer].
Topics: Aged; Antimetabolites, Antineoplastic; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Disease Progression; Female; Fluorouracil; Hemorrhage; Hepatectomy; Humans; Liver Neoplasms; Ovarian Neoplasms; Sigmoid Neoplasms | 2013 |
Downfall of iniparib: a PARP inhibitor that doesn't inhibit PARP after all.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bias; Carboplatin; Clinical Trials as Topic; Deoxycytidine; Drugs, Investigational; Female; Gemcitabine; Humans; Lung Neoplasms; Molecular Targeted Therapy; Ovarian Neoplasms; Poly(ADP-ribose) Polymerase Inhibitors; Research Design; Treatment Failure; Triple Negative Breast Neoplasms | 2014 |
In vitro chemosensitivity assay of ascites in epithelial ovarian cancer.
Topics: Antineoplastic Agents; Ascites; Carboplatin; Carcinoma, Ovarian Epithelial; Coloring Agents; Deoxycytidine; Disease Progression; Drug Screening Assays, Antitumor; Epirubicin; Etoposide; Female; Fluorouracil; Gemcitabine; Humans; Kaplan-Meier Estimate; Ki-67 Antigen; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Predictive Value of Tests; Retrospective Studies; Survival Rate; Tetrazolium Salts; Thiazoles; Time Factors; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2013 |
Gemcitabine as a molecular targeting agent that blocks the Akt cascade in platinum-resistant ovarian cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Cisplatin; Deoxycytidine; Disease Models, Animal; Drug Resistance, Neoplasm; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Matrix Metalloproteinase 9; Mice; Neoplasm Metastasis; Neovascularization, Pathologic; Ovarian Neoplasms; Platinum; Proto-Oncogene Proteins c-akt; Signal Transduction; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2014 |
Human ovarian cancer multicellular spheroids: a model for testing antiproliferation activity of Devil's club (Oplopanax horridus) and anticancer agents.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Cell Cycle; Cell Proliferation; Chromatography, High Pressure Liquid; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Oplopanax; Ovarian Neoplasms; Paclitaxel; Plant Bark; Plant Extracts; Plants, Medicinal; Proteome; Spheroids, Cellular; Tumor Cells, Cultured | 2014 |
Treatment outcomes of gemcitabine in refractory or recurrent epithelial ovarian cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Organoplatinum Compounds; Ovarian Neoplasms; Treatment Outcome | 2014 |
Sequential combination therapy of ovarian cancer with degradable N-(2-hydroxypropyl)methacrylamide copolymer paclitaxel and gemcitabine conjugates.
Topics: Acrylamides; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Cycle; Deoxycytidine; Female; Gemcitabine; Humans; Mice; Mice, Nude; Ovarian Neoplasms; Paclitaxel; Tissue Distribution; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed | 2014 |
Chk1 inhibition as a novel therapeutic strategy for treating triple-negative breast and ovarian cancers.
Topics: Benzodiazepinones; Biomarkers, Tumor; Cell Line, Tumor; Checkpoint Kinase 1; Cisplatin; Deoxycytidine; Drug Synergism; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; HT29 Cells; Humans; Indoles; MCF-7 Cells; Ovarian Neoplasms; Protein Kinase Inhibitors; Protein Kinases; Pyrazoles; Pyridones; Thiophenes; Triple Negative Breast Neoplasms; Urea | 2014 |
Anion exchange chromatography for the determination of 5-methyl-2'-deoxycytidine: application to cisplatin-sensitive and cisplatin-resistant ovarian cancer cell lines.
Topics: Anion Exchange Resins; Antineoplastic Agents; Cell Line, Tumor; Chromatography, Ion Exchange; Cisplatin; Deoxycytidine; DNA Methylation; Female; Humans; Ovarian Neoplasms | 2015 |
Efficacy of permanent iodine-125 seed implants and gemcitabine chemotherapy in patients with platinum- resistant recurrent ovarian carcinoma.
Topics: Adenocarcinoma, Mucinous; Antimetabolites, Antineoplastic; Brachytherapy; Chemoradiotherapy; Cystadenocarcinoma, Serous; Deoxycytidine; Drug Resistance, Neoplasm; Endometrial Neoplasms; Female; Follow-Up Studies; Gemcitabine; Humans; Iodine Radioisotopes; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Platinum; Prognosis; Tomography, X-Ray Computed | 2014 |
Cost-effectiveness of gemcitabine versus PEGylated liposomal doxorubicin for recurrent or progressive ovarian cancer: comparing chemotherapy with nanotherapy.
Topics: Antineoplastic Agents; Cost-Benefit Analysis; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Humans; Nanomedicine; Ovarian Neoplasms; Polyethylene Glycols; Quality-Adjusted Life Years | 2014 |
Defective hCNT1 transport contributes to gemcitabine chemoresistance in ovarian cancer subtypes: overcoming transport defects using a nanoparticle approach.
Topics: Antimetabolites, Antineoplastic; Biological Transport; Cell Line, Tumor; Cisplatin; Deoxycytidine; Drug Resistance, Neoplasm; Drug Synergism; Female; Gemcitabine; Humans; Inhibitory Concentration 50; Membrane Transport Proteins; Nanocapsules; Ovarian Neoplasms | 2015 |
A retrospective clinical study of bevacizumab combined with gemcibabine or paclitaxel in the treatment of recurrent ovarian cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Prognosis; Retrospective Studies; Survival Rate | 2014 |
Bevacizumab combined with chemotherapy in the treatment of recurrence or platinum-refractory ovarian cancer: a retrospective study of 37 cases.
Topics: Adenocarcinoma, Papillary; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Transitional Cell; Cystadenocarcinoma, Serous; Deoxycytidine; Drug Resistance, Neoplasm; Epirubicin; Female; Follow-Up Studies; Gemcitabine; Humans; Ifosfamide; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Prognosis; Retrospective Studies; Survival Rate | 2014 |
APR-246 overcomes resistance to cisplatin and doxorubicin in ovarian cancer cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cells, Cultured; Cisplatin; Deoxycytidine; Docetaxel; Doxorubicin; Drug Resistance, Neoplasm; Enzyme Activation; Female; Gemcitabine; Glutathione; Humans; Mice; Mice, Nude; Ovarian Neoplasms; Protein Folding; Quinuclidines; Random Allocation; Taxoids; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays | 2015 |
Comparison of bevacizumab alone or with chemotherapy in recurrent ovarian cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cyclophosphamide; Deoxycytidine; Disease-Free Survival; Doxorubicin; Fallopian Tube Neoplasms; Female; Gemcitabine; Humans; Lymphatic Metastasis; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Peritoneal Neoplasms; Polyethylene Glycols; Radiography; Response Evaluation Criteria in Solid Tumors; Retrospective Studies; Survival Rate; Taxoids; Topotecan; Young Adult | 2015 |
[A Patient with Recurrent Ovarian Cancer Who Was Hypersensitive to Carboplatin Exhibited Complete Response to Gemcitabine and Nedaplatin].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Drug Hypersensitivity; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Ovarian Neoplasms; Recurrence | 2015 |
Prognostic factors modifying the treatment-free interval in recurrent ovarian cancer.
Topics: Age Factors; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Cisplatin; Cytoreduction Surgical Procedures; Deoxycytidine; Disease-Free Survival; Docetaxel; Doxorubicin; Female; Gemcitabine; Humans; Middle Aged; Multivariate Analysis; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm, Residual; Neoplasms, Cystic, Mucinous, and Serous; Ovarian Neoplasms; Paclitaxel; Prognosis; Proportional Hazards Models; Retrospective Studies; Survival Analysis; Taxoids; Time Factors; Topotecan | 2015 |
[Intraperitoneal chemotherapy--a method of improving treatment effectiveness in ovarian cancer].
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Deoxycytidine; Female; Gemcitabine; Infusions, Intravenous; Infusions, Parenteral; Maximum Tolerated Dose; Melphalan; Mitomycin; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Rats; Rats, Wistar; Triazines | 2015 |
Singapore Cancer Network (SCAN) Guidelines for Front-Line Systemic Therapy of Newly Diagnosed Advanced Epithelial Ovarian Cancer.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Cytoreduction Surgical Procedures; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Humans; Infusions, Parenteral; Neoadjuvant Therapy; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Ovariectomy; Paclitaxel; Polyethylene Glycols; Singapore | 2015 |
An open-label, dose-escalation study to evaluate the safety and pharmacokinetics of CEP-9722 (a PARP-1 and PARP-2 inhibitor) in combination with gemcitabine and cisplatin in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carbazoles; Cisplatin; Colorectal Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Lung Neoplasms; Lymphoma, Mantle-Cell; Male; Melanoma; Middle Aged; Neoplasms; Ovarian Neoplasms; Phthalimides; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases | 2016 |
Operability and chemotherapy responsiveness in advanced low-grade serous ovarian cancer. An analysis of the AGO Study Group metadatabase.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Case-Control Studies; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials, Phase III as Topic; Cytoreduction Surgical Procedures; Deoxycytidine; Disease-Free Survival; Epirubicin; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Grading; Neoplasm, Residual; Neoplasms, Cystic, Mucinous, and Serous; Ovarian Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic; Survival Rate; Topotecan; Treatment Outcome; Young Adult | 2016 |
The Efficacy of Low-Dose Paclitaxel Added to Combination Chemotherapy of Carboplatin and Gemcitabine or Pegylated Liposomal Doxorubicin.
Topics: Adenocarcinoma, Clear Cell; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinosarcoma; Cystadenocarcinoma, Serous; Deoxycytidine; Dose-Response Relationship, Drug; Doxorubicin; Endometrial Neoplasms; Female; Follow-Up Studies; Gemcitabine; Humans; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Pilot Projects; Polyethylene Glycols; Prognosis; Remission Induction; Retrospective Studies; Survival Rate | 2016 |
Cost Effectiveness Analysis of Different Management Strategies between Best Supportive Care and Second-line Chemotherapy for Platinum-resistant or Refractory Ovarian Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cost-Benefit Analysis; Deoxycytidine; Doxorubicin; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Gemcitabine; Humans; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Platinum; Polyethylene Glycols; Prognosis; Quality-Adjusted Life Years; Salvage Therapy; Survival Rate; Topotecan | 2016 |
Gemcitabine-Induced Subacute Cutaneous Lupus Erythematosus: A Case Report.
Topics: Administration, Oral; Anti-Inflammatory Agents; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Gemcitabine; Humans; Lupus Erythematosus, Cutaneous; Lymph Nodes; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Positron Emission Tomography Computed Tomography; Prednisone; Skin; Treatment Outcome | 2016 |
Cyclic RGDfK Peptide Functionalized Polymeric Nanocarriers for Targeting Gemcitabine to Ovarian Cancer Cells.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Deoxycytidine; Drug Carriers; Drug Delivery Systems; Female; Gemcitabine; Humans; Membrane Potential, Mitochondrial; Nanoparticles; Ovarian Neoplasms; Peptides; Peptides, Cyclic; Polymers; Reactive Oxygen Species | 2016 |
Insights from HuR biology point to potential improvement for second-line ovarian cancer therapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cell Cycle Proteins; Cell Line, Tumor; Cell Nucleus; Cytoplasm; Deoxycytidine; Deoxycytidine Kinase; ELAV-Like Protein 1; Female; G2 Phase Cell Cycle Checkpoints; Gemcitabine; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Recurrence, Local; Nuclear Proteins; Ovarian Neoplasms; Protein Transport; Protein-Tyrosine Kinases; Retrospective Studies | 2016 |
Xenopatients show the need for precision medicine approach to chemotherapy in ovarian cancer.
Topics: Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carboplatin; Cell Proliferation; Deoxycytidine; Dioxoles; Doxorubicin; Female; Gemcitabine; Humans; Mice; Middle Aged; Neoadjuvant Therapy; Ovarian Neoplasms; Polyethylene Glycols; Precision Medicine; Tetrahydroisoquinolines; Trabectedin; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2016 |
Gemcitabine-oxaliplatin (GEMOX) for epithelial ovarian cancer patients resistant to platinum-based chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin; Platinum | 2016 |
Nanoscale Coordination Polymers Codeliver Carboplatin and Gemcitabine for Highly Effective Treatment of Platinum-Resistant Ovarian Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Nanoparticles; Ovarian Neoplasms; Platinum; Polymers; Treatment Outcome | 2016 |
Response to and toxicity of gemcitabine for recurrent ovarian cancer according to number of previous chemotherapy regimens.
Topics: Adult; Antimetabolites, Antineoplastic; Deoxycytidine; Drug Resistance; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Outcome Assessment, Health Care; Ovarian Neoplasms | 2017 |
Effects of sequential paclitaxel-carboplatin followed by gemcitabine-based chemotherapy compared with paclitaxel-carboplatin therapy administered to patients with advanced epithelial ovarian cancer: A retrospective, STROBE-compliant study.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Retrospective Studies; Survival Analysis; Young Adult | 2016 |
The telomere-binding protein TRF2 is required for metronomic therapeutic effects of gemcitabine and capecitabine.
Topics: Administration, Metronomic; Animals; Capecitabine; Cell Line, Tumor; Deoxycytidine; Drug Resistance; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Mice; Mice, Nude; Neoplasm Proteins; Ovarian Neoplasms; Telomere Homeostasis; Telomeric Repeat Binding Protein 2 | 2017 |
Cisplatin can be safely administered to ovarian cancer patients with hypersensitivity to carboplatin.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Deoxycytidine; Doxorubicin; Drug Hypersensitivity; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Polyethylene Glycols; Retrospective Studies | 2017 |
Backbone Degradable N-(2-Hydroxypropyl)methacrylamide Copolymer Conjugates with Gemcitabine and Paclitaxel: Impact of Molecular Weight on Activity toward Human Ovarian Carcinoma Xenografts.
Topics: Acrylamides; Animals; Cell Line, Tumor; Deoxycytidine; Female; Gemcitabine; Humans; Mice; Mice, Nude; Ovarian Neoplasms; Paclitaxel; Polymers; Xenograft Model Antitumor Assays | 2017 |
[Recurrence of Jejunal Carcinoma in the Ileum and Ovary - A Case Report].
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Colectomy; Deoxycytidine; Female; Fluorouracil; Humans; Ileal Neoplasms; Jejunal Neoplasms; Middle Aged; Ovarian Neoplasms; Ovariectomy; Oxaloacetates; Recurrence | 2016 |
Ras-MEK Signaling Mediates a Critical Chk1-Dependent DNA Damage Response in Cancer Cells.
Topics: Animals; Bone Neoplasms; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Checkpoint Kinase 1; Deoxycytidine; DNA Damage; Female; Gemcitabine; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Heterocyclic Compounds, 3-Ring; Humans; MAP Kinase Signaling System; Mice; Osteosarcoma; Ovarian Neoplasms; Piperidines; Proto-Oncogene Proteins p21(ras); Xenograft Model Antitumor Assays | 2017 |
Activity of bevacizumab-containing regimens in recurrent low-grade serous ovarian or peritoneal cancer: A single institution experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Bevacizumab; Carboplatin; Cyclophosphamide; Databases, Factual; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Cystic, Mucinous, and Serous; Niacinamide; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Phenylurea Compounds; Retrospective Studies; Sorafenib; Young Adult | 2017 |
Gemcitabine pulmonary toxicity in ovarian cancer.
Topics: Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Papillary; Deoxycytidine; Female; Gemcitabine; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Palliative Care; Pneumonia | 2008 |
Tumor heterogeneity in ovarian cancer as demonstrated by in vitro chemoresistance assays.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Docetaxel; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Prospective Studies; Taxoids; Topotecan | 2008 |
Combination gemcitabine, platinum, and bevacizumab for the treatment of recurrent ovarian cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; CA-125 Antigen; Carboplatin; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Retrospective Studies | 2008 |
Triple cytotoxic therapy for advanced ovarian cancer: a failed application, not a failed strategy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Deoxycytidine; Doxorubicin; Drug Administration Schedule; Epirubicin; Female; Gemcitabine; Humans; Ovarian Neoplasms; Paclitaxel; Topotecan; Treatment Failure | 2009 |
MicroRNAs and their target messenger RNAs associated with ovarian cancer response to chemotherapy.
Topics: Antineoplastic Agents; Cell Growth Processes; Cell Line, Tumor; Cisplatin; Deoxycytidine; Docetaxel; Doxorubicin; Female; Gemcitabine; Humans; Linear Models; MicroRNAs; Ovarian Neoplasms; Paclitaxel; RNA, Messenger; Taxoids; Topotecan | 2009 |
Clinical utility of CA-125 for maintenance therapy in the treatment of advanced stage ovarian carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CA-125 Antigen; Carboplatin; Deoxycytidine; Female; Gemcitabine; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Prognosis; Retrospective Studies | 2009 |
Gallbladder carcinoma presenting as a pelvic mass with elevated serum testosterone: a case report.
Topics: Abdominal Pain; Adenocarcinoma; Antineoplastic Agents; CA-125 Antigen; Cholecystectomy; Cisplatin; Deoxycytidine; Diagnosis, Differential; Fallopian Tubes; Fatal Outcome; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Hysterectomy; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Ovariectomy; Testosterone; Tomography, X-Ray Computed; Ultrasonography | 2009 |
Gemcitabine and carboplatin treatment in patients with relapsing ovarian cancer.
Topics: Adenocarcinoma, Mucinous; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Endometrioid; Cystadenocarcinoma, Serous; Deoxycytidine; Disease Progression; Endometrial Neoplasms; Female; Gemcitabine; Humans; Immunoenzyme Techniques; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Prognosis; Prospective Studies; Survival Rate; Treatment Outcome; Young Adult | 2009 |
Acute rhabdomyolysis as a complication of paclitaxel-gemcitabine chemotherapy for ovarian cancer.
Topics: Adenocarcinoma, Papillary; Antineoplastic Agents; Deoxycytidine; Female; Gemcitabine; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Rhabdomyolysis | 2009 |
[Phalanges necrosis--a rare manifestation of "hand-foot" syndrome induced by gemcitabine used in the second--line therapy for progressive ovarian cancer. A case report].
Topics: Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Finger Phalanges; Foot Dermatoses; Gemcitabine; Hand Dermatoses; Humans; Necrosis; Ovarian Neoplasms; Syndrome | 2009 |
Carboplatin-gemcitabine in the therapy of advanced ovarian cancer: dose reduction consideration.
Topics: Adenocarcinoma; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; Deoxycytidine; Epistaxis; Fatigue; Female; Gemcitabine; Humans; Leukopenia; Liver Neoplasms; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Pelvic Neoplasms; Remission Induction; Splenic Neoplasms; Thrombocytopenia | 2010 |
Cisplatin-Ifosfamide-gemcitabine as salvage chemotherapy in ovarian cancer patients pretreated with platinum compounds and Paclitaxel.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Ifosfamide; Middle Aged; Ovarian Neoplasms; Paclitaxel; Patient Compliance; Salvage Therapy | 2009 |
Expression of nucleoside transporters, deoxycitidine kinase, ribonucleotide reductase regulatory subunits, and gemcitabine catabolic enzymes in primary ovarian cancer.
Topics: 5'-Nucleotidase; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Cell Line, Tumor; Cell Proliferation; Cytidine Deaminase; Deoxycytidine; Deoxycytidine Kinase; Dose-Response Relationship, Drug; Equilibrative Nucleoside Transporter 1; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Kaplan-Meier Estimate; Membrane Transport Proteins; Middle Aged; Nucleoside Transport Proteins; Ovarian Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; Ribonucleoside Diphosphate Reductase; Survival Rate; Tumor Suppressor Proteins | 2010 |
Gemcitabine: new indication. Relapsed ovarian cancer: simply more toxic. Increases haematologic toxicity but not overall survival.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Drug Approval; Europe; Female; Gemcitabine; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Randomized Controlled Trials as Topic; Ribonucleotide Reductases | 2009 |
ABC transporter gene expression in benign and malignant ovarian tissue.
Topics: Antineoplastic Combined Chemotherapy Protocols; ATP-Binding Cassette Transporters; Carboplatin; Cyclophosphamide; Cystadenoma; Deoxycytidine; Female; Gemcitabine; Gene Expression; Humans; Multidrug Resistance-Associated Protein 2; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; ROC Curve; Up-Regulation | 2010 |
Ovarian metastasis following gallbladder carcinoma: a case report.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Incidental Findings; Lymph Node Excision; Middle Aged; Organoplatinum Compounds; Ovarian Neoplasms; Ovariectomy; Oxaliplatin; Treatment Outcome | 2010 |
Molecular basis of chemosensitivity of platinum pre-treated ovarian cancer to chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cisplatin; Deoxycytidine; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Female; Gemcitabine; Humans; Ovarian Neoplasms; Topotecan | 2010 |
Chemoresistance testing of human ovarian cancer cells and its in vitro model.
Topics: Antineoplastic Agents; Carboplatin; Carcinoma; Cell Line, Tumor; Cisplatin; Deoxycytidine; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Etoposide; Female; Gemcitabine; Humans; Models, Biological; Ovarian Neoplasms; Paclitaxel; Topotecan | 2010 |
Sister Mary Joseph's nodule as a metastasis of ovarian adenocarcinoma.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Capecitabine; Carboplatin; Colonoscopy; Deoxycytidine; Female; Fluorouracil; Humans; Liver Neoplasms; Neprilysin; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin; Paclitaxel; Receptors, Estrogen; Receptors, Progesterone; Sister Mary Joseph's Nodule; Skin Neoplasms; Treatment Outcome; Umbilicus; Vimentin; WT1 Proteins | 2010 |
Simultaneous breast and ovarian metastasis from gallbladder carcinoma.
Topics: Adenocarcinoma; Antineoplastic Agents; Breast Neoplasms; Cholecystectomy; Deoxycytidine; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Mastectomy; Middle Aged; Ovarian Neoplasms; Ovariectomy; Salpingectomy | 2010 |
Outcomes after multiple lines of chemotherapy for platinum-resistant epithelial cancers of the ovary, peritoneum, and fallopian tube.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; CA-125 Antigen; Carcinoma; Carcinoma, Ovarian Epithelial; Cisplatin; Cytotoxins; Deoxycytidine; Disease-Free Survival; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Fallopian Tube Neoplasms; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Platinum; Polyethylene Glycols; Prognosis; Proportional Hazards Models; Retrospective Studies; Survival Analysis; Taxoids; Treatment Outcome | 2011 |
Congenital retroperitoneal vascular anomalies: impact on pelvic surgery.
Topics: Adenocarcinoma, Papillary; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Female; Gemcitabine; Humans; Lymphatic Metastasis; Middle Aged; Ovarian Neoplasms; Pelvis; Radiography; Treatment Outcome; Vascular Malformations; Vena Cava, Inferior | 2011 |
[Application of ATP-tumor chemosensitivity assay in recurrent epithelial ovarian cancer].
Topics: Adenosine Triphosphate; Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; Carcinoma, Endometrioid; Cystadenocarcinoma, Serous; Deoxycytidine; Disease-Free Survival; Doxorubicin; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Etoposide; Female; Follow-Up Studies; Gemcitabine; Humans; Luminescent Measurements; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Predictive Value of Tests; Retrospective Studies; Sensitivity and Specificity; Survival Rate; Topotecan | 2010 |
Peritoneal fibrosis leading to small bowel obstruction two years after first-line intraperitoneal chemotherapy for optimally debulked ovarian cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; Cisplatin; Cystadenocarcinoma, Serous; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Humans; Intestinal Obstruction; Intestine, Small; Liver Neoplasms; Membrane Proteins; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peritoneal Fibrosis; Treatment Outcome | 2011 |
Capecitabine monotherapy as salvage treatment after failure of chemotherapy containing oxaliplatin and irinotecan in patients with metastatic colorectal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Camptothecin; Capecitabine; Child; Child, Preschool; Colorectal Neoplasms; Deoxycytidine; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Infant; Irinotecan; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin; Peritoneal Neoplasms; Remission Induction; Retrospective Studies; Salvage Therapy; Survival Rate; Treatment Outcome; Young Adult | 2011 |
Exploring palliative treatment outcomes in women with advanced or recurrent ovarian clear cell carcinoma.
Topics: Adenocarcinoma, Clear Cell; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Deoxycytidine; Etoposide; Female; Gemcitabine; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Palliative Care; Topotecan; Treatment Outcome | 2011 |
Single nucleotide polypmorphisms in ERCC1 are associated with disease progression, and survival in patients with advanced stage ovarian and primary peritoneal carcinoma; a Gynecologic Oncology Group study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Disease Progression; DNA-Binding Proteins; Doxorubicin; Endonucleases; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Polymorphism, Single Nucleotide; Topotecan | 2011 |
Novel mechanism of reduced proliferation in ovarian clear cell carcinoma cells: cytoplasmic sequestration of CDK2 by p27.
Topics: Adenocarcinoma, Clear Cell; Cell Growth Processes; Cell Line, Tumor; Cisplatin; Cyclin-Dependent Kinase 2; Cyclin-Dependent Kinase Inhibitor p27; Cytoplasm; Deoxycytidine; Doxorubicin; Enzyme Activation; Female; Gemcitabine; Gene Knockdown Techniques; Humans; Ovarian Neoplasms; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation | 2011 |
The HIV reverse transcriptase inhibitor tenofovir induces cell cycle arrest in human cancer cells.
Topics: Adenine; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Nucleus; Cell Proliferation; Cytostatic Agents; Deoxycytidine; DNA Breaks, Double-Stranded; Doxorubicin; Drug Combinations; Drug Screening Assays, Antitumor; Emtricitabine; Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; Female; Histones; HIV Reverse Transcriptase; Humans; Organophosphonates; Organophosphorus Compounds; Ovarian Neoplasms; Reverse Transcriptase Inhibitors; Tenofovir; Time Factors | 2012 |
Feasibility of intravenous gemcitabine and an intraperitoneal platinum agent in the treatment of ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intravenous; Infusions, Parenteral; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Ovarian Neoplasms; Retrospective Studies; Thrombocytopenia; Treatment Outcome | 2011 |
[A case of advanced rectal cancer resected successfully after preoperative XELOX chemotherapy].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Combined Modality Therapy; Deoxycytidine; Diagnosis, Differential; Female; Fluorouracil; Humans; Neoplasm Staging; Ovarian Neoplasms; Oxaloacetates; Rectal Neoplasms; Tomography, X-Ray Computed | 2011 |
Acute digital ischemia complicating gemcitabine and carboplatin combination chemotherapy for ovarian cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Female; Gemcitabine; Hand; Humans; Ischemia; Middle Aged; Ovarian Neoplasms | 2011 |
Initial experience with repetitive transarterial chemoembolization (TACE) as a third line treatment of ovarian cancer metastasis to the liver: indications, outcomes and role in patient's management.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoembolization, Therapeutic; Cisplatin; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Liver Neoplasms; Middle Aged; Mitomycin; Ovarian Neoplasms; Palliative Care; Survival Rate; Treatment Outcome | 2012 |
Salvage chemotherapy for recurrent or persistent clear cell carcinoma of the ovary: a single-institution experience for a series of 20 patients.
Topics: Adenocarcinoma, Clear Cell; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Ovarian Epithelial; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Retrospective Studies; Salvage Therapy; Survival Rate; Taxoids | 2013 |
[Results of chemotherapy for gynecologic cancer patients in ambulatory care].
Topics: Ambulatory Care; Ambulatory Care Facilities; Anemia, Hypochromic; Antineoplastic Agents; Carboplatin; Cisplatin; Cyclophosphamide; Deoxycytidine; Doxorubicin; Endometrial Neoplasms; Female; Gemcitabine; Genital Neoplasms, Female; Hospitalization; Humans; Middle Aged; Neutropenia; Outpatients; Ovarian Neoplasms; Paclitaxel; Quality of Life; Russia; Thrombocytopenia; Treatment Outcome; Uterine Cervical Neoplasms | 2011 |
Combined treatment of L1CAM antibodies and cytostatic drugs improve the therapeutic response of pancreatic and ovarian carcinoma.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cytostatic Agents; Deoxycytidine; Disease Models, Animal; Female; Gemcitabine; Mice; Mice, SCID; Neural Cell Adhesion Molecule L1; Ovarian Neoplasms; Paclitaxel; Pancreatic Neoplasms | 2012 |
Effect of PI3K/Akt pathway inhibition-mediated G1 arrest on chemosensitization in ovarian cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzylamines; Cell Line, Tumor; Chromones; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Drug Synergism; Female; G1 Phase Cell Cycle Checkpoints; Gemcitabine; Humans; Morpholines; Ovarian Neoplasms; Paclitaxel; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinoxalines; Signal Transduction; Topotecan | 2012 |
Navitoclax (ABT-263) reduces Bcl-x(L)-mediated chemoresistance in ovarian cancer models.
Topics: Aniline Compounds; Antineoplastic Combined Chemotherapy Protocols; bcl-X Protein; Cell Line, Tumor; Deoxycytidine; Drug Synergism; Female; Gemcitabine; Humans; Immunohistochemistry; Ovarian Neoplasms; Paclitaxel; Sulfonamides | 2012 |
Noxa enhances the cytotoxic effect of gemcitabine in human ovarian cancer cells.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Carcinoma; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Female; Gemcitabine; Genetic Therapy; Humans; Mice; Mice, Nude; Neoplasm Transplantation; Ovarian Neoplasms; Plasmids; Proto-Oncogene Proteins c-bcl-2; Transfection | 2012 |
Outcome of single agent generic gemcitabine in platinum-resistant ovarian cancer, fallopian tube cancer and primary peritoneal adenocarcinoma.
Topics: Adenocarcinoma; Adenocarcinoma, Clear Cell; Adult; Aged; Antimetabolites, Antineoplastic; Cystadenocarcinoma, Serous; Deoxycytidine; Drug Resistance, Neoplasm; Endometrial Neoplasms; Fallopian Tube Neoplasms; Female; Follow-Up Studies; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Organoplatinum Compounds; Ovarian Neoplasms; Peritoneal Neoplasms; Prognosis; Retrospective Studies; Salvage Therapy; Survival Rate | 2012 |
Short response duration even in responders to chemotherapy using conventional cytotoxic agents in recurrent or refractory clear cell carcinomas of the ovary.
Topics: Adenocarcinoma, Clear Cell; Camptothecin; Deoxycytidine; Female; Humans; Male; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Taxoids | 2013 |
The O-glycan pathway is associated with in vitro sensitivity to gemcitabine and overall survival from ovarian cancer.
Topics: Antimetabolites, Antineoplastic; Biosynthetic Pathways; Cell Line, Tumor; Cell Survival; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Gene Expression Profiling; Glycosylation; Humans; Inhibitory Concentration 50; Kaplan-Meier Estimate; Oligonucleotide Array Sequence Analysis; Ovarian Neoplasms; Polysaccharides; Principal Component Analysis; Protein Processing, Post-Translational; Signal Transduction; Transcription, Genetic | 2012 |
Malignant fibrous histiocytoma of the ovary: a case report.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Deoxycytidine; Docetaxel; Fatal Outcome; Female; Gemcitabine; Histiocytoma, Malignant Fibrous; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Ovarian Neoplasms; Taxoids | 2012 |
Is renal thrombotic angiopathy an emerging problem in the treatment of ovarian cancer recurrences?
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Bevacizumab; Creatinine; Deoxycytidine; Doxorubicin; Fatal Outcome; Female; Gemcitabine; Humans; Middle Aged; Ovarian Neoplasms; Platinum; Polyethylene Glycols; Quality of Life; Recurrence; Renal Insufficiency, Chronic; Retrospective Studies; Risk Factors; Taxoids; Thrombosis; Topotecan | 2012 |
sMEK1 enhances gemcitabine anti-cancer activity through inhibition of phosphorylation of Akt/mTOR.
Topics: Carcinoma, Ovarian Epithelial; Cell Cycle Proteins; Cell Line, Tumor; Cell Movement; Deoxycytidine; Down-Regulation; Female; Gemcitabine; Humans; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Phosphoprotein Phosphatases; Phosphorylation; Proto-Oncogene Proteins c-akt; TOR Serine-Threonine Kinases; Tumor Suppressor Protein p53; Tumor Suppressor Proteins | 2012 |
Derivation and characterization of matched cell lines from primary and recurrent serous ovarian cancer.
Topics: Adult; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Ascites; Blotting, Western; Carboplatin; Cell Line, Tumor; Cisplatin; Cystadenocarcinoma, Serous; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Humans; Immunohistochemistry; Mice; Mice, SCID; Middle Aged; Ovarian Neoplasms; Paclitaxel; Topotecan; Xenograft Model Antitumor Assays | 2012 |
Salvage chemotherapy using gemcitabine for taxane/platinum-resistant recurrent ovarian cancer: a single institutional experience.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Bridged-Ring Compounds; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Ovarian Neoplasms; Retrospective Studies; Salvage Therapy; Taxoids | 2012 |
Evidence for different mechanisms of 'unhooking' for melphalan and cisplatin-induced DNA interstrand cross-links in vitro and in clinical acquired resistant tumour samples.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cisplatin; Deoxycytidine; DNA; DNA Damage; DNA Repair; DNA Replication; Drug Resistance, Neoplasm; Female; Gemcitabine; Histones; Homologous Recombination; Humans; Melphalan; Multiple Myeloma; Ovarian Neoplasms; Rad51 Recombinase; Signal Transduction | 2012 |
[Chemotherapy for recurrent ovarian cancer].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Doxorubicin; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Molecular Targeted Therapy; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum Compounds; Polyethylene Glycols; Topotecan | 2012 |
[Treatment of recurrent ovarian cancer].
Topics: Antineoplastic Agents; Carcinoma, Ovarian Epithelial; Deoxycytidine; Doxorubicin; Etoposide; Female; Gemcitabine; Humans; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Polyethylene Glycols; Reoperation; Topotecan | 2012 |
Potential use of drug loaded nano composite pectin scaffolds for the treatment of ovarian cancer.
Topics: Antimetabolites, Antineoplastic; Cell Adhesion; Cell Line, Tumor; Cell Survival; Chitosan; Deoxycytidine; Drug Delivery Systems; Female; Fibrin; Gemcitabine; Humans; Nanocomposites; Ovarian Neoplasms; Pectins; Porosity; Tissue Scaffolds | 2013 |
Sequence-dependent synergism between the new generation platinum agent ZD0473 and paclitaxel in cisplatin-sensitive and -resistant human ovarian carcinoma cell lines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Division; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Doxorubicin; Drug Synergism; Female; Flow Cytometry; Gemcitabine; Humans; Organoplatinum Compounds; Ovarian Neoplasms; Paclitaxel; Topotecan; Tumor Cells, Cultured; Vinblastine; Vinorelbine | 2002 |
[Updates on gemcitabine at the American Society of Clinical Oncology congress (ASCO, 2002) ].
Topics: Antibodies, Monoclonal; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Docetaxel; Enzyme Inhibitors; Female; Gemcitabine; Glutamates; Guanine; Humans; Immunotherapy; Lung Neoplasms; Mitomycins; Multicenter Studies as Topic; Neoplasms, Unknown Primary; Organoplatinum Compounds; Ovarian Neoplasms; Paclitaxel; Pancreatic Neoplasms; Pemetrexed; Radiotherapy; Remission Induction; Taxoids; Treatment Outcome; Urinary Bladder Neoplasms; Vinblastine; Vinorelbine | 2002 |
Effect of gemcitabine and cis-platinum combinations on ribonucleotide and deoxyribonucleotide pools in ovarian cancer cell lines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Deoxyribonucleotides; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Ovarian Neoplasms; Ribonucleotides; Tumor Cells, Cultured | 2003 |
[Two cases of complete response to combination chemotherapy of gemcitabine and docetaxel for recurrent ovarian cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Endometrioid; Cystadenocarcinoma, Serous; Deoxycytidine; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Pelvic Neoplasms; Taxoids | 2003 |
Gemcitabine potentiates cisplatin cytotoxicity and inhibits repair of cisplatin-DNA damage in ovarian cancer cell lines.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Cisplatin; Deoxycytidine; DNA Adducts; DNA Damage; DNA Repair; Drug Synergism; Female; Gemcitabine; Humans; Ovarian Neoplasms; Tetrahydrofolate Dehydrogenase; Tumor Cells, Cultured | 2003 |
Efficacy of gemcitabine in heavily pretreated advanced ovarian cancer patients.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma, Endometrioid; Deoxycytidine; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Ovarian Neoplasms; Retrospective Studies; Thrombocytopenia; Treatment Outcome | 2003 |
[Combination chemotherapy with Hemzar (gemcitabine) and cisplatin for relapsing and cisplatin-resistant ovarian cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Middle Aged; Ovarian Neoplasms; Recurrence; Treatment Outcome | 2003 |
[Experience with xeloda (capecitabine) as a component of chemotherapy for relapsing cisplatin-resistant ovarian tumors].
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Cisplatin; Deoxycytidine; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Prodrugs; Treatment Outcome | 2003 |
Peripheral neuropathy due to therapy with paclitaxel, gemcitabine, and cisplatin in patients with advanced ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Neurologic Examination; Ovarian Neoplasms; Paclitaxel; Peripheral Nervous System Diseases | 2003 |
A new therapeutical approach: topotecan plus gemcitabine in the treatment of patients with relapsed ovarian cancer after failure of first-line chemotherapy with paclitaxel and platinum.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Deoxycytidine; Female; Gemcitabine; Humans; Leukopenia; Neoplasm Recurrence, Local; Neutropenia; Ovarian Neoplasms; Paclitaxel; Platinum Compounds; Survival Rate; Thrombocytopenia; Topotecan; Treatment Failure | 2003 |
Gemcitabine-induced radiation recall dermatitis following whole pelvic radiation therapy.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Cystadenocarcinoma, Papillary; Cystadenocarcinoma, Serous; Deoxycytidine; Female; Gemcitabine; Humans; Ovarian Neoplasms; Radiation-Sensitizing Agents; Radiodermatitis | 2003 |
Gemcitabine associated vasculitis leading to necrotizing enterocolitis and death in women undergoing primary treatment for epithelial ovarian/peritoneal cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Enterocolitis, Necrotizing; Fatal Outcome; Female; Gemcitabine; Humans; Middle Aged; Ovarian Neoplasms; Peritoneal Neoplasms; Vasculitis | 2004 |
Recurrent ovarian cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Clinical Trials, Phase I as Topic; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Retreatment; Topotecan; Treatment Failure | 2004 |
Costs of treatment and outcomes associated with second-line therapy and greater for relapsed ovarian cancer.
Topics: Adolescent; Adult; Aged; Deoxycytidine; Drug Costs; Drug Resistance, Neoplasm; Female; Gemcitabine; Health Care Costs; Humans; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Ovarian Neoplasms; Paclitaxel; Salvage Therapy; Topotecan | 2004 |
Survival following the documentation of platinum and taxane resistance in ovarian cancer: a single institution experience involving multiple phase 2 clinical trials.
Topics: Adult; Aged; Aged, 80 and over; Bridged-Ring Compounds; Clinical Trials, Phase II as Topic; Deoxycytidine; Docetaxel; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Fallopian Tube Neoplasms; Female; Gemcitabine; Humans; Middle Aged; Organoplatinum Compounds; Ovarian Neoplasms; Peritoneal Neoplasms; Retrospective Studies; Survival Rate; Taxoids; Topotecan | 2004 |
Long-term disease-free survival effected by gemcitabine in a heavily pretreated patient with recurrent ovarian carcinoma.
Topics: Antimetabolites, Antineoplastic; Cystadenocarcinoma, Serous; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Gynecologic Surgical Procedures; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Ovarian Neoplasms; Treatment Outcome | 2005 |
Detection of an alternatively spliced form of deoxycytidine kinase mRNA in the 2'-2'-difluorodeoxycytidine (gemcitabine)-resistant human ovarian cancer cell line AG6000.
Topics: Alternative Splicing; Amino Acid Sequence; Animals; Antimetabolites, Antineoplastic; Base Sequence; Cell Line; Deoxycytidine; Deoxycytidine Kinase; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Female; Gemcitabine; Humans; Molecular Sequence Data; Ovarian Neoplasms; Rats; RNA, Messenger; RNA, Neoplasm; Tumor Cells, Cultured | 2004 |
Gemcitabine in heavily pretreated patients with recurrent ovarian, peritoneal and fallopian tube carcinoma.
Topics: Adult; Aged; Deoxycytidine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Fallopian Tube Neoplasms; Female; Gemcitabine; Humans; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Peritoneal Neoplasms; Prognosis; Registries; Retrospective Studies; Risk Assessment; Salvage Therapy; Survival Analysis; Treatment Outcome | 2004 |
Gemcitabine and cisplatin chemotherapy is an active combination in the treatment of platinum-resistant ovarian and peritoneal carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Drug Resistance, Neoplasm; Fallopian Tube Neoplasms; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Peritoneal Neoplasms; Retrospective Studies; Survival Rate; Treatment Outcome | 2004 |
Severe neurotoxicity caused by gemcitabine treatment.
Topics: Aged; Antimetabolites, Antineoplastic; Central Nervous System Diseases; Confusion; Deoxycytidine; Female; Gemcitabine; Headache; Humans; Lung Neoplasms; Male; Middle Aged; Ovarian Neoplasms; Seizures; Urinary Bladder Neoplasms | 2004 |
The in vitro effect of gefitinib ('Iressa') alone and in combination with cytotoxic chemotherapy on human solid tumours.
Topics: Adenocarcinoma; Adenosine Triphosphate; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Busulfan; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Colorectal Neoplasms; Deoxycytidine; Drug Screening Assays, Antitumor; Female; Gefitinib; Gemcitabine; Humans; Melanoma; Neoplasms; Neoplasms, Unknown Primary; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin; Quinazolines; Sarcoma; Skin Neoplasms; Stomach Neoplasms; Uveal Neoplasms | 2004 |
Response of combination platinum and gemcitabine chemotherapy for recurrent epithelial ovarian carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Cisplatin; Cystadenocarcinoma, Papillary; Cystadenocarcinoma, Serous; Deoxycytidine; Drug Synergism; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Retrospective Studies; Survival Analysis | 2004 |
[Significance of tissue thymidine phosphorylase and dihydropyrimidine dehydrogenase activities in ovarian cancer].
Topics: 5'-Nucleotidase; Adenocarcinoma, Scirrhous; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); Female; Floxuridine; Fluorouracil; Humans; Middle Aged; Ovarian Neoplasms; Survival Rate | 2004 |
Expression of Bcl-xL in ovarian carcinoma is associated with chemoresistance and recurrent disease.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; bcl-X Protein; Cell Line, Tumor; Cisplatin; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Mice; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Proto-Oncogene Proteins c-bcl-2; Topotecan; Xenograft Model Antitumor Assays | 2005 |
Three cases of hemolytic uremic syndrome in ovarian cancer patients treated with combination gemcitabine and pegylated liposomal doxorubicin.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Hemolytic-Uremic Syndrome; Humans; Middle Aged; Ovarian Neoplasms | 2005 |
Combination of gemcitabine and Ad5/3-Delta24, a tropism modified conditionally replicating adenovirus, for the treatment of ovarian cancer.
Topics: Adenocarcinoma; Adenovirus E1A Proteins; Adenoviruses, Human; Animals; Antiviral Agents; Bone Marrow Cells; Cell Line, Tumor; Combined Modality Therapy; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Genetic Therapy; Liver; Mice; Neoplasms, Experimental; Oncolytic Virotherapy; Oncolytic Viruses; Ovarian Neoplasms; Virus Replication | 2005 |
Prolonged stabilization of platinum-resistant ovarian cancer in a single patient consuming a fermented soy therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Complementary Therapies; Deoxycytidine; Doxorubicin; Drug Resistance, Neoplasm; Female; Gemcitabine; Genistein; Glucuronides; Humans; Isoflavones; Middle Aged; Ovarian Neoplasms; Paclitaxel; Soy Milk; Topotecan | 2006 |
Effects of gemcitabine on cis-platinum-DNA adduct formation and repair in a panel of gemcitabine and cisplatin-sensitive or -resistant human ovarian cancer cell lines.
Topics: Antimetabolites, Antineoplastic; Cisplatin; Deoxycytidine; DNA Adducts; DNA Repair; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Ovarian Neoplasms; Tumor Cells, Cultured | 2006 |
Re: "Gemcitabine and liposomal doxorubicin in the salvage treatment of ovarian cancer: updated results and long-term survival".
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Humans; Ovarian Neoplasms; Randomized Controlled Trials as Topic; Salvage Therapy | 2006 |
Molecular mechanism of phenoxodiol-induced apoptosis in ovarian carcinoma cells.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Blotting, Western; Carboplatin; Carcinoma; Caspase 2; Caspases; Cell Line, Tumor; Deoxycytidine; Drug Interactions; Enzyme Activation; Female; Gemcitabine; Humans; Isoflavones; Mice; Ovarian Neoplasms; Paclitaxel; Proteasome Endopeptidase Complex; Transplantation, Heterologous | 2006 |
Glucocorticoid-mediated inhibition of chemotherapy in ovarian carcinomas.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Cell Culture Techniques; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cisplatin; Deoxycytidine; Dexamethasone; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Dual Specificity Phosphatase 1; Female; Gemcitabine; Glucocorticoids; Humans; Immediate-Early Proteins; Mice; Ovarian Neoplasms; Phosphoprotein Phosphatases; Protein Phosphatase 1; Protein Serine-Threonine Kinases; Protein Tyrosine Phosphatases | 2006 |
Is thrombotic microangiopathy associated with antitumoral activity?
Topics: Acute Kidney Injury; Antihypertensive Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Female; Gemcitabine; Hemolytic-Uremic Syndrome; Humans; Kidney; Middle Aged; Ovarian Neoplasms | 2006 |
Simultaneous determination of gemcitabine di- and triphosphate in human blood mononuclear and cancer cells by RP-HPLC and UV detection.
Topics: Antimetabolites, Antineoplastic; Cell Line, Tumor; Chromatography, High Pressure Liquid; Deoxycytidine; Female; Gemcitabine; Humans; Monocytes; Ovarian Neoplasms; Reference Standards; Reproducibility of Results; Sensitivity and Specificity; Spectrophotometry, Ultraviolet | 2006 |
Not in the BNF.
Topics: Aged; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Emergency Service, Hospital; Fatal Outcome; Female; Fluorouracil; Heart Arrest; Humans; Ovarian Neoplasms; Pharmacopoeias as Topic | 2006 |
Bevacizumab combination therapy in recurrent, platinum-refractory, epithelial ovarian carcinoma: A retrospective analysis.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cohort Studies; Cyclophosphamide; Deoxycytidine; Docetaxel; Doxorubicin; Drug Resistance, Neoplasm; Female; Fluorouracil; Gemcitabine; Humans; Intestinal Perforation; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Platinum Compounds; Retrospective Studies; Taxoids; Tomography Scanners, X-Ray Computed; Treatment Outcome | 2006 |
Heavily pretreated ovarian cancer patients treated by single-agent gemcitabine. A retrospective outcome comparison between platinum-sensitive and platinum-resistant patients.
Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Endometrioid; Cystadenocarcinoma, Serous; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Retrospective Studies; Ribonucleotide Reductases; Salvage Therapy; Survival Rate | 2006 |
Role of chemotherapy for patients with recurrent platinum-resistant advanced epithelial ovarian cancer: A cost-effectiveness analysis.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cost-Benefit Analysis; Deoxycytidine; Doxorubicin; Drug Resistance, Neoplasm; Epithelial Cells; Female; Gemcitabine; Humans; Models, Economic; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum | 2006 |
Growth inhibition and apoptosis induction in ovarian cancer cells.
Topics: Antibodies, Monoclonal; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Apoptosis; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Female; Gemcitabine; Genes, p53; Humans; Ovarian Neoplasms; Paclitaxel; Tetrazolium Salts; Thiazoles; Tumor Suppressor Protein p53 | 2006 |
Combination of gemcitabine antagonizes antitumor activity of paclitaxel through prevention of mitotic arrest and apoptosis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Breast Neoplasms; Cell Proliferation; Deoxycytidine; Female; Flow Cytometry; Gemcitabine; Humans; I-kappa B Kinase; Mitosis; Ovarian Neoplasms; Paclitaxel; Proto-Oncogene Proteins c-bcl-2; Tumor Cells, Cultured | 2006 |
[Experience with gemcitabine-carboplatin chemotherapy in relapsed ovarian cancer].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Retrospective Studies; Survival Analysis; Treatment Outcome | 2006 |
A step in the right direction.
Topics: Antimetabolites, Antineoplastic; Deoxycytidine; Drug Approval; Endpoint Determination; Female; Gemcitabine; Humans; Neoplasms; Ovarian Neoplasms; Survival Analysis; United States; United States Food and Drug Administration | 2006 |
Severe pulmonary toxicity in patients with leiomyosarcoma after treatment with gemcitabine and docetaxel.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Arm; Deoxycytidine; Docetaxel; Fatal Outcome; Female; Gemcitabine; Humans; Leiomyosarcoma; Middle Aged; Ovarian Neoplasms; Respiratory Distress Syndrome; Severity of Illness Index; Taxoids; Tomography, X-Ray Computed; Treatment Outcome | 2007 |
Improved survival with single-agent paclitaxel consolidation/maintenance therapy in advanced ovarian carcinoma.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Survival Rate | 2006 |
A case of drug resistant clear cell ovarian cancer showing responsiveness to gemcitabine at first administration and at re-challenge.
Topics: Antimetabolites, Antineoplastic; Deoxycytidine; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Treatment Outcome | 2007 |
A heavily pretreated patient with recurrent clear cell adenocarcinoma of the ovary in whom carcinomatous peritonitis was controlled successfully by salvage therapy with gemcitabine.
Topics: Adenocarcinoma, Clear Cell; Antimetabolites, Antineoplastic; Deoxycytidine; Fatal Outcome; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Peritonitis; Salvage Therapy | 2008 |
Developmental chemotherapy and management of recurrent ovarian cancer.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Clinical Trials as Topic; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Doxorubicin; Drugs, Investigational; Enzyme Inhibitors; Etoposide; Female; Gemcitabine; Humans; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic; Recurrence; Research Design; Taxoids; Topoisomerase I Inhibitors; Topotecan; Treatment Outcome | 2003 |
Management of platinum-sensitive recurrent ovarian cancer: a cost-effectiveness analysis.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cost-Benefit Analysis; Deoxycytidine; Disease-Free Survival; Drug Costs; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Quality of Life | 2007 |
Gemcitabine-induced hemolytic uremic syndrome in ovarian carcinoma.
Topics: Antimetabolites, Antineoplastic; Deoxycytidine; Female; Gemcitabine; Hemolytic-Uremic Syndrome; Humans; Middle Aged; Ovarian Neoplasms; Treatment Outcome | 2007 |
Oncolytic adenovirus Ad5/3-delta24 and chemotherapy for treatment of orthotopic ovarian cancer.
Topics: Adenocarcinoma; Adenoviridae; Animals; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Combined Modality Therapy; Deoxycytidine; Drug Administration Schedule; Epirubicin; Female; Gemcitabine; Humans; Mice; Mice, SCID; Oncolytic Virotherapy; Ovarian Neoplasms; Virus Replication; Xenograft Model Antitumor Assays | 2008 |
Carbon beam therapy in recurrent ovarian cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carbon; Carboplatin; Carcinoma, Endometrioid; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Hysterectomy; Irinotecan; Lymph Node Excision; Neoplasm Recurrence, Local; Omentum; Ovarian Neoplasms; Ovariectomy; Paclitaxel; Radiotherapy, High-Energy; Remission Induction; Salvage Therapy | 2008 |
[Acral necrosis in metastatic ovarian carcinoma. A single episode of Moschowitz syndrome during gemcitabine chemotherapy].
Topics: Deoxycytidine; Female; Fingers; Gemcitabine; Hand Dermatoses; Humans; Middle Aged; Necrosis; Ovarian Neoplasms; Purpura, Thrombotic Thrombocytopenic; Treatment Outcome | 2008 |
Predictive value of individualized tumor response testing by ATP-based chemotherapy response assay in ovarian cancer.
Topics: Adenosine Triphosphate; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Predictive Value of Tests; Sensitivity and Specificity; Single-Blind Method; Treatment Outcome; Tumor Cells, Cultured | 2008 |
A pilot study evaluating the efficacy and toxicity of biweekly gemcitabine and pegylated liposomal doxorubicin in recurrent platinum-resistant epithelial ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Doxorubicin; Drug Administration Schedule; Drug Evaluation; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Pilot Projects; Polyethylene Glycols | 2008 |
Induction of resistance to 2',2'-difluorodeoxycytidine in the human ovarian cancer cell line A2780.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Base Sequence; Cell Division; Cytidine Deaminase; Deoxycytidine; Deoxycytidine Kinase; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Molecular Sequence Data; Nucleoside Deaminases; Ovarian Neoplasms; Phenotype; Ribonucleotide Reductases; RNA, Messenger; Tumor Cells, Cultured; Vincristine | 1995 |
Schedule-dependent antitumor effect of gemcitabine in in vivo model system.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma; Carcinoma, Squamous Cell; Colonic Neoplasms; Deoxycytidine; Drug Administration Schedule; Drug Screening Assays, Antitumor; Female; Gemcitabine; Head and Neck Neoplasms; Humans; Infusions, Intravenous; Injections, Intraperitoneal; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Ovarian Neoplasms; Sarcoma; Soft Tissue Neoplasms | 1995 |
Interaction between cisplatin and gemcitabine in vitro and in vivo.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Division; Cisplatin; Colonic Neoplasms; Deoxycytidine; DNA Damage; DNA, Neoplasm; Drug Administration Schedule; Drug Resistance, Neoplasm; Drug Synergism; Drug Tolerance; Female; Fluorometry; Gemcitabine; Head and Neck Neoplasms; Humans; Injections, Intraperitoneal; Injections, Intravenous; Mice; Mice, Inbred BALB C; Mice, Nude; Ovarian Neoplasms; Tumor Cells, Cultured | 1995 |
Ovarian cancer--new insights into systemic therapy.
Topics: Antimetabolites, Antineoplastic; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Drug Therapy, Combination; Female; Gemcitabine; Humans; Ovarian Neoplasms; Paclitaxel | 1995 |
Synergistic interaction between cisplatin and gemcitabine in ovarian and colon cancer cell lines.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Division; Cell Line; Cisplatin; Colonic Neoplasms; Cytidine Deaminase; Deoxycytidine; Deoxycytidine Kinase; Drug Screening Assays, Antitumor; Drug Synergism; Female; Gemcitabine; Humans; Kinetics; Mice; Nucleoside Deaminases; Ovarian Neoplasms; Time Factors; Tumor Cells, Cultured | 1994 |
Schedule dependence of sensitivity to 2',2'-difluorodeoxycytidine (Gemcitabine) in relation to accumulation and retention of its triphosphate in solid tumour cell lines and solid tumours.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Division; Colonic Neoplasms; Deoxycytidine; Drug Screening Assays, Antitumor; Female; Gemcitabine; Humans; Mice; Ovarian Neoplasms; Phosphates; Ribonucleotides; Tumor Cells, Cultured | 1994 |
Development and molecular characterization of a 2',2'-difluorodeoxycytidine-resistant variant of the human ovarian carcinoma cell line A2780.
Topics: Animals; Antimetabolites, Antineoplastic; Base Sequence; Deoxycytidine; Deoxycytidine Kinase; Drug Resistance; Female; Gemcitabine; Humans; Mice; Mice, Nude; Molecular Sequence Data; Ovarian Neoplasms; RNA, Messenger; Tumor Cells, Cultured | 1994 |
The influence of the schedule and the dose of gemcitabine on the anti-tumour efficacy in experimental human cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Division; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Evaluation; Female; Gemcitabine; Humans; Mice; Mice, Nude; Neoplasm Transplantation; Ovarian Neoplasms; Sarcoma; Soft Tissue Neoplasms; Transplantation, Heterologous; Tumor Cells, Cultured | 1993 |
Regulation of phosphorylation of deoxycytidine and 2',2'-difluorodeoxycytidine (gemcitabine); effects of cytidine 5'-triphosphate and uridine 5'-triphosphate in relation to chemosensitivity for 2',2'-difluorodeoxycytidine.
Topics: Cytidine Deaminase; Cytidine Triphosphate; Deoxycytidine; Deoxycytidine Kinase; Enzyme Inhibitors; Female; Gemcitabine; Humans; Kinetics; Nucleoside Deaminases; Ovarian Neoplasms; Phosphorylation; Tumor Cells, Cultured; Uridine Triphosphate | 1996 |
Activity of gemcitabine in platinum-resistant ovarian germ cell cancer.
Topics: Adult; Antimetabolites, Antineoplastic; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Germinoma; Humans; Ovarian Neoplasms; Platinum Compounds | 1996 |
Activity of gemcitabine in a human tumor cloning assay as a basis for clinical trials with gemcitabine. San Antonio Drug Development Team.
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Ovarian Neoplasms; Tumor Stem Cell Assay | 1996 |
Fatal pulmonary toxicity resulting from treatment with gemcitabine.
Topics: Antimetabolites, Antineoplastic; Deoxycytidine; Fatal Outcome; Female; Gemcitabine; Humans; Hypoxia; Lung Diseases; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Ovarian Neoplasms; Pulmonary Edema; Respiratory Distress Syndrome | 1997 |
Gemcitabine induces programmed cell death and activates protein kinase C in BG-1 human ovarian cancer cells.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Deoxycytidine; Enzyme Activation; Female; Gemcitabine; Humans; Microscopy, Electron, Scanning; Ovarian Neoplasms; Protein Kinase C; Tumor Cells, Cultured | 1998 |
Cross-resistance of the gemcitabine resistant human ovarian cancer cell line AG6000 to standard and investigational drugs.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Cell Division; Clone Cells; Deoxycytidine; DNA Damage; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Ovarian Neoplasms; Tumor Cells, Cultured | 1998 |
Cell cycle arrest in ovarian cancer cell lines does not depend on p53 status upon treatment with cytostatic drugs.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Cell Cycle; Deoxycytidine; Drug Screening Assays, Antitumor; Female; Flow Cytometry; Gemcitabine; Humans; Ovarian Neoplasms; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 1998 |
Gemcitabine after bone marrow transplantation for refractory juvenile granulosa cell tumor.
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Deoxycytidine; Female; Gemcitabine; Granulosa Cell Tumor; Humans; Ovarian Neoplasms | 1998 |
Postconfluent multilayered cell line cultures for selective screening of gemcitabine.
Topics: Antimetabolites, Antineoplastic; Colonic Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Female; Gemcitabine; Humans; Nucleotides; Ovarian Neoplasms; Tumor Cells, Cultured | 1998 |
Combination chemotherapy studies with gemcitabine and etoposide in non-small cell lung and ovarian cancer cell lines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Deoxycytosine Nucleotides; DNA Damage; Drug Synergism; Etoposide; Female; Gemcitabine; Humans; Lung Neoplasms; Ovarian Neoplasms; Tumor Cells, Cultured | 1999 |
The effects of gemcitabine and TPA on PKC signaling in BG-1 human ovarian cancer cells.
Topics: Alkaline Phosphatase; Antimetabolites, Antineoplastic; Blotting, Western; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Isoenzymes; Mitogen-Activated Protein Kinase 1; Ovarian Neoplasms; Protein Kinase C; Subcellular Fractions; Tetradecanoylphorbol Acetate; Time Factors; Tumor Cells, Cultured | 1998 |
The Gynecologic Oncology Group experience in ovarian cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Decision Making; Deoxycytidine; Female; Gemcitabine; Humans; Ovarian Neoplasms; Paclitaxel; Treatment Outcome | 1999 |
Mechanisms of synergism between cisplatin and gemcitabine in ovarian and non-small-cell lung cancer cell lines.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Lewis Lung; Carcinoma, Non-Small-Cell Lung; Cell Division; Cisplatin; Deoxycytidine; DNA; DNA Adducts; DNA Damage; Dose-Response Relationship, Drug; Drug Synergism; Female; Fluorometry; Gemcitabine; Humans; Intracellular Fluid; Lung Neoplasms; Mice; Ovarian Neoplasms; Platinum; RNA; Time Factors; Tumor Cells, Cultured; Tumor Stem Cell Assay | 1999 |
Gemcitabine salvage chemotherapy for patients with gynecologic malignancies of the ovary, fallopian tube, and peritoneum.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Fallopian Tube Neoplasms; Female; Gemcitabine; Hematologic Diseases; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Peritoneal Neoplasms; Salvage Therapy; Survival Rate; Treatment Outcome; United States | 1999 |
Differential effects of gemcitabine on ribonucleotide pools of twenty-one solid tumour and leukaemia cell lines.
Topics: Animals; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Gemcitabine; Head and Neck Neoplasms; Humans; Leukemia; Lung Neoplasms; Mice; Ovarian Neoplasms; Rats; Ribonucleotide Reductases; Ribonucleotides; Tumor Cells, Cultured | 2000 |
Severe hemolytic uremic syndrome in an advanced ovarian cancer patient treated with carboplatin and gemcitabine.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Female; Gemcitabine; Hemolytic-Uremic Syndrome; Humans; Middle Aged; Ovarian Neoplasms | 1999 |
Cross-resistance in the 2',2'-difluorodeoxycytidine (gemcitabine)-resistant human ovarian cancer cell line AG6000 to standard and investigational drugs.
Topics: Antineoplastic Agents, Phytogenic; Cell Division; Deoxycytidine; DNA Damage; DNA, Neoplasm; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drugs, Investigational; Female; Flow Cytometry; Gemcitabine; Humans; Ovarian Neoplasms; Tumor Cells, Cultured | 2000 |
The role of laparoscopy in second-look evaluations for ovarian cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Injections, Intraperitoneal; Injections, Intravenous; Laparoscopy; Middle Aged; Mitoxantrone; Ovarian Neoplasms; Paclitaxel; Reoperation; Retrospective Studies | 2001 |
The ex vivo effect of high concentrations of doxorubicin on recurrent ovarian carcinoma.
Topics: Adenosine Triphosphate; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Dose-Response Relationship, Drug; Doxorubicin; Drug Screening Assays, Antitumor; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Tumor Cells, Cultured | 2000 |
Cell cycle effects of gemcitabine.
Topics: Antimetabolites, Antineoplastic; Cell Cycle; Cell Survival; Deoxycytidine; DNA Replication; DNA, Neoplasm; Dose-Response Relationship, Drug; Female; Flow Cytometry; Gemcitabine; Humans; Ovarian Neoplasms; S Phase; Tumor Cells, Cultured | 2001 |
Gemcitabine in the treatment of ovarian cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Female; Gemcitabine; Humans; Ovarian Neoplasms; Treatment Outcome | 2001 |
Sustained complete remission in a patient with platinum-resistant ovarian yolk sac tumor.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Docetaxel; Drug Resistance, Neoplasm; Endodermal Sinus Tumor; Female; Gemcitabine; Humans; Ovarian Neoplasms; Paclitaxel; Taxoids; Thalidomide | 2001 |
Second-line carboplatin and gemcitabine in platinum sensitive ovarian cancer--a dose-finding study by the Arbeitsgemeinschaft Gynäkologische Onkologie (AGO) Ovarian Cancer Study Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Female; Gemcitabine; Germany; Humans; Middle Aged; Neutropenia; Ovarian Neoplasms; Thrombocytopenia; Treatment Outcome | 2001 |
Antagonistic effect of the combination gemcitabine/topotecan in ovarian cancer cells.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Division; Deoxycytidine; Dose-Response Relationship, Drug; Drug Interactions; Female; Flow Cytometry; Gemcitabine; Humans; Inhibitory Concentration 50; Ovarian Neoplasms; Time Factors; Topotecan; Tumor Cells, Cultured; Tumor Protein, Translationally-Controlled 1 | 2000 |
Individualized long-term chemotherapy for recurrent ovarian cancer after failing high-dose treatment.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cisplatin; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Humans; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Treatment Failure | 2002 |
Thymidine kinase in epithelial ovarian cancer: relationship with the other pyrimidine pathway enzymes.
Topics: Aged; Antimetabolites, Antineoplastic; Capecitabine; Cytosol; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); Female; Fluorouracil; Humans; Middle Aged; Multivariate Analysis; Ovarian Neoplasms; Ovary; Oxidoreductases; Prognosis; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; Thymidine Kinase; Thymidine Phosphorylase; Thymidylate Synthase; Time Factors | 2002 |
Recurrent ovarian cancer as chronic disease.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Chronic Disease; Deoxycytidine; Doxorubicin; Enzyme Inhibitors; Etoposide; Female; Gemcitabine; Humans; Ovarian Neoplasms; Recurrence; Topotecan; Trastuzumab | 2002 |
Synergistic action of tiazofurin and difluorodeoxycytidine on differentiation and cytotoxicity.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Differentiation; Cell Line; Cell Survival; Deoxycytidine; Dose-Response Relationship, Drug; Drug Synergism; Female; Gemcitabine; Humans; IMP Dehydrogenase; Kinetics; Leukemia, Promyelocytic, Acute; Liver Neoplasms, Experimental; Models, Biological; Ovarian Neoplasms; Pancreatic Neoplasms; Rats; Ribavirin; Tetradecanoylphorbol Acetate; Tretinoin; Tumor Stem Cell Assay | 1992 |
Deoxycytidine protects normal bone marrow progenitors against Ara-C and gemcitabine cytotoxicity without compromising their activity against cisplatin-resistant human ovarian cancer cells.
Topics: Antimetabolites, Antineoplastic; Blotting, Western; Bone Marrow Cells; Cisplatin; Cystadenocarcinoma; Cytarabine; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Glutathione Transferase; Humans; Injections, Intraperitoneal; Injections, Intravenous; Ovarian Neoplasms; RNA, Messenger; Stem Cells; Tumor Cells, Cultured | 1992 |
Concentration and time dependent growth inhibition and metabolism in vitro by 2',2'-difluoro-deoxycytidine (gemcitabine).
Topics: Animals; Antimetabolites, Antineoplastic; Biotransformation; Carcinoma, Squamous Cell; Cell Division; Cell Line; Colonic Neoplasms; Deoxycytidine; Drug Screening Assays, Antitumor; Female; Gemcitabine; Head and Neck Neoplasms; Humans; Kinetics; Mice; Ovarian Neoplasms | 1991 |